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The rise of antibiotic resistance (AMR) is one of the world’s major health threats1. The infections 
caused by antimicrobial resistance bacteria are increasing faster than the introduction of new 
antibiotics2,3. The emergence of a multi-drug resistant bacteria has pushed towards bacteriophage 
therapy as one of the alternatives to antibiotics4. Bacteriophages are viruses that infect bacteria. 
Lytic phages have been examined as a potential therapy against drug resistant bacteria because they 
propagation involves killing of their bacterial host5–7. In addition to vast number of advantages as 
therapeutics, bacteriophages have several limitations i.e. narrow host range and pharmokinetics – 
not being able to get high enough phage concentration to the site of infection. A variety of methods 
have been used for the genetic modification of bacteriophage genomes to undercome bacteriophage 
limitations, including Yeast Artificial Chromosome (YAC), CRISPR/Cas systems and marker-
based methods. However, no direct comparison has been carried to standardise the methods in 
question. This study aimed to establish the most efficient method by comparing effectiveness of 
CRISPR/Cas and marker-based systems (Chapter 3) followed by implementation of the method to 
address narrow host range and tissue binding specificity. I show that the most optimal engineering 
method is trxA marker-based method (Chapter 3). I then modify T7 tail fibers using the method 
established to retarget an alternative host, Bordetella pertussis (Chapter 4) and characterise them 
on E. coli expressing the receptor of interest as well as Bordetella pertussis and Bordetella 
bronchiseptica strains (Chapter 4). This uncovered an unexpected T7 infectivity of Bordetella 
bronchiseptica strains.  Furthermore, I uncovered a novel way for T7 infection, a co-infection 
between T7 and genetically modified (chimeric phage) (Chapter 5). I hypothesised that dependence 
arose from T7 lack of host factor gene (trxA) and chimeric phage lack of infective tail fibers. I 
examined the co-dependency by inducing the bacterial lysis after secondary addition of either of 
the phages to verify that both phages were required to yield the lysis. I further demonstrate that 
phage genetic modification can allow phage to carry additional cargo, that can be used to kill 
bacteria in addition to the phages natural host. To do this I engineered phage T4 to express three 
different endolysins, and verify the ability of these phage to also lyse S. aureus, C. difficile and B. 
subtilis. Finally, I examined ways of making T7 phage tissue specific. This was achieved by 
genetically modifying T7 capsid, major and minor proteins, with small homing peptides that 
specifically bind to lung epithelial tissue (Chapter 7). This study provides an important leap forward 
in our understanding of bacteriophage engineering towards therapeutics. In so doing it also 
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Chapter 1   Introduction   
 14 
1.1 Antimicrobial resistance   
 
The rise of antibiotic, or antimicrobial, resistance (AMR) is one of the world’s major health 
threats1. The infections caused by antimicrobial resistant bacteria are increasing faster than the 
introduction of new antibiotics2,3. AMR genes have been discovered in bacterial strains that 
pre-date the first use of antibiotics by humans, suggesting that AMR is a naturally existing 
phenomenon that was potentially aggravated by societal use of antibiotics8.  AMR seen in 
humans is closely related to AMR in other animal populations Figure 1-19. This similarity is 
due to a close interplay between the environment, animals and humans facilitates the movement 
of the drugs, the bacteria as well as mobile genetic elements (MGEs)10. The complexity of the 
interaction is scaled up by the broad range of antibiotics that affect multiple bacterial species 
and the fact that the acquired resistance can be obtained via MGEs. It has been suggested that 












Figure 1-1.  Diagram of AMR generation and transmission between humans, farm animals and the environment. 
Adapted from Woolhouse et al. 2015. High usage of antimicrobials i.e. antibiotics in human disease treatment as 
well as farming can lead to antibiotic persistence in manure and sewage which is then deposited in the 
environment. The environmental antibiotic deposits cycle back to humans as well as farming industry. 
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The introduction of antibiotics in the 1940s, that started with penicillin and streptomycin, 
revolutionised medicine allowing effective treatment of bacterial infections12–14. Antibiotic 
discovery is a difficult process, mainly due to poor penetration of various compounds into 
bacterial cells15. Most drugs used in today’s clinic were discovered by screening cultivable soil 
microorganisms in the 1960s12.  However, this limited resource eventually came to an end with 
no synthetic approaches able to replace the antibiotics previously discovered via natural 
product mining15,18. The deceleration of new drug invention and manufacturing resulted in a 
lack of financial incentive by pharmaceutical companies13. The emergence of multidrug 
resistant bacteria spurred research into alternative treatments4. This lead towards a revival of 
studies on potential replacements for antibiotics such as probiotics, vaccines, antibodies and 
immune stimulation, as well as bacteriophage and bacteriophage-based product therapy4,19–28. 
 
1.2 Bacteriophages  
 
Bacteriophages (phages) are viruses that infect bacteria. They are obligate parasites that are 
made up of genetic information, encoding all viral characteristics, packaged in a protein coat. 
They are parasites that exploit their host machinery for their propagation, which can be affected 
by a variety of factors such as nutrients, temperature and light29. Phages are arguably the most 
abundant biological particles on the planet, with an estimated 1031 in the biosphere30. Phages 
have two main lifestyles: lytic and temperate, that will be discussed in sections 1.3 and 1.4. 
Specifically, lytic phages have been examined as a potential therapy against drug resistant 
bacteria because their propagation involves the killing of their bacterial host5–7. 
 
1.3 Lytic or virulent phages  
 
 A lytic phage is a phage that induces lysis, or cell death, of its host upon replication. Lytic or 
virulent phages have been used in a variety of areas including food processing, bacterial biofilm 
removal and biotechnology31–34. Upon bacterial infection a lytic phage replicates faster than its 
host, with a complete infection to lysis cycle taking between 15 minutes to 36 hours35–37. In 
brief, the main stages for the lytic phage cycle are attachment, replication and lysis. During the 
attachment step, the phage tail fibers bind to a specific receptor on the surface of the target, or 
host, bacterium38. During the entry step, the phage injects its DNA into the host cytoplasm39. 
The following step is DNA replication, during which phage protein synthesis also takes place39. 
This is followed by assembly of phage capsid proteins and DNA packaging inside the 
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assembled protein capsids39. Late in the lytic cycle the phage expresses genes for holins and 
lysis that generate holes in the cell membrane of the host cell, resulting in the disbalance of 
water flowing inside the cell40. This causes the host cell to undergo lysis and death, that in 
parallel liberates progeny phage particles, which are each then ready to start another cycle by 
infecting new host cells40. The lytic phage cycle described above is referred to as ‘lysis from 
within’, as bacterial lysis is caused by phage proteins intracellularly41. At high concentrations 
lytic phages can also cause an alternative phage lysis, the phenomenon of ‘lysis from without’, 
in which bacteria lyse solely due to adsorption of external agents42,43, such as phage. This 
phenomenon has been most frequently studied for T2 and T4 phages43,44. It arises when 
substantial numbers of phages adsorb to the bacterial cell envelope, causing multiple 
penetrations and cell-wall damage44. Even only minimal damage to the cellular wall will result 
in cellular lysis45,46. 
 
1.4 Temperate phages  
 
Temperate phages can either act as lytic phages and kill their host upon infection, or form a 
stable relationship with their host by either integrating into the host chromosome or by forming 
a replicative plasmid47–50. If they form a plasmid they become prophages and replicate together 
with the bacterial genome upon cell division, a process referred to as the lysogenic cycle51. 
This lysogenic cycle allows phage reproduction without host death. In the lysogenic phage life 
cycle the attachment and DNA injection steps are the same as for the lytic phages51. However, 
once the DNA has been injected into the host cell, gene transcription and DNA replication does 
not happen immediately52. Instead the phages undergo a recombination event with an insertion 
site in their host genomes, allowing them to be integrated into the host genome52. This allows 
them to replicate alongside the host for multiple generations, co-existing with instead of lysing 
the host29. This phenomenon is termed ‘polylysogeny’, only happens in heteroimmune phages, 
which is a characteristic of two temperate phages where a prophage of one type fails to show 
immunity against the second time53. These phages can undergo polylysogeny because they are 
different enough and do not display immunity against each other. In contrast, homoimmune 
phages, show immunity against each other’s’ prophages and thus cannot undergo polylysogeny 
ensuring only one phage copy per one host cell, with some exceptions. 
It has been shown that two Stx phages with identical immunity patterns, φE85539-Stx21 and 
φE85539-Stx22, were isolated from the same strain, indicating the homoimmunity rule 
described above is not always the case54.When two phages have different immunity profiles, 
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they are referred to as heteroimmunity phage groups. Two temperate phages that present 
heteroimmunity to each other are able to have lytic and lysogenic cycles that are independent 
and do not interfere with each other’s repressors55,56. Heteroimmunity could potentially lead to 





In addition to lytic and lysogenic phage life cycles, pseudolysogeny has been proposed as a 
third potential path of phage development57–60. Although the genetic mechanism of this phage-
host interaction has not been characterised, it has been seen and defined experimentally61,62.  
Pseudolysogeny is a carrier state, in which a ‘lytic’ phage is able to remain inside the bacterial 
cell until cell conditions are suitable for the phage to enter the lytic infection cycle. It is a state 
where the phage remains in the host cell without undergoing replication by lysing its host, 
integrating into the host genome or forming a replicative plasmid63. This phage state is caused 
by unfavourable growth conditions, or stress caused to the host bacterium64. Although difficult 
to study, this was determined after carrying out experiments in Pseudomonas aeruginosa 
strains, where F116 and UT1 phage-postponed lysis was observed under nutrient deficient 
conditions, followed by addition of nutrients that resulted in immediate cell lysis and phage 
production64,65. Furthermore, pseudolysogeny was identified in other systems including phages 
infecting Escherichia coli (E. coli) and cyanobacteria58,66. In the previous work it was 
demonstrated that E. coli-infecting phage T4 was able to form pseudolysogens when exposed 
to low nutrient levels58. Another study suggested that obligately lytic Synechococcus phage S-
PM2 when used to infect Synechococcus sp. WH7803 in phosphate-depleted media resulted in a 
80% reduction in burst size and hence the potential formation of pseudolysogens66.  
 
1.6 Phage therapy as an alternative to antibiotics 
 
Even though phage therapy has only recently received a lot of attention as a possible treatment 
for multidrug-resistant pathogens, its potential was initially discovered over a century ago4,67.  
Frederick Twort was the first to describe and characterise the signature zones of lysis of phage 
infection in 191567. However, Felix d’Herelle identified the actual source of this observation 
and associated it to bacterial viruses, called them “bacteriophage” (literally “bacteria-eater”)67. 
He was also the first to notice the potential of phage to be used to treat bacterial infections, and 
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successfully used phage to treat four paediatric cases of bacterial dysentery67. Even though the 
scientific community condemned Felix d’Herelle`s work and results due to them being poorly 
carried out, he continued to pioneer phage therapy with treatment of the bubonic plague, 
dysentery and cholera68,5. One of his clinical trials involved treatment of cholera in the Punjab 
region of India. The study, consisting of 73 treatment subjects and 118 control subjects, showed 
that treating patients using phage therapy resulted in a 90% reduction in mortality67. 
 
Recent studies have examined the potential of phage to be used against a range of clinical 
pathogens. One such study examined ileocecitis caused by Clostridium difficile (C. difficile) in 
mice, in which the pathogen and a dose of phage were administrated at the same time, 
preventing the initiation of the disease69. In addition, when a phage was administered post 
infection with the pathogen only 1 mouse died out of 12, while all 12 mice that were only 
administered the antibiotic clindamycin died within 96 hours69. Bacteremia models have been 
used to show that intraperitoneal application of phage was enough to generate 100% 
Enterococcus faecium (E. faecium) and P. aeruginosa infection free mice70,71.   In addition to 
using single phage for treatment in animal models, phage cocktails have been used for 
antibiotic-resistant P. aeruginosa infections present in multiple organs including intestines, 
skin and lungs72,73. 
 
Over the last century, phage therapy has been applied to humans in a few institutes, including 
the Institute of Immunology and Experimental Therapy in Wroclaw, Poland and the Eliava 
Institute of Bacteriophage in Tbilisi, Georgia74,75. The Institute of Immunology and 
Experimental Therapy in Wroclaw, Poland has a vast range of phages at their disposal76–78. The 
institute continuously isolates new phages to expand its collection78. They followed 550 of 
their patients throughout 1981–1986 and reported cure rates ranging from 75 to 100% 
depending on infection type79–83. 
 
There have been multiple attempts to classify phage-based treatment within EU framework84–
87. The current agreement among the European Medicines Agency is to monitor phage-based 
therapeutics as biological medicinal products88. One of the key issues for phages is the 
indecision as to whether phage therapy medicinal products (PTMPs) require patenting and 
marketing authorisation89. Since phage cocktails would potentially be customised, the PTMPs 
are placed somewhere between industrially made medicinal products and magistral formulas. 
This classification uncertainty is due to a contradiction within the specifics of the treatment89. 
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A phage cocktail and its constituent parts would be tailored towards each individual patient, 
while at the same time each of the active ingredients would have to fulfil the characteristics of 
an industrial process in compliance with the Good Manufacturing Practices (GMP) 
requirements89. Even though phage therapy has not been accepted as a licensed drug, EU 
legislation as well as the USA Food and Drug Administration (FDA), allows their use as a 
compassionate, last resort medicine89,90. 
 
The Eliava Institute has an extensive collection of phages that work against most common 
bacterial pathogens including P. aeruginosa, S. aureus, E. coli as well as species of Proteus, 
Salmonella, Enterococcus, Streptococcus91. The phages collected are mainly used for 
prophylactic and therapeutic applications, including treatment of gastroenterological issues and 
post-surgical infections91. In six cases antibiotic-unresponsive diabetic foot ulcers were 
successfully treated using pathogen specific, topically applied phage92. Recently phage therapy 
has been used as a last resort medicine in Belgium as well as the USA93–95. In one instance, a 
2-year old experiencing multidrug-resistant Pseudomonas aeruginosa infection with 
bacteremia was treated using a two phage cocktail that resulted in clearing of bacteremia94. 
Currently no licensed products are approved for human treatment either in the United States or 
Europe. However, this is not the case when it comes to the food industry. There are multiple 
commercial phage products against meticillin-resistant Staphylococcus aureus (MRSA), 
Listeria monocytogenes, E. coli O157:H7, Mycobacterium tuberculosis, Salmonella spp, that 
have been approved by the FDA96–99. The use of naturally occurring phages for use in the food 






1.7 Bacteriophage Host Range  
 
A phage’s ‘host range’ consists of the pathogens which a  phage is able to infect101. Phage host 
range determination can be difficult due to the fact that measured host ranges rely on the 
technique used101. It has been stated that “host range is often, but not always, determined by 
success or failure of adsorption” but for phage therapy, host cell lysis rather than phage 
adsorption to the host plays a key role in host range determination101,102. Phage host range can 
be limited to a specific species of bacteria101. However, there are multiple examples where 
phages evolved to expand their host range within a species and to a different species by binding 
to a new host receptor or overcoming restriction immunity (see section 1.23)103–105. Moreover, 
there are phages that can even adapt to infect new genera106,107. Phage binding specificity to its 
host comes from the phage receptor binding domain (RBD) of its tail fiber protein or receptor 
binding protein (RBP)108. The interaction between RBP and its bacterial cell surface receptor 
is one of the key parameters that determine phage infection kinetics109. While host specificity 
might be useful in certain scenarios, a broader host range may be desired in a clinical setting. 
This is one of the reasons why the use of broad-spectrum antibiotics was preferred to that of 
specific host targeting phage therapeutics in the early 1940s110. To overcome the narrow host 
range of some phages, cocktails containing several phages have been used to provide 
pharmacologically diverse formulations111.  
 
Both phage and their hosts undergo selective pressure, where cells evolve resistance to phage 
infection and phage adapt to overcome this, in a continuous arms race known as the red queen 
principle112. There are multiple ways which can be employed by a phage to expand its host 
range113. Point mutations in the phage tail fiber gene is one example of host range expansion114. 
This has been seen experimentally in tail fiber mutant T7 variants which were shown to infect 
LPS mutant E. coli strains that were immune to the wild type T7114. Another possibility is one 
phage obtaining a fragment of a tail fiber gene from another phage, allowing phage host 
expansion between unrelated phages. This has been observed in such as phages P2, Mu and 
P1115. Furthermore, phage host range can be expanded by picking up a piece of genetic debris 
that remained in the host chromosome from another bacteriophage, as demonstrated by T2 and 
K3 phages116. Phages may also be able to recognize multiple receptors via the same tail fiber. 
For instance, the T4 phage can recognize both the outer membrane protein OmpC and the 
lipopolysaccharide as a receptor117. In some instances phages may have two adsorption 
systems, allowing different receptor recognition118. One such example is phage T5. The T5 
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RBP, pb5, binds to the E. coli outer membrane protein FhuA119–121. T5 also has an additional 
adsorption apparatus via three long shaped fibers (LTFs), formed by Pb1 protein121. It has been 
shown that LTFs bind to the bacterial lipopolysaccharide (LPS) O-antigen, providing an 
additional binding site for the T5 phage122,123.  
 
In some instances, phages are able to adapt their RBP when their host receptor changes. An 
example system is that of the temperate bacteriophage, BPP1, infecting Bordetella 
bronchiseptica124. In this system, BPP1 changes its tropism by genetically altering the DNA 
sequence of its host receptor-binding protein, referred to as the major tropism determinant 
(Mtd)125. BPP1 needs to be able to variate the Mtd sequence to adapt to the Bordetella surface 
variation, which is regulated by BvgAS phosphorelay pathway responsible for the infectious 
cycle126–128. BPP1 encodes a unique diversity-generating system that allows for Mtd sequence 
variation and hence attachment to different host receptor molecules that are displayed 
throughout Bordetella infectious cycle124,129. The Bordetella surface receptor profile depends 
on its infection phase, therefore phage BPP1 adapts to Bordetella surface receptor change by 
varying the Mtd sequene125. Mtd sequence variation is possible due to transcription followed 
by reverse transcription and integration with site-directed, adenine-specific mutagenesis124,130. 
Chapter 4 will provide further details on BPP1 phage versatility. 
 
1.8 Advantages of phage use for therapy over antibiotics 
 
Some but not all antibiotics are bacteriostatic agents (e.g. tetracycline), that prevent bacteria 
from replication without necessarily inducing bacterial death131–133. The stunted microbes are 
more likely to evolve resistance towards the drug131–133. In contrast, phages are bactericidal 
agents which cause bacterial death, reducing the potential for evolution of resistance132. In 
addition to their bactericidal properties, phages are able to replicate at the site of infection. This 
allows single, instead of multiple, dosages when there is a greater amount of pathogen than 
expected at the site of infection. The phage ability to amplify sufficiently depending on the 
bacteria present is termed as ‘auto dosing’51,53,134,135. Furthermore, phages are made up mainly 
of proteins and nucleic acids and hence they are inherently nontoxic136,137. Other phage 
advantages include their rapid discovery and potential for biofilm clearance138–143. In the case 
of  their rapid discovery, phages are widely distributed in soil, sewage, water and animal 
organisms, therefore their abundance contributes towards quick and efficient isolation144–146. 
Furthermore, experimental studies have also identified that phages may both prevent biofilm 
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and aid eradication of biofilm forming bacteria147. In particular, phage depolymerases facilitate 
the degradation of extracellular polymeric substances (EPS), enabling phage penetration to 




1.9 Disadvantages of phage use for therapy as compared to antibiotics 
 
Lytic phages are preferred over temperate phages for phage therapy, due to temperate phages’ 
association with  bacterial virulence factors and toxins genes148. In addition, establishment of 
lysogeny may cause the pathogen to become immune to infection by other phages148.  One of 
the current disadvantages of using phages for therapeutic purposes is the lack of understanding 
of the pharmokinetics and pharmacodynamics of phages in the human body149. This includes 
both phage interactions with tissues and organs as well as interactions with the body’s 
microbial flora150. Moreover, it has been suggested that phage application will eventually result 
in the evolution of phage resistance, in a similar manner as has occurred for antibiotics151,152. 
This could happen due to multiple bacterial defence strategies that include receptor mutations, 
restriction modification (R/M) systems in particular DISARM, abortive infection systems that 
trigger cell death or metabolic inactivation upon infection (toxin-antitoxin system) and 
acquired immunity (CRISPR)152–158.  
Another disadvantage of phages is the presence of lipopolysaccharide (LPS, endotoxin, 
pyrogen) in their crude lysates produced in Gram-negative bacteria159. The presence of LPS 
and endotoxins can cause innate immunity response, as they act as an ‘alarm molecule’ 
indicating the invasion of Gram-negative bacteria160–162. To counter act this multiple methods 
have been developed for pyrogen removal from phage lysates162,163. As a consequence, highly 
purified phages can be prepared to elucidate anaphylactic responses from pyrogens such as 
endotoxins and LPS that are found in unpetrified phage lysates135,136,164,165.  
Another two disadvantages, narrow host range and lack of tissue specificity will be discussed 
in more detail in the next two subsections. 
 
1.10 Phage host range disadvantage over antibiotics 
 
The narrowness of a phage host range (a few strains or single species) may limit the pace at 
which the treatment can be applied, as suitable phage has to be found to target the bacteria 
causing infection, prior to phage administration101. This is often combated by combining 
multiple phages, generating phage ‘cocktails’, that have broader host range than single phages 
and at the same time are more selective when compared ‘narrow-spectrum’ antibiotics166,167. 
This on the other hand could also be viewed as an advantage when it comes to preserving the 
good bacteria found in body as the phage administered would only target the bacteria of 
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interest133. In addition, having a phage cocktail reduces bacterial resistance due to an increased 
number of mutations required to achieve this 168,169 . When bacterial resistances were compared 
after single versus phage cocktail, it was found up to 43% resistance for the single phage treated 
bacterial strains and 24% resistance for the cocktail treated strains168.  
 
1.11 Phage penetration into the bloodstream and organs 
 
Multiple studies have shown that intravenous administration of phages results in the rapid 
distribution of phage into the blood stream and spread throughout the organism170,171. However, 
phage localisation in various organs, including kidney, lungs and brain, tends to be 
approximately 100-fold lower when compared to the blood after 3 hours of intravenous therapy 
administration170,171. Furthermore, after 12 hours of administrations, no phages can be detected 
in the blood, kidney, brain lung, however phage particles can still be recovered from liver, 
intestines and in significantly higher amounts from spleen172. When administered orally, it was 
found 103 PFU/ml of phage are excreted in the faeces for mice as well as human volunteers, 
implying that phage can cross the acid stomach barrier173,174. The phage clearance is facilitated 
by the immune system as it triggers an immunogenic response (see section 1.11)175–178. Greater 
understanding of phage host interactions while in the human body is required to precisely 
determine the effective phage concentration at a site of infection i.e. organ or a tissue site. In 
the recent studies, a precise number for phage concentration has been deduced for the minimum 
phage concentration required to prevent bacterial culture from spreading179,153,180. The required 
concentration for mildly growing bacterial infections  is  ³ 107 phages/ml, however, more 
actively growing infection may need higher phage concentrations180. In order to clear bacteria 
completely concentrations ³ 108 phages/ml are required180. Therefore, phages would need to 
be applied directly to the target tissue or alternatively ways of localising them in specific tissues 
and organs are required181. The human lung is exposed to airborne pathogens on the regular 
basis which can lead to a formation of chronic and severe infections in the airways182. In 
addition, the human lung causing infections were identified to commonly develop resistance 
to their common treatments183. In chapter 7, the lung epithelial cells were chosen as a case 
study to identify if phage engineering can be used to increase effective phage concentration at 




1.12 Phage Immunogenicity  
 
There is increasing evidence that while in the blood, phages cause an immune response175–178.  
Immunogenicity of phages has been exploited for the evaluation of humoral (associated with 
the body fluids) immunity in diagnosing and observing patients suffering from 
immunodeficiencies176,184. Phage ΦX174 is able to trigger different levels of humoral response 
after intravenous injection to patients184. The use of ΦX174 is accepted as one of the standard 
antigens for humoral immunity determination185. It has been showed that antibodies pre-
existing in animal serum are able to recognise phages causing initiation of complement 
activation186. It has been showed that complement binding can be overcome by modifying 
phage T7 capsids with carboxy-terminal arginine or lysine186. The amino acid residue 
substitution protects T7 against C-reactive protein binding and hence phage inactivation via 
complement mediation in rats186. In a further study E. coli phage l and Sa. tyhpimurium phage 
P22 were examined in germ-free mice187. A single mutation resulting in the substitution of 
lysine with glutamic acid, yielded long-circulating phage phenotypes for both phages187. A 
short-circulating phage phenomenon has been described for phage T4, whereby the loss of  
nonessential capsid protein Hoc results in the removal from a mouse circulatory system faster 
than the wild type188. It was suggested that some phage proteins are able to regulate interaction 
with the immune system188,189. In further studies the blood plasma clearance time for phage 
M13 was also examined190. It was determined that conjugation of either succinic acid or 





1.13 The release of bacteriophage progeny 
 
There are two known strategies of bacteriophage release from their host. The first one consists of 
filamentous phages (e.g., MI3, fd) that evolved a mechanism allowing phage production without 
killing the bacterial cells191. In this instance, instead of phage particles forming in the cytoplasm, 
they are constantly removed by secretion across the host membranes as soon as they are 
assembled192,193. All phage structural proteins are mobilised in the host inner membrane before 
they are assimilated into phage particles192,194.The second strategy achieves progeny release while 
damaging the host membrane and cell wall eventually causing host lysis, killing the bacterial host43. 
This second strategy is employed by non-filamentous phages. The disruption of the bacterial cell 
wall can come in two forms, inhibition of the peptidoglycan synthesis (small ssDNA or RNA 
phages) or cleavage of peptidoglycan by a holin-lysin system (large dsDNA phages)195. Holins and 
lysins (lysins) are phage proteins that are expressed during the late phase of gene expression195. 
The two protein system operates by the holin forming breaks that allow the lysin to reach and cut 
peptidoglycan195,196. Phage l, in particular, was used to study holin-lysin interactions. Upon its 
infection, phage l can be induced to allow a timed lysis event195. Both holin (S) and lysin (R) 
genes, are located at the start of the late transcriptional region, which is normally activated eight 
minutes into the infection cycle195. The active lysin concentrates in the cytosol until the holin forms 
a membrane abrasion allowing the lysin to access the peptidoglycan while crossing the cytoplasmic 
membrane (Figure 1-2)195. In Figure 1-2, the fate of the fate of Gram-negative bacterium envelope 
during holin-endolysin lysis is described. Prior to hole formation lysins concentrate in the cytosol 
whereas holins tend to aggregate in membrane in clusters. This is then followed by holin forming 
a membrane break allowing lysin to attack the murein. One of the traits of the holin based systems 
is their dependency on the energized membrane; addition of an energy providing substance triggers 
induction of an early lysis43,197. The data available indicates that any holin will work with any lysin 
when holin-lysin pair is made from any Gram-positive and Gram-negative bacteria198. 
Furthermore, it has been shown that if applied externally, the lysins are capable of degrading 
peptidoglycan layer causing lysis of Gram-positive bacteria due to their ability to make a direct 







Figure 1-2. Gram-negative bacterium envelope fate during holin-endolysin lysis. The envelope is made up of 
inner (IM) and (OM) membranes, murein, that is attached to the OM via oligopeptide (OP), lipoprotein (LLP) and 
lipid chain. (A) Prior to hole formation. Lysins (notched white circles) concentrate in the cytosol whereas holins 
(white ovals) aggregate in membrane in clusters. (B) Hole formation. Membrane break is formed by holin 
facilitating lysin escape allowing them to attack the murein. The image was adopted from a previous study195. 
A B 
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1.14 Bacteriophage T4 
 
Bacteriophage T4 is a member of the Myoviridae family of the order Caudovirales due to its 
contractile tail and can infect only E. coli, closely related Shigella species as well as a non-
enterobacterial vibrio species and Yersinia202–206. The main T4 receptor is the outer membrane 
lipopolysaccharide (LPS)207. The T4 genome is made up of 168 kbp and it contains 289 open 
reading frames202. T4 main structural features are the capsid, tail, baseplate, LTFs and STFs208. 
The mature phage has a 115 nm long and 85 nm wide head that encages the DNA208.The T4 
contractile tail is 92.5 nm long and 24 nm wide and is attached to a portal vertex located at the 
end of the head. The distal end of the tail is attached to a 27 nm height and 52 nm width 
hexagonal baseplate208. Six LTFs that recognise host receptors are attached to the baseplate208, 
with six STFs located underneath the baseplate208. The capsid is made up of 155 hexamers of 
the major protein, gene product 23209,210. At its surface the capsid also possesses two accessory 
proteins, Hoc (highly antigenic outer capsid protein) and Soc (small outer capsid protein)211. A 
cascade of transcriptional events is started by T4 infection of E. coli via LPS212. Firstly, the T4 
early genes are transcribed post infection using the host RNA polymerase202. Since the early 
genes’ promoters have good matches for σ70 sequences, they do not need T4-encoded 
transcription factors213. In the case of middle T4 promoters, they require two transcriptional 
activators obtained from the early transcription:  MotA and AsiA214–216. Furthermore, the late 
T4 promoters require T4 sigma factor, Gp55, in addition to other T4 specific activators and 
coactivators212. The induction of T4 DNA replication within infected E. coli is incredibly 
complex as it consists of the numerous circularly permuted linear copies of the phage genome 
that show as concatamers, during the middle and late steps of infection, launching the strand 
synthesis217. The T4 replisome has two parts, the DNA replicase as well as primosome. The 
DNA replicase consists of a phage encoded DNA polymerase (Gp43), the gene 32 encoded 
single-stranded DNA binding protein (Gp32), the genes 44 and 62 encoded ATP-dependent 
clamp loader complex (Gp44, Gp62) and the gene 45 sliding clamp (Gp45)218. ATP-dependent 
clamp loader complex (Gp44 and Gp62) make up an accessory protein that is necessary for 
gp45 loading onto DNA219. The Gp32 facilitates the unwinding of DNA whereas Gp43 DNA 
polymerase lengthen the primer of the invading strand into the next genome220. At the start of 
the elongation process consists of replication of the leading strand template where the Gp43 
can repeatedly process a daughter strand. The primosome initiates the lagging strand sectional 
synthesis of Okazaki fragments218. The T4 replication complex is made up of the Gp61 primase 
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and Gp41 helicase, homohexamere that encompasses the lagging strand and process it in the 





Figure 1-3. The above schematics represents the distribution of early, middle and late promoter transcription, as 
well as links the T4 transcriptional pattern with different mechanisms of DNA replication and recombination. The 
top part of the diagram presents the transcripts started from early, middle, and late promoters by host RNA 
polymerase. In some instances, hairpins in multiple early and middle transcripts inhibit the translation of the late 
genes. The bottom part of the diagram represents the pathways of DNA replication and recombination. The image 
was taken from the previous work by Miller et al. 2003. 
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1.15 Bacteriophage T7  
 
Bacteriophage T7 is a member of the Podoviridae family and can infect  Escherichia coli, 
Shigella, Salmonella, and selected T7 mutants can infect Yersinia pestis223. Phage T7 is double-
stranded DNA (dsDNA) virus that has 39,937 bp long genome encoding for 56 genes223. Its 
main structural features consist of a 60 nm icosahedral capsid and a short tail (32 nm in length) 
224,223,225. The infection and replication cycle of phage T7 has been widely studied and is well 
characterised226,227. The first step of this process is adsorption and infection initiation228–230. 
Adsorption occurs when the tail fiber interacts with the outer membrane lipopolysaccharide 
(LPS)223. The binding is followed by the inner core injection from the capsid into the outer 
membrane periplasm, where it most likely degrades the peptidoglycan and forms a stable 
channel for DNA translocation223. About ~850 bp of the genome is thought to be ejected into 
the cell allowing the initiation of transcription by E. coli RNA polymerase that recognises the 
three early promoters A1, A2, and A3 that are located at the start of the genome230. The rest of 
the phage genome is pulled in by transcription of the T7 genome by the endogenous 
polymerases230. Gradual entry into the bacterial cell facilitates a form of gene regulation223. T7 
possesses essential as well as non-essential genes that have been identified by making 
mutations at different locations in T7 genome231. The T7 gene transcriptome divides T7 genes 
into three classes223. The earliest genes transcribed, within the first 8 min, are referred to as 
Class I genes and are located at the start of the genome232. Class I genes constitute 9 genes, 
from gene 0.3 to 1.3231,233. The two most important genes are gene 0.7 and gene 1234,235. The 
product of gene 0.7 inactivates transcription of multiple host genes as well inhibits host 
proteins, including RNAse III and E, and E. coli polymerase subunits234. Gene 1 encodes T7 
RNA polymerase that transcribes T7 class II and class III genes from T7 promoters235–237. Class 
II genes are transcribed at around 6 to 15 minutes after the initial transcription and mainly those 
genes that are required for T7 DNA replication223. One of the Class II genes is g2 which is 
responsible for E. coli RNA polymerase inhibition238. g2 expression results in the inhibition of 
transcription of the Class I genes as they are under control of host polymerase238. g5 encodes 
for T7 DNA polymerase that replicates the T7 genome once it forms a complex with a E. coli 
host factor, (trxA)239–241. T7 Class III genes encode for proteins involved in DNA packaging, 
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Figure 1-4. Representation of three classes of gene expression of bacteriophage T7. Class I consists of early, class 
II consists of middle and class III consists of late transcription genes. Class I generates host-virus interaction 
transcripts as well as RNA polymerase. Class II generates transcripts required for DNA replication, including 
DNA polymerase (g5). Class III generates transcripts required for virus structure and assembly including major 
and minor capsid proteins (g10), as well as host cell lysis proteins.  
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1.16 Phage T7 tail machinery  
 
The T7 tail machinery is made up of the following proteins, Gp7.3 Gp8, Gp11, Gp12, and 
Gp17 (Figure 1-3)247. The most characterisation data has been gathered for Gp8 that assembles 
into a dodecamer and Gp17 that assembles into trimers forming the T7 tail fibers244,248,249. Gp11 
and Gp12 assemble into the core structure of the tail247. The precise role of Gp7.3 remains 
unclear although it has been proposed that 32 subunits of this protein have role in the tail 



















1.17 Phage T7 DNA replication  
 
The T7 replisome is formed of Gp4, Gp5, Gp2.5 and TrxA proteins251,252. First, the helicase 
domain of Gp4 unwinds double stranded DNA (dsDNA) resulting in single stranded DNA 
(ssDNA) that serves as a template for Gp5, DNA polymerase227. Gp5 forms a complex with its 
processivity factor TrxA (provided by the host bacteria) which then allows the leading DNA 
strand synthesis227. The lagging DNA strand is synthesised in fragments that are then processed 
to form a continuous strand227. The primase domain of Gp4 initiates the Okazaki fragments, 
Figure 1-5. Schematic diagram of the T7 virion. The image was adapted from a previous study by 
Serwer et al. 2008. The outer shell is made up of Gp10A and B. The internal tapered cylinder (that is 
made up of Gp6.7, 14, 15 and 16) and tail (Gp7.3, 11, 12) are shown attached to the outer shell by a 
connector (Gp8). Tail fibers, that are trimers of Gp17, are attached to the tail.  
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while Gp2.5, ssDNA binding protein protects ssDNA generated during replication as well as 




Thioredoxin is a 12-kDa redox-active protein expressed in various bacteria and mammals254–
256. In the case of E. coli, it is a nonessential gene referred as trxA254–256. TrxA contains a 
universally conserved dithiol active site, as well as NADPH, flavoprotein and thioredoxin 
reductase (TrxR), TrxA serves as one of the main antioxidant systems in the cell254–257.While 
being a non-essential protein in E. coli, TrxA is essential for the replication of T7, as it acts as 
a co-enzyme for T7 DNA polymerase (Gp5)114,258. TrxA binds to DNA polymerase via a 
thioredoxin binding domain (TBD) which is a loop of 76 flexible amino acids (See Figure 1-
4)259. The interface between Gp5 and TrxA occurs at Cys-275 and Cys-313 of the TBD and 













Figure 1-6. Structure of Gp5/TrxA complex on DNA. DNA, Gp5 and TrxA are presented in cyan, blue and grey 
respectively. Gp5 has three domains: palm, finger and thumb. TrxA is bound to Gp5 at a flexible loop of 76 amino 
acids long referred as TBD (shown in orange). The interference between TBD and TrxA occurs at TBD and TrxA 







1.19 Phage T7 DNA polymerase processivity  
 
TrxA binds to the thioredoxin binding domain on Gp5, in a 1:1 ratio, resulting in 20-80 fold 
greater DNA polymerase processivity due to reorganisation of Gp5 that allows it to better bind 
DNA257,260–262. It has been shown that upon TrxA binding to Gp5 a closed Gp5 confirmation is 
formed that results in greater Gp5 resistance to salt concentration changes in the environment  
as well as facilitation of more efficient Gp5 processing of the DNA strand239. The TrxA and 
Gp5 complex prevents from constant Gp5 dissociation from phage DNA stabilising Gp5 
attachment to the DNA239. 
 
1.20 Lysins  
 
Lysins, also called phage endolysins, are peptidoglycan hydrolases (PGHs) that are used by 
most phages to degrade peptidoglycan from within the cell263. Lysins fall into four main groups 
according to their mode of action against different covalent linkages present in the bacterial 
cell wall195. The four groups are amidase, endopeptidase (both target the oligopeptide cross-
linkages), glycosylase and transglycosylase activities (both target the glycosidic linkages)195. 
It has been shown that lysins have no signal sequence and as a consequence tend to concentrate 
in bacterial cytosol during infection195. Due to the ability of lysins to disrupt the peptidoglycan 
layer in a very specific manner, lysins are treated as a novel class of antibacterial agents with 
a potential for pathogen killing circumventing effects on non-target species present in our 
microflora200. 
 
1.21 Lysin structure and the mechanism of action  
 
The lysins that target Gram-positive and Gram-negative bacteria have distinguishing features due 
to the very different structure of these two bacterial groups264. Lysins targeting Gram-positive 
bacteria have two different types of functional domains that are called cell wall binding domains 
(CBDs) and enzymatically active domains (EADs)201,265,266. The EAD cleaves specific bonds of 
the bacterial peptidoglycan, whereas CBD facilitates the protein to substrate binding as well as 
tight binding to the cell wall267. In comparison, lysins targeting Gram-negative bacteria are 
generally small single-domain globular proteins and normally do not contain a CBD module268,269. 
Both Gram-positive and Gram-negative targeting lysins are not limited to two functional domains, 
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different domain combinations and orientations have been identified270. One of the examples is 
staphylococcal lysins that frequently have two N-terminal EADs and one C-terminal CBD271,272. 
 
Lysins consist of two domains—a peptidoglycan hydrolase activity is commonly located at the 
N terminus and can consist of one or more of a variety of glycosidases, amidases, or peptidases, 
while the lysin’s specificity is achieved by a cell wall binding domain that recognizes cell 
surface features that are specific to the bacteria that it targets273. 
 
1.22 Lysins as antimicrobials  
Phage lysins target genus or species-specific bacteria, thus are advantageous over current 
broad-spectrum antibiotics. Due to the fact that phages coevolved with their hosts, it is most 
likely that lysins adapted as well by binding and cleaving conserved cell wall targets 
circumventing a possibility of bacterial resistance, that would require a fundamental change in 
cell wall structure201. In general, the development of resistance against lysins has not been 
identified274–276. However, several studies suggested that intracellular resistance mechanisms 
including active efflux of compounds from cytosol as well as reduction in membrane 
permeability are employed to circumvent the action of lysins277,278. There are multiple 
examples where lysins have been employed as antimicrobials. In the first instance two 
pneumococcal phage lysins, differing in their target cleavage site, were examined in vitro 
against several serotypes of Streptococcus pneumoniae, including penicillin-resistant 
strains279. This resulted in synergistic cleavage of the bacterial strains with a potential for the 
prevention and elimination of pneumococcal colonization and infection. The Cpl-1 lysin was 
then introduced intravenously to already pneumococci bacteremic mice that resulted in 100% 
survival after 48 hours compared to 20% survival of the control animals280. It was also verified 
that despite lysins being immunogenic proteins, the efficacy of the Cpl-1 lysin against 
pneumococci colonised mice was not significantly altered due to previous intravenous 
exposure and antibody production280. In another study, the lysin PlyG which active against B. 
anthracis and other members of the B. anthracis cluster of B. cereus was identified281. 
Multiple rounds of PlyG exposure to the B. anthracis did not cause bacterial resistance 
suggesting that its peptidoglycan catalytic target cannot be easily altered by the bacterium 
to interfere with PlyG action281. PlyGBS is a recombinant streptococcal lysin that was shown 
to lyse group A, B, C, G and L streptococci282. It was originally developed for Group B 
streptococcal (GBS) vaginal colonization in pregnant women prophylactics with an intention 
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to reduce the rate of neonatal meningitis and sepsis in new-borns282. PlyGBS was used in mice 
models where a single dose of PlyGBS reduced cell titer by 1000-fold282. In another study lysin 
LysK from staphylococcal phage K showed activity against nine species of Staphylococcus 
strains, including vancomycin resistant Staphylococcus aureus (VRSA) and MRSA, isolated 
from both human and bovine sources283–285. Further lysin activities against target strains were 
identified, such as staphylococcal lysin LysH5 against S. aureus growing in milk, and Phi11 
against mastitis-causing Coagulase-negative Staphylococcus286,287. 
1.23 Safety & Immunogenicity  
 
Due to the proteinaceous nature of lysins they are biodegradable and noncorrosive288. Once 
systematically administered in animals they may cause a release of post lysis bacterial cellular 
debris such as lipoteichoic and teichoic acids, that may result in  septic shock289.  It has been 
showed there is an increase of proinflammatory cytokine concentrations in rats after a 
continuous treatment with Cpl-1 (a pneumococcal lysin)290. However, in another study the 
opposite effect was observed when applying the same enzyme every 12 hours291. This 
difference was explained by the fact that the continuous administration causes a greater 
generation of cellular debris leading to an increased immune response201.  
Several studies have shown that the antibodies can be potentially raised against lysins201. 
However, in animal models antibodies did not inactivate administered lysins and no side effects 
such as anaphylaxis were observed292,293. It has been reasoned that these findings are due to 





1.24 CRISPR/Cas Systems  
The abundant nature of bacteriophages has forced bacteria to develop a variety of target 
mechanisms to prevent phage infection, which target different steps of the phage life cycle295–
298. Bacterial interference inhibits phage adsorption, its DNA injection as well as abortive 
infection296,299,300. It has been shown that one of bacterial defence mechanisms is an adaptive 
microbial immune system, consisting of clustered regularly interspaced short palindromic 
repeats (CRISPR), that provides an acquired defence against viruses and plasmids301. CRISPR 
is a family of DNA repeats whilst discovered in Escherichia coli in 1987, it was not formally 
described until 2000s after identification in different bacterial as well as archaeal 
genomes302,303. CRISPR loci are made up from multiple non-contiguous direct repeats that are 
disjointed by stretches of variable sequences, often referred as spacers304. Spacers represent 
fragments of integrated viral and plasmid sequences. Both direct repeats and spacers are 
positioned next to cas genes (CRISPR-associated)304. CRISPR together with Cas proteins make 
up the CRISPR/Cas systems. Six main cas genes have been determined305–307. CRISPR direct 
repeats are highly conserved for a particular organism, however, it varies across different 
bacterial species and their sequence range between 23 to 47 base pairs bp301,303,308.  The 
CRISPR spacer regions are hypervariable, even between related strains and their sequence 
range between 21 to 72 bp301,309–311. 
 
In a nut shell CRISPR/Cas functions in the following way. Firstly, once the genetic invader 
enters the bacterial cell, a fragment of its DNA sequence (called protospacer or precursor, 
spacer) is integrated in the CRISPR loci as a spacer sequence (see Figure 1-5)298. The frequency 
of spacer acquisition in bacterial population may be affected by a variety of environmental and 
other factors including quorum sensing, certain catalytic enzymes (encoding adenylate 
cyclase)312–315. A promoter found in the leader sequence, transcribes the repeat-spacer region 
into CRISPR RNA (pre-crRNA) molecule (see Figure 1-5). The pre-crRNA is the processed 
by multiple maturation events that yield singular mature crRNAs composed by a fragment of 
a repeat and spacer regions. These crRNAs operate as guide RNAs that recruit and direct Cas 
proteins that help cleave target sequences (see Figure 1-5). More details about two specific 






























Genetic engineering has exploited CRISPR/Cas systems for specific targeting and removal of 
desired genetic elements, including harmful genes and antibiotic resistance markers301. As well 
as acting as an immunity system, CRISPR/Cas targeting RNA may affect the transcript stability 
of chromosomal elements (Figure 1-6)301.  
 
Recent research has brought more in depth understanding about CRISPR/Cas mechanism and 
origin, however, multiple aspects are yet to be uncovered such as the pathway involved in 




Figure 1-7. Summary of CRISPR/Cas immunity to viruses of bacteria and archaea. (A) Initially, phage infection is 
identified by Cas proteins and a short sequence of phage DNA (spacer) is incorporated at the end of the CRISPR array, 
that generates a new spacer sequence and a duplicated repeat. The cas operon encoding all Cas proteins is shown. It is 
located closely to the CRISPR array that is comprised of the leader sequence followed a multiple repeat/spacer units. 
(B) After the initial infection CRISPR array is transcribed from a promoter within the leader sequence generating a 
precursor CRISPR RNA (pre-crRNA) transcript. The pre-crRNA transcript is then processed into individual crRNAs. 
(C)  The mature crRNAs target DNA sequence that is complementary to the spacer sequence in the crRNAs. In some 
instances, a Cas nuclease (represented in orange oval) is employed to interfere and aid in destruction of the target 























Figure 1-8. Summary of CRISPR interference. The CRISPR/Cas systems target can target DNA sequences 
impeding particular nucleic acid sequences (such as plasmid DNA or phage). This can be adapted to target 
genes of interest via genetic engineering. The CRISPR/Cas can also target RNA sequences which in turn can 
affect the transcript	stability	of	chromosomal	elements.	The image has been adapted from the previous study by 
Horvath & Barrangou, 2010. 
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1.25 Aims and Objectives 
Given the advances in biotechnology, diagnostics, molecular biology and synthetic biology 
wild type phage limitations can be addressed using genome manipulations bringing phage 
therapeutics closer to the clinical setting. The aims of this study concern first establishing the 
most efficient way for bacteriophage engineering followed by the use of the determined 
technique to address multiple limitations of wild type phages. Therefore, the aims were:  
1) To determine the most efficient way of bacteriophage engineering and selection by 
comparing marker-based and marker-less methods (Chapter 3). 
2) To examine if the host range of phage T7 can be altered by fusion of its tail fibers with 
those from genetically distant phage tail fibers (Chapter 4).  
3) To determine if T4 can lyse an additional, to its host E. coli, pathogen by engineering 
it to deliver a cargo i.e. lysin targeting S. aureus, B. subtilis and C. difficile (Chapter 6).  
4) To examine whether T7 engineered with tissue targeting peptides could allow increased 



































2.1 General  
 
The methods presented in this chapter are used throughout this thesis. More chapter specific methods 
are presented in each of the chapters. This chapter is subdivided into general, bacteria specific, phage, 
tissue culture and protein analysis sections. In all protocols, O/N (overnight) refers to approximately 12 
hours of incubation.  
 












3) hsdR514 rph-1 
LB, 37°C Received from Jaramillo Lab, 
University of Warwick 
E. coli MG1655 K-12 F– λ– ilvG– rfb-50 rph-
1 
LB, 37°C Received from Jaramillo Lab, 
University of Warwick 





LB, 37°C KEIO collection258 
E. coli BW25113Dcmk F-, Δ(araD-
araB)567, ΔlacZ4787(::rrnB
-3), λ-, Δcmk-734::kan, rph-
1, Δ(rhaD-
rhaB)568, hsdR514 
LB, 37°C KEIO collection258 
E. coli BW25113Dwaac F-, Δ(araD-
araB)567, ΔlacZ4787(::rrnB
-3), λ-, Dwaac k-
734::kan, rph-1, Δ(rhaD-
rhaB)568, hsdR514 
LB, 37°C KEIO collection258 
E. coli BL21 E. coli B 




LB, 37°C Received from David Scanlan 
Lab, University of Warwick 
Bordetella pertussis Tohama I WT 37°C, charcoal Received from Andrew 




WT 37°C, LB and 
charcoal 
Received from Andrew 
Preston Lab, University of 
Bath 
pSMART N/A N/A IDT 
pWUR397 N/A N/A Brouns et al. 2008 
pWUR400 N/A N/A Brouns et al. 2008 
pCas9 N/A N/A Marraffini Lab, The 
Rockefeller University 
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pET30+ N/A N/A Mark van Raaij Laboratory 
pMAT N/A N/A IDT 
pET24-gp5 N/A contains gp5 Received from Jaramillo Lab, 
University of Warwick 




Received from Jaramillo Lab 
(made by Paul MacDonald), 
University of Warwick 
Phage T7 WT N/A Richardson Lab, University of 
Harvard 
T4 like phage Genome 95% similar to the 
WT T4 
N/A Isolated by Pavelas Sazinas, 
sequence attached in the CD 
Q12 T7 Amber mutation in 12th 
amino acid of Gp17 of WT 
T7 




2.1.2 List of buffers  
 
Buffer/media/Agar Constituents Comments 
SM 50 mM Tris-HCl, pH 7.5, 
containing 100 mM NaCl, 10 mM 
MgSO4, and 0.01% gelatin 
Used for phage storage 
DMEM Potassium Chloride (KCl) – 400 
mg/L, Sodium Bicarbonate 
(NaHCO3) – 3700 mg/L, Sodium 
Chloride (NaCl) – 6400 mg/L. 
Used for mammalian tissue 
maintenance. 
Fetal bovine serum FBS (10%) Bovine IgG, ≤1 mg/mL  
Hemoglobin, ≤20 mg/dL 
Used for mammalian 
tissuemaintenance. 
TBE x 5 54 g Tris base and 27.5 g boric acid 
dissolved in 900 ml of water 
 
 
SOC 2% tryptone, 0.5% yeast extract, 10 
mM NaCl, 2.5 mM KCl, 10 mM 




8 g of NaCl. 
0.2 g of KCl. 
1.44 g of Na2HPO4. 
0.24 g of KH2PO4. 
Add distilled water to a total 
volume of 1 liter. 
 
TBS-Tween 50mM Tris, 150mM NaCl, 
0.1%Tween 20 
 
Chromoagar Orientation selective 
medium (ChroMagar, UK) 
N/A Used for strain verifications 
Charcoal Agar Peptone – 10g, starch – 10g, 
charcoal – 10g, sodium chloride – 
5g, nicotinic acid – 0.001g, 
agar.12g (for 1 litre) 






2.1.3 Agarose gel electrophoresis  
 
1% (w/v) agarose (14170829, Geneflow Limited, UK) gels were made and run using 1 x TBE 
buffer (section 2.1.2). Gels were run at 100 V with for 40 mins using Electrophoresis power 
supply (PowerPacTM, Biorad, USA). Gels were stained with SybrSafe (S33102, Thermo Fisher 
Scientific, USA) used to visualize DNA bands; it was added to final concentration of 1:1000 
to molten agarose gel. DNA samples were mixed with 6 x loading buffer (New England biolabs 
(NEB) B7024S, UK), prior to loading on to the gel. All samples were run alongside a DNA 
size marker (SM0313 GenerulerTM 1 kb DNA ladder, Thermo Fisher Scientific, UK). 
 
2.1.4 Gel extraction  
 
After running gel electrophoresis (see section 2.1.3) the fragment of interest was cut out from 
the gel and placed in a 1.5 ml Eppendorf tube (Eppendorf, Germany). 390 µl of QG 
buffer (28506, Qiagen, Germany) was added and dissolved in 50°C for 10 min. 130 µl of 
isopropanol (Fisher Scientific, USA) was added and then the entire sample was transfer to a 
purification column (28506, Qiagen, Germany). This was then centrifuged (5810 R, Eppendorf, 
Germany), for 1 min, followed by a 750 µl of PE wash (28506, Qiagen, Germany). It was then 
centrifuged twice (removing the overflow after the first centrifugation). This was the followed 
by elution of the DNA using elution buffer (28506, Qiagen, Germany).  
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2.1.5 PCR - Polymerase Chain Reaction  
 
Polymerase Chain Reaction (PCR) was carried out in 0.2 ml volume Eppendorf tubes in a 
thermal cycler (T100 Thermal cycler, Biorad, USA). HF Phusion Master mix (M0531S, New 
England Bio Labs, UK) and BSA (B9000S, New England Bio Labs, UK labs) were used for 
the reactions. The volume and contents of the final reactions are described below (Table 2-1). 
PCR amplifications were performed with cycling profile as described below (Table 2-2).  
 
Table 2-1. PCR reaction components. 






10 µM Forward 
Primer 
1.25 µl 2.5 µl 0.5 µM 
10 µM Reverse 
Primer 
1.25 µl 2.5 µl 0.5 µM 
DMSO 
(optional) 
(0.75 µl) (1.5 µl) (3%) 
2X Phusion 
Master Mix 
12.5 µl 25 µl 1X 
Template DNA variable variable < 250 ng 
Nuclease-free 
water 




Table 2-2. Thermocycler conditions for a PCR reaction. 
Step Temperature (°C) Time Cycles 







15-30 sec per kb 
25-35 
Final Extension 72 5-10 min 1 





2.1.6 PCR product clean-up  
 
Single product PCR reactions were purified using PCR purification kit (28106, Qiagen, 
Germany) following the manufacturer’s instructions. The reaction products were eluted in 20-
40µl of elution buffer (28106, Qiagen, Germany).  
 
2.1.7 Gibson Assembly 
 
Gibson assembly was used as described previously316. Fragments required for the assembly 
were PCR amplified using primers detailed in Appendix 2.  Gel electrophoresis was followed 
by gel extraction (see sections 2.1.3 and 2.1.4 respectively). Each reaction was set up to a total 
volume of 20 µl (see the Table 2-3 below). For the assembly of three or more fragments an 
equilmolar ratio of fragments was used; when inserting one fragment into a vector, a ratio of 
1:2 (vector to insert) was used. The reaction was incubated at 50°C for 30 min when assembling 
2 fragments or 60 min when assembling 3 fragments and then incubated at 37°C for 60 min. 
When using the Gibson Assembly Master Mix (section 2.1.8) for electroporation, it was diluted 
3-fold and 1 µl was used in a transformation reaction (Section 2.2.2). The Gibson Assembly 
Master Mix was stored at -20ºC. 
 
Table 2-3. Gibson assembly reaction components. 
Components Amount /µl 
Vector X 
Fragment 1 X 
Fragment 2 X 
Gibson Master Mix* 15 
Make up with H20 to 20 µl X 




2.1.8 Gibson Assembly Master Mix Preparation  
 
8 ml of 5X ISO Buffer (Table 2-4) was prepared in a 15 ml falcon tube as described in Table 
2-4. Gibson assembly master mix was prepared as described in Table 2-5. The 5X ISO buffer 
was stored at -20°C. A 60 µl aliquot of the Gibson assembly master mix was thawed and kept 
on ice until used. 
 
Table 2-4. 5X ISO buffer preparation components. 
Reagents Amounts 
1M Tris-HCl pH 7.5 4 ml 
2 M MgCl2 200 µl 
100 mM dNTP mix (25 mM each: dGTP, dCTP, 
dATP, dTTP) 
320 µl 
1M DTT 400 µl 
PEG-8000 2 g 
100 mM NAD 400 µl 
dH20 to 8 ml of total volume 
 
 
Table 2-5. Gibson assembly master mix preparation components. 
Reagents Amounts 
5X ISO Buffer 320 µl 
10 U/ µl T5 exonuclease 0.64 µl 
2 U/ µl Phusion polymerase 20 µl 
40 U/ µl Taq ligase 160 µl 







2.1.9 Golden Gate Cloning  
 
The Golden Gate protocol was adapted from a previous study317. Initial step for the golden gate 
protocol required primer preparation as follows. 0.5 µl of each primer (pair of annealing 
primers at 100 mM concentration) was mixed together with 49 µl of sterile water. The mixture 
of both primers was incubated at 95 °C for 5 min. The primer mixture was then diluted ten 
times. The Golden Gate reaction was set up as in Table 2-6. The assembly was then performed 
using the thermocycler with the conditions presented in Table 2-7. The samples were then left 
O/N at room temperature and transformed the following day using electro-transformation 
protocol (section 2.2.2). 
 
Table 2-6. Golden Gate reaction components. 
Reagent Amount/ µl 
vector (approx. 100ng) 1 
Primer mixture 2 
10X NEB T4 Buffer 1.5 
100X BSA 0.15 
BsaI 1 
NEB T4 Ligase, 2 million cohesive end units / 
µl 
1 
Water* to make up the total of 15 µl  
 
 
Table 2-7. Golden Gate reaction thermocycler conditions. 
Step Time (min) Temperature (°C) Cycles 
1 3 37 25 
2 4 16 
3 5 50 1 




2.2 Bacterial methods 
 
2.2.1 Colony PCR 
A single colony was picked from a plate and resuspended in 50 µl of sterile water, by vortex 
for 30 sec in a 200 µl Eppendorf. For PCR, 2 µl of the resuspension was used to provide the 
template DNA in the PCR protocol (Section 2.1.5). The remaining resuspension was platted 




Prior to use, the electroporation cuvettes (2 mm) (Thermo Fisher Scientific, USA) and DNA 
samples in Eppendorf tubes were chilled on ice for 10 min and LB-agar plates were placed in 
a 37°C incubator for 30 min to warm. Once the cuvettes were cold the competent cells were 
removed from the -80°C freezer and thawed on ice for 10 min. 1-2 µl of purified DNA for low 
and high plasmid copy number, was added to 50 µl of previously prepared electrocompetent 
cells and mixed by gentle swirling, prior to transfer into a electroporation cuvette. The 
electroporator (Gene Pulser, Biorad, USA) was set to 2.5 kV and the cells shocked. SOC 
medium (Section 2.1.2) was immediately added to the cells, prior to transferring the cells to a 
1.5 ml Eppendorf and chilled on ice for 2 min. The cells were then incubated for 1 hr at 37°C, 




2.2.3 Growth Curve 
 
A single colony was picked off a plate and grown O/N in 5 ml of medium at 37 ºC whilst 
shaking at 200 rpm. The O/N bacterial culture was diluted 1% and grown until an OD600 of 
0.2-0.3 was reached. 200 µl of each bacterial culture was loaded into 96-well plate. The OD 
was measured every 5 min, with 200 rpm orbital shaking in between the readings, using a plate 
reader (FLUOstar Omega, BMG LabTech, UK) at 37 ºC.  The growth curves generated were 
then exported to an Excel and later analysed using Prism software. 
 
2.2.4 Colony forming units (CFU) assay  
 
The cells were inoculated O/N and 1:200 of the culture was diluted into an appropriate medium 
and grown until it reached to OD600 of 0.3-0.4 on the day of the experiment. Cells were then 
10-fold serially diluted in Eppendorf tubes. 100 µl of each dilution was spread on an 
appropriate agar plate. 
 
2.2.5 E. coli co-culture experiments with or without phage 
 
The cells of two strains of interest (E. coli and wither B. subtilis or S. aureus) were separately 
inoculated O/N and 1:200 of the culture was diluted into an appropriate medium and grown 
until it reached to OD600 of 0.4 on the day of the experiment. Two of the strains were then 
mixed in equal ratios and grown for 4 hours with or without any phage added followed by their 
OD measurements every 30 mins. In the case of phage addition, T4-lysin phage was added at 
MOI of 0.1. 
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2.3 Bacteriophage Methods  
 
2.3.1 Storage of Bacteriophage Isolates 
 
For long term storage of bacteriophage isolates, 100-200 µl of lysate was diluted into 1 ml of 
SM buffer (2.1.2) and stored in cryovial (BR114831, Sigma-Aldrich, USA) at 4°C. For short 
term storage, phage lysates were diluted and stored in LB medium at 4°C. 
 
 
2.3.2 Phage Lysate concentration  
 
An appropriate volume of lysate was generated (see section 2.3.3).  Amicon Ultra-50 (100,000 
kDa MWCO, Merk Millipore ) columns were used for phage concentration. The columns were 
filled with phage suspension and centrifuged at 4000 g for 20 min until most of the supernatant 
passed through the filter. This was repeated until all of the phage lysate was filtered. 0.5-1.5 
ml of phage suspension was retained in the column. The media only filtrate was discarded and 
the concentration column was vortexed to release phage particles from the filter membrane. 
Phage filtrate was then collected into Eppendorf tube. The filtrate was then filtered using a 
0.45um pore sized syringe filter to remove any potential bacterial contamination. Phage 
concentrate was subsequently stored at 4° C until further use.  
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2.3.3 Phage lysate preparation  
 
O/N bacterial culture was diluted 1:200 with fresh medium; the final volume was experiment 
dependent, most frequently a volume of 10 ml of LB was used. When the culture reached an 
OD600 of 0.3, phage was added at MOI of 0.1. The culture was left to grown at 37° C, with 
shaking at 200 rpm until lysis occurred (liquid became clear, OD600 ≤ 0.1). 1 µl of chloroform 
was added and the cell debris was spun down at 4000 g for 10 min. The lysate was then filtered, 
transferred into a new tube and stored at 4° C until further use.  
 
2.3.4 Phenol Chloroform-DNA extraction  
 
0.4 ml of a phage sample was centrifuged at 13,000 g for 15 mins and the supernatant was 
transferred to a clean Eppendorf. This was followed by the addition of 0.4 ml of phenol and 
vortexing for 30 s. The supernatant was centrifuged for 10 min at 4°C, prior to extraction of 
the aqueous layer, which was mixed with an equal volume of phenol:chloroform (1:1) followed 
by vortexing for 30s and centrifugation at 13,000 g for 10 min at 4°C. Finally, the aqueous 
layer was extracted and mixed with an equal volume of phenol:chloroform:isoamlyalcohol 
(25:24:1) followed by vortexing for 30s and centrifugation for 10 min (13,000 g) at 4°C. The 
aqueous layer was then extracted and mixed with 1/10th volume of 7.5 M Ammonium Acetate 
and two volumes of ice cold ethanol were added and precipitated at -20°C O/N. A final 
centrifugation was carried out at 13,000 g for 30 min at 4°C. The DNA pellet was washed twice 
in 70% ethanol, air dried and then re-suspended in 10-30 µl of nuclease-free water. 
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2.3.5 Plaque assay 
 
An overnight culture was diluted 1:200 in LB medium and grown until it reached an OD600 
of 0.3-0.4 on the day of the experiment. Phage samples were 10-fold serially diluted in 
Eppendorf tubes. 300 µl of the culture at OD of 0.3 was added into 15 ml falcon tube followed 
by the addition of 100 µl of phage from the first dilution. The bacteria and phage mixture was 
incubated at room temperature for no longer than 10 min. 3 ml of 0.4% agar was added into 
the bacteria and phage containing falcon tube, which was then poured onto an appropriate agar 
plate (with/without antibiotics). The same procedure was repeated for each phage dilution. The 
plates were then incubated at 37° C O/N. 
 
2.3.6 Spot Assay  
 
O/N bacterial culture was diluted 1:200 into an appropriate medium and grown until it reached 
to OD600 of 0.3-0.4 on the day of the experiment. 300 µl of the bacterial culture were mixed 
with 3 ml of soft agar (0.4%) and poured onto the LB agar (1%) base layer in 90 mm diameter 
petri dish (if square plates were used, 1 ml of the culture was mixed with 9 ml of soft agar). 
The plate was left to dry for 10 -15 min. Phage dilutions were prepared in the same way as 
described in the plaque assay (see section 2.3.5). 5 µl of each phage dilution was then spotted 




2.3.7 One-step growth protocol 
 
The cells were inoculated O/N and 1:200 of the culture was diluted into an appropriate medium 
and grown until it reached to OD600 of 0.3-0.4. 900 µl of bacteria was combined with 100 µl 
of phage providing a total concentration of MOI of 0.1. The mixture was incubated at 37ºC for 
1 min. 10 µl of the mixture was then added to 25 ml of LB. 1 ml x 12 was aliquoted into 1.5 
ml Eppendorf tubes and placed in thermomixer at 37ºC, shaking at 300rpm. Every 5 min, one 
of the tubes was removed from the thermomixer and mixed by vortexing. The sample was then 
processed either with spot or plaque assay, sections 2.3.6 and 2.3.5respectively. 
 
2.3.8 Lysin kill spot assay 
 
0.05% (v/v) of an O/N E. coli (Section 2.1.1) was inoculated into LB medium (Thermo Fisher 
Scientific, USA) and grown until and OD600 of 0.3-0.4 was reached. 0.3 ml of cells were 
combined with 3 ml of soft LB agar (0.4% w/v) and poured onto a 1 % LB agar plate and left 
to dry. 5 µl of T4-lysin mixture was spotted (Section 2.1.5) on to the lawn of cells.  
 
2.3.9 Preparation of T4-lysin supernatant  
 
The supernatant from the lysis of E. coli infected with phages T4 mutant phages (Table 6-2) 
was prepared by the infection of 10 ml of E. coli at an MOI of 1. Samples were taken every 3 
hrs and immediately placed on ice, prior to spotting (Section 2.3.6).  
 
2.3.10 Lysin Serial Transfer 
 
Two cultures were prepared by inoculating 0.5 ml of O/N E. coli culture (Section 2.1.1) into 
100 ml of LB medium and incubated at 37°C with shaking at 200 rpm, until it reached an 
OD600 of 0.2-0.3. Acriflavine (ACR) solution (Sigma Aldrich, USA) was added into one of 
the flasks at 1mg/ml concentration. Bacteriophage were added to both flasks at an MOI of 0.01. 
A 1 ml sample was taken every 30 min for 4 hr. Samples were centrifuged at 13,000 g for 15 
min, prior to being filtered through a 0.22 µm pore size filter. 1 µl of sample was used as DNA 




2.3.11 Homologous recombination  
 
A culture containing homologous recombination plasmid (HR) was prepared by inoculating 
O/N culture at 1:200 into an appropriate medium and grown until it reached to OD600 of 0.3-
0.4. Phage of interest was then added at MOI 0.01. This was then followed by incubation at 
37°C at 200rpm for 3 hours if T7 phage, and 5 hours if T4 phage was used. The lysate was then 
processed as described in section 2.3.3. 
 
2.3.12 Plaque PCR 
 
A plaque of interest was stabbed with a pipette. The plaque residue collected on the pipette was 
then diluted in 100 µl SM buffer (section 2.1.2). 1 µl of this diluted residue was then used to 
perform PCR as described in 2.1.5. 
 
2.3.13 Plaque purification  
 
Plaque residue was collected as describe in section 2.3.12. It was then further diluted in 500 µl 
of SM buffer and used to make appropriate dilutions to perform plaque assays as described in 
section 2.3.5. The plaque collection, dilution and plaque assay were repeated three times to 
yield purified phage samples. 
 
2.3.14 Bacterial lysis by phage 
 
Bacterial culture was set up as in section 2.2.3, followed by addition of 20 µl an appropriate 
concentration of phage Optical density at 600 nm was measured and recorded periodically with 
a Microplate Reader for 8 hours.  
 
2.3.15 Virulence assay  
 
100 µl of O/N cultures were used to inoculate in 10 ml of LB and grown at 200 rpm at 37°C 
until 0.3 at OD 600 nm. Phage stocks were serially diluted from a concentration of 108 pfu/ml 
to 10 pfu/ml in a volume of 200 µl, yielding MOIs ranging from 1 to 10-7. 100 ul of bacterial 
culture was combined with 200 µl of phage sample for each phage dilution in 96-well plates. 
Four wells of phage-free bacteria were included on every plate as control experiments, in 
addition to four media-blanks for reference. Optical density at 600 nm was measured and 
recorded periodically with a Microplate Reader. Measurements were taken until the control 
cultures reached stationary phase. Measurements were taken until the control cultures reached 
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stationary phase. Once all data was collected, areas underneath the optical density vs. time 
curves were calculated for each well, from the time of infection to the time corresponding to 
the onset of stationary phase in the phage-free control, using the trapezoid rule. The ratio 
between the area under the curve at one MOI and the area under the curve of the phage-free 
controls is termed the local virulence. This is obtained for each well (each MOI). Plotting the 
local virulence of the wells against the log of initial MOI (from -7 to 0) provides the graph for 
the virulence index. The virulence index is equal to the area under that curve. This protocol has 
been adapted from Storms ZJ, Teel MR, Mercurio K and Sauvageau D paper under review. 
 
2.3.16 TEM prep protocol  
 
To image phages of interest Transmission Electron Microscope (TEM) was used. 10 µl of high 
titre stock of phage was added to a glow discharged formvar copper grid (200 mesh), left for 2 
mins, gently wiped off by allowing an edge of a filter paper to absorb access liquid, and 10 µl 
of water was used to wash the grid prior to being wiped off with filter paper. 10 µl of 2% uranyl 
acetate (w/v) stain was added to the gird and left for 30 secs, prior to its removal. The grid was 




2.4 Tissue Culture 
 
2.4.1 Thawing A549 
 
To thaw the frozen vial was placed in a 37°C water bath for approximately 2 mins. The vial 
was then removed from the water bath decontaminate by spraying with 70% ethanol. The vial 
contents were transferred to a 15mL centrifuge tube containing 5mL DMEM (Thermo Fisher 
Scientific, USA) and spun down at 1000 rpm for 5 mins using centrifuge (5810 R, Eppendorf, 
Germany), at room temperature. The supernatant was then removed and the cell pellet was re-
suspended in 1mL DMEM. The hemocytometer was used to count the cells. The cells were 
then diluted to achieve a density of 5 x 105 cells/mL DMEM and transferred to T75 flask and 
incubated at 37°C. 
2.4.2 Splitting of A549 cells 
 
Prior to sub-culturing the cells, the fresh DMEM culture medium was placed in a 37°C water 
bath or incubator for at least 30 min. The medium in a T75 flask was removed using a pitpette 
and aspirator. 5 mL of sterile PBS (see section 2.1.2) was added into the flask followed by 
tipping the flask gently a few times. This was then followed by aspiration of the PBS. 2 ml of 
trypsin EDTA (see section 2.1.2) was added and incubated in 37°C incubator for 2 min. This 
was followed by addition of 8 ml of culture DMEM medium using this cell suspension, a 
required volume of cells into new flasks was pipetted at a required split ratio. 
2.4.3 Adsorption/absorption assay  
 
The following was carried out on 80-90% confluent cells, seeded two days prior to the 
experiment in a six well plate. The O/N medium in each well was replaced with 1 ml of DMEM 
containing the desired phage concentration. The plate was incubated either for one or four 
hours. The media was then removed and followed by the addition of 0.5 ml of PBS with gentle 
pipetting up and down. The 0.5 ml of PBS was collected from each well in 1.5 ml Eppendorf 
tubes. The PBS wash was repeated one more time. 1 ml of 0.5 % saponin (Sigma Aldrich, 
USA) was added to each well and the plate was incubated for 15 min at 37ºC. After the 
incubation, the saponin in each well was pipetted up and down followed by sample collection 
in 1.5 ml Eppendorf tubes. The samples collected after PBS and saponin additions were then 
processed either with spot or plaque assay, section 2.3.6 and 2.3.5 respectively. 
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2.5 Protein Analysis 
 
2.5.1 Pertactin IPTG induction and phage-killing growth assays 
Strains with the pertactin constructs of interest (see section 2.1.1) were grown O/N at 37°C. 
The cells were then re-inoculated into fresh LB medium and grown to at least 0.2 at OD600nm. 
In each 96-well plate well 100 µl of cells were added to 100µl of media containing a given 
IPTG concentration and the appropriate antibiotics. During the phage killing experiments, the 
medium also contained the appropriate phage at an MOI of ~ 0.1. Growth was assayed by 
measuring absorbance at OD600 (FLUOstar Omega, BMG LabTech, UK) over a period of 5 
h.  
2.5.2 Preparation of protein samples 
Strains with the construct of interest were grow O/N at 30°C. 200 µl of O/N culture was re-
inoculated into 20 ml of pre-warmed LB medium and grown to between 0.2 and 0.6 OD600, 
then induced with 1 mM IPTG. 5 ml samples were taken prior to induction, then at 1 h and at 
3 h post-induction. These were pelleted by centrifugation for 10 min at 5,000 g and stored at -
80 °C before fractionation. The cell pellets were then separated as described by Charles et al. 
1994 and summarised in 2.5.3318. 
2.5.3 Cell pellet separation 
 
Cells were disrupted using 3 x 30 s sonification bursts followed by 30 s periods of incubation 
on ice. Unbroken cells, large cellular debris and insoluble materials were pelleted by low speed 
centrifugation at 3362 g for 10 min. Inner and outer membrane enriched fractions were 
collected by high speed centrifugation at 100000g for 45 min. The supernatant containing 
extracellular, cytosolic and other soluble components was also harvested. The membrane pellet 
was resuspended in ENV (10 mM sodium phosphate, pH 7.2) buffer containing 1% sodium 
(w/v) sodium lauroyl sarcosinate (Sarkosyl) and incubated at room temperature with frequent 
vortexing to aid the solubilization of the inner membrane. The insoluble outer-membrane 
fraction was re-pelleted by ultracentrifugation at 100000g for 90 min. The supernatant was the 
removed and the pellet resuspended in ENV buffer. 
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2.5.4 SDS-PAGE, Western Blotting and Membrane transfer 
SDS-PAGE was carried out using 8-16% Mini-PROTEAN TGX Precast Protein gels (BioRad, 
USA). 2x Laemmli sample buffer (Biorad, USA) was mixed with pelleted samples at a ratio of 
100 µl per 1 OD 600 and liquid samples at 1 ratio of 1:1. The samples were then boiled for 10 
min, before loading 10 µl into the gel. The Colour Prestained Protein Standard, Broad Range 
(NEB, UK) was used to determine the size of the protein bands. The gel was run at 120 V for 
20 min using power pack (Biorad, USA) then 180V for 50 min. The polypeptides were then 
transferred to a PVDF membrane (Biorad, USA) using the Trans-Blot Turbo Transfer System 
(BioRad, USA) according to the manufacturer’s instructions.  
2.5.5 Western Blotting 
Rabbit anti-pertussis pertactin polyclonal antibodies (Alpha Diagnostic International, USA) 
were pre-incubated O/N at a concentration of 1:2500 on a gel containing only E. coli BL21 
cells, together with blocking buffer consisting of TBS-Tween (TBST; Section 2.1.2) + 10% 
milk (Marvel, UK). The post-transfer membrane (Biorad, USA) was blocked for 1h in the 
blocking buffer, prior to addition of the primary antibody and O/N incubation. The next day 
the membrane was washed in TBST three times within 1h, and a goat anti-rabbit HRP- 
conjugated secondary antibody (Alpha Diagnostic International, USA) was incubated on the 
membrane for 1h at a concentration of 1:2500 in blocking buffer. It was then washed in TBST 
as above and incubated O/N in TBST. Finally, it was then visualised using the Western ECL 































3.1.1 Current methods for bacteriophage engineering 
A variety of methods have been used for the genetic modification of bacteriophage genomes.  
This includes the utilization of Saccharomyces cerevisiae and a Yeast Artificial Chromosome 
(YAC). A phage genome can be cloned into a YAC, in one piece or as PCR fragments 
assembled through gap-repair cloning, where phage DNA overlapping fragments are first 
mixed together with yeast/E. coli shuttle backbone allowing this DNA to be integrated into 
yeast spheroplast chromosome after transformation319,320. In particular, this technology enabled 
the genetic engineering of phages that naturally target E. coli to target pathogenic Yersinia and 
Klebsiella bacteria, and conversely, Klebsiella phage scaffolds to target E. coli by modular 
swapping of phage tail components allowing host range modifications321. One of the most 
prominent tools is homologous recombination which has originated as an in vivo analytical 
method used for bacterial gene manipulation322. Furthermore BRED (bacteriophage 
recombineering with electroporated DNA) has been used to genetically modify 
mycobacteriophages and coliphages323,324. BRED exploits the mycobacterial recombineering 
system, in which expression of the RecE/RecT-like proteins of mycobacteriophage Che9c 
confers high levels of homologous recombination and facilitates simple allelic exchange using 
a linear DNA substrate325. In BRED, phage DNA template and a targeting substrate are co-
electroporated into Mycobacterium smegmatis cells that have been induced for recombineering 
functions323. BRED was used for the construction of unmarked deletions of both essential and 
non-essential genes, mutations, foreign gene insertions and gene tags additions323,324. The 
downside of BRED as a method is that it is limited to only temperate phage engineering and 
hence it will not be used for lytic phage engineering in this study326. 
Homologous recombination could potentially be used for engineering of the lytic phage 
genomes. If an exogenous gene is introduce in between homologous arms into a plasmid in E. 
coli that are then infected with wild-type phage T7, some of the phage progeny will undergo 
homologous recombination. However, this method does not provide a selection mechanism for 
recombinant phages, since there is no reliable way to couple the possession of a selection 
marker and the survival of the lytic phage. Using known antibiotic resistance genes when 
selecting for bacterial recombinants, is not possible as phage infection causes cell lysis327. In 
the absence of selection, either high frequency recombination systems are required or an 
examination of a large number of plaques created by potentially recombinant phages323,326. 
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Therefore, a reliable method of selection is required for isolation of genetically engineered lytic 
phages using homologous recombination.   
 
3.1.2 Marker-based selection 
 
A selective marker can be used to select for recombinant phage after homologous 
recombination114. An antibiotic marker for a lytic phage like T7 cannot be used because it does 
not confer a selective advantage to the phage. However, a host co-factor gene that is essential 
to the chosen phage for replication and infection can be employed instead. Such examples in 
E. coli are thioredoxin and cytidine monophosphate kinase, encoded by trxA and cmk genes 
respectively, which are the only known co-factors essential for the replication of the phage T7, 
but are non-essential for E. coli growth328. The homologous recombination of a heterologous 
fragment with the genome of wild type T7 requires a plasmid containing the trxA or/and the 
cmk gene flanked by short T7 homologous sequences. Selection for recombinant phages is 
performed using cmk/trxA as a marker, since only phages that contain cmk or trxA will 
propagate in cmk/trxA deficient E. coli cell lines1. 
 
3.1.3 CRSIPR/Cas (marker-less) selection 
 
An alternative to marker-based selection is a marker-less method that is based on CRISPR-Cas 
systems. As previously described in Chapter 1 (section 1.24 ) CRISPR is a type of adaptive 
immune response system in prokaryotes300. During homologous recombination, it is possible 
to exploit a bacterial immune system against phages to eliminate genome copies that have not 
undergone homologous recombination. The endogenous CRISPR system of some bacteria is 
appropriate for this because of its reprogrammability. In one report, the innate CRISPR-Cas 
Type II-A system of Streptococcus thermophilus was shown to successfully genetically modify 
the genome of the virulent phage 2972, by the introduction of mutations, large deletions and 
even the addition of a new gene by means of selective pressure to increase recombination 
efficiencies and allow more effective modified genome efficiency329. Another report used the 
I-E CRISPR-Cas system from E. coli combined with homologous recombination to target a 
non-essential gene327. Therefore, homologous recombination can be used to change the wild-
type phage genome sequence followed by CRISPR targeting the wild-type sequence, favouring 
recombinant bacteriophage generation, acting as selection mechanism. T7 genes can either be 
essential or non-essential for T7 replication, thus non-essential gene sequences can potentially 
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avoid CRISPR targeting via CRISPR escape mutants (CEM) while not affecting phage 
vitality327. These escape mutants for non-essential genes can result in synonymous or non-
synonymous mutations. This would not be the case for the essential genes as non-synonymous 
mutations are less likely to be tolerated by the phage and result in decreased phage infectivity.  
 
As type I-E CRISPR-Cas is a Type-I CRISPR, in this study it will be referred as CRISPR type 
I; and as CRISPR/Cas9 in a Type-II CRISPR, it will be referred as CRISPR type II. An 





























Figure 3-1. CRISPR arrays, comprised of direct repeats (DRs; dark blue and dark green) and spacer regions (light 
blue and light green) are first transcribed into a single large pre-crRNA. The resulting pre-crRNA transcript is 
then cleaved into individual crRNAs by the Cas6 endonuclease (one of Cascade enzymes, CRISPR Type I) or the 
ubiquitous RNase III enzyme (CRISPR Type II). Mature crRNAs are guided to invading nucleic acids through 
homology between crRNAs and the corresponding invader protospacer sequence. Type I and II interference 
mechanisms require recognition of one of multiple protospacer adjacent motif (PAM) sequences, which 
collectively make up the consensus PAM element (red). The image adapted from the previous  study483.  
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3.1.4 CRISPR-type I  
The CRISPR type I system used in this study originated from E. coli K12 W3110 
(BW25113)330. This system is comprised of three components: a five protein complex that 
consists of  CasA, CasB, CasC, CasD, and CasE, often referred to as cascade, a Cas3 enzyme, 
and DNA repeat-spacer (a repeated sequence called ‘repeats’ and a specific target sequence 
called ‘spacers’)305,330. Once the DNA of repeat-spacer region is transcribed into RNA, the 
repeat regions form secondary structures (hairpins). This single large RNA transcript is now 
referred to as pre-crRNA305,330. It is cleaved by one of the cascade components, endonuclease, 
into individual crRNAs305,330. The remaining cascade enzymes aid in finding the target DNA 
sequence by first recognising the protospacer adjacent motif (PAM) and by a homology 
between cr-RNA and the target sequence331. Cascade then recruits Cas3 enzyme that cleaves 
and degrades the target DNA331. It has been shown that the I-E type CRISPR-Cas PAM motif 
for E. coli is AWG, and that out all of the possibilities AGG generated the highest targeting 
effieciency332. The other two essential parts for the crRNA are 3’ and 5’ handles (which are 
well defined repeat sequences before and after the spacer) that are on both sites of the pre-
crRNA and later allow crRNA binding to Cascade subunits306.  
3.1.5 CRISPR type II 
 
The type II system used in this study originated from Streptococcus pyogenes333. This system 
consists of four components: a Cas9 enzyme, DNA repeat-spacer, trans-activating CRISPR 
RNA (tracrRNA), ubiquitous RNAase II enzyme334. Once the DNA of the repeat-spacer region 
is transcribed into a single large RNA, the tracrRNA binds to repeat regions forming pre-
crRNA. This pre-crRNA is then cleaved into individual crRNAs by ubiquitous RNAase II 
enzyme equivalent to Cascade in CRISPR type I. The Cas9 handle is formed of two stems in 
each side of crRNA. crRNA recruits and forms a complex with Cas9 protein. Cas9:crRNA 
complex finds the target DNA sequence by first recognising PAM and by a homology between 




3.1.6 Aims  
Both marker-based and marker-less methods can be used for selection of engineered phage 
selection. In the first case the desired modification together with the selection marker (host 
factor) could be inserted using homologous recombination and then selected for in E. coli DtrxA 
strains. The marker-less selection could be achieved by first introducing the desired genomic 
change using homologous recombination followed by CRISPR targeting wild-type sequence 
and allowing selection for engineered phage. Therefore, both methods must reduce the wild-
type phage background. 
The main aim of the work presented in this chapter is to compare the efficiencies of marker-
based and marker-less methods in reducing wild-type progeny i.e. the selection efficiency for 
engineered bacteriophages. For the verification of both methods g17 region, coding for T7 tail 
fibers will be used as a target region. 
The aim of this chapter was divided into the following sub-aims:  
1) To test CRISPR type I efficiency for selection of phage T7 mutants; 
2) To test CRISPR type II efficiency for selection of phage T7 mutants; 
3) To test the efficiency of marker-based selection using trxA and cmk for the selection of 
phage T7 mutants. 
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3.2 Methods  
 
3.2.1 CRISPR type I gRNA delivery vector component/vector design  
 
In a previous study the bacteriophage T7 genome was engineered using CRISPR type I, where 
all of the three components (Cas3, Cascade and gRNA) were placed on separate vectors to 
increase orthogonality of the system327. Therefore, all of the three components were required 
to replicate the system in this study. The enzyme cascade and Cas3 containing vectors, 
pWUR400 and pWUR397 respectively were obtained from the Udi Qimron Lab (Tel Aviv 
University)335.  However, the third component of the system, a vector containing a gRNA to 
target specific sites of interest had to be designed and synthesized as part of this work. The 
layout of the construct design is presented in Figure 3-2 where only the designed fragment is 
presented. It was synthesized as a synthetic fragment and placed in pSMART amp vector (by 
IDT (Appendix 1 – plasmid map, Appendix 3 – sequence) and was used as a negative non-





The main components to include in the design were: a) T7 RNA polymerase promoter at the 
5’of the construct; b) 5’ handle (responsible for Cas3 and Cascade binding); c) gRNA for a 
target gene sequence; d) restriction enzyme sites flanking the gRNA region; e) 3’ handle 
(responsible for Cas3 and Cascade binding); f) T7 terminator. The T7 promoter was chosen to 
drive high expression of the gRNA construct upon T7 entry into a cell. A 5’ handle repeat 
sequence (5’ GAGTTCCCCGCGCCAGCGGGG 3’) was chosen followed by eight well-
defined bases of the repeat sequence (5’ ATAAACCG 3’)330.  
The BbsI restriction recognition site was used to flank the target/spacer sequence for the 
Golden Gate Assembly (Section 2.1.9) to later replace gRNA(scr) and generate pSMART 
vectors with multiple target sequences. The 3’ handle was constructed by adding 21 nucleotides 
(5’GAGTTCCCCGCGCCAGCGGGG 3’) as described by other studies331, 336. 
Figure 3-2. Schematic representation of the sequence inserted into pSMART gRNA delivery vector synthesized 
by IDT. of the gRNA delivery vector. The total length of the construct is 130 bp. It consists of a T7 promoter two 
handle regions, non-targeting gRNA(scr) with two surrounding BbsI cut sites and T7 terminator. 
5’ handleT7 promoter gRNA(scr)BbsI T7 terminatorBbsI 3’ handle
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3.2.2 CRISPR type I gRNA design  
 
As described in the section 3.1.1 the gRNA delivery vector contains all of the requisite 
components for the target sequence transcription, processing and identification; however, it 
does not contain the actual target sequences i.e. gRNAs. Each of the CRISPR type I gRNAs 
for g17 were designed manually taking into consideration PAM requirements for the system. 
Previous research has identified that the PAM that fits most efficiently is AGG332. The main 
principle for the design is to first identify the AGG sequence; the 32bp following AGG 
comprise the target sequence.  All AGG motifs were identified in g17. Ten out of 37 identified 
potential gRNAs were chosen for gRNA design: four targeting the 5` region and six targeting 
the 3` region of the gene respectively (see Figure 3-3). They were designed and synthesized as 



























RNA no Coding/non-coding strand Sequence 5' to 3’ on g17 bp in g17 
1 coding TCCTTACGATTAATACAGACTATCGCTTTGCT 128 - 159 
2 coding AAATATTCACGCTAACGGGCGCCTTTACATGA 864-895 
3 coding CGGTAACATCCAGTTAGTAGTAAACGGACAGA 1032-1063 
4 non-coding TTACTCGACGTAACTCGATGGTCGTGTAGCCA 204 - 235 
5 non-coding TACAGTCATTGTTGTTATCTGACCCTCTACCA 1194-1225 
6 coding CGTGGACTCAGGTGTGGTCTGGTAGTGCTGGC 1406-1437 
7 coding TGTGGTCTGGTAGTGCTGGCGGTGGGGTAAGT 1418-1449 
8 coding ATCTCCGCTTCCGCAATATCTGGATTAAGTGT 1466-1497 
9 Non-coding CTATGAAGTAGATTCCATCGGGGCCAGTACGG 1521-1552 




(373-464 aa 1119-1392 bp)
C terminus, 
tip domain 
(465-553 aa or 1392-1659 bp)  
N terminus 












Figure 3-3. Representation of gRNAs designed for CRISPR type I. (A) distribution of gRNAs across g17. (B) Summary of the position, sequence as well as 







3.2.3 gRNA design for CRISPR type II 
 
In contrast to CRISPR type I, here the CRISPR components (gRNA, tracrRNA and 
Cas9) required for the system were placed on one vector pCas9-Marafini (see 
Appendix A), received from Marafini lab already containing gRNA (scr) that will be 
used as a negative control for the experiments, as it does not target any region in T7. 
DNA 2.0 (Autumn) was used to design gRNAs against g17.  The following criteria 
were selected when using the software: NGG was entered for the desired PAM and 
species off target verification was based on E. coli. Each of the gRNAs generated by 
the software were appended with BsaI enzyme restriction sites. A total of 11 gRNAs 
was designed and then synthesised as a complementary single stranded DNA 























gRNA n Coding/non-coding strand Sequence 5' to 3’ on g17 bp in g17 
gRNA1 coding AAGTGTGACTGTTTCACAGG 1446-1465 
gRNA2 non-coding AGGCGTGGACTCAGGTGTGG 1403-1422 
gRNA3 coding AGTGTGCCAACAACTCTTGG 1493-1512 
gRNA4 coding TTCCGCTGCGCATCAATCTG 684-703 
gRNA5 coding ACGCTACGAACACAAAGCAG 575-594 
gRNA6 non-coding CAGCATCCGCTAACTCTGCTC 728-747 
gRNA7 non-coding TACAGTTCCGTAATGAGGCT 506-525 
gRNA8 coding GGTAAGTGTGACTGTTTCAC 1443-1462 
gRNA9 coding GATCTCCGCTTCCGCAATAT 1466-1485 
gRNA10 non-coding CTTCCGCAATATCTGGATTA 1473-1492 
gRNA11 non-coding AATACACTCCAACGGTCTCG 1581-1600 
C terminus, 
pyramid domain 
(373-464 aa 1119-1392 bp)
C terminus, 
tip domain 
(465-553 aa or 1392-1659 bp)  
N terminus 











Figure 3-4. Representation of gRNAs designed for CRISPR type II. (A) distribution of gRNAs across g17. (B) Summary of the position, sequence as well as 






3.3 Results  
 
3.3.1 Determination of CRISPR type I efficiency as a method for engineered phage T7 
selection  
 
A total of ten vectors containing DNA fragments designed in 3.2.2 was constructed by first 
annealing the single stranded fragment pairs and then cloned in pAG1 (Section 3.2.1) vector 
using Golden Gate cloning protocol (Section 2.1.9). The resulting vectors are presented in 
Table 3-1. 
 
Table 3-1. Summary of CRISPR type I gRNA containing vectors. 







Designed in this study, IDT 
synthesised, Appendix 1 
pAG_2 gRNA1 pAG1 Generated in this study 
pAG_3 gRNA2 pAG1 Generated in this study 
pAG_4 gRNA3 pAG1 Generated in this study 
pAG_5 gRNA4 pAG1 Generated in this study 
pAG_6 gRNA5 pAG1 Generated in this study 
pAG_7 gRNA6 pAG1 Generated in this study 
pAG_8 gRNA7 pAG1 Generated in this study 
pAG_9 gRNA8 pAG1 Generated in this study 
pAG_10 gRNA9 pAG1 Generated in this study 
pAG_11 gRNA10 pAG1 Generated in this study 
 
The efficiency of each gRNA was determined by EOP (Section2.3.5) with respect to a 
reference E. coli BW25113 strain containing a non-targeting (scrambled) gRNA (Figure 3-5).  
It was found that gRNA7 was the most effective as it reduced T7 progeny by ~90-fold. The 
majority of gRNAs (gRNA2-gRNA5 and gRNA8) showed a reduction in progeny by ~10-fold. 















































Figure 3-5. Efficiency of plating for T7 against E. coli strain BW25113 containing CRISPR type I gRNAs; the T7 
efficiency of plating was determined with respect to a reference E. coli strain BW25113/pAG1. EOP data are presented 
as the mean of three independent experiments, n=3. 
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3.3.2 Determination of CRISPR type II efficiency as a method for engineered phage T7 
selection 
 
A total of eleven vectors containing DNA fragments designed in 3.2.3 was constructed by first 
annealing the single stranded fragment pairs and then cloned in pCas9-Marafini vector using 
Golden Gate cloning protocol (Section 2.1.9). The resulting vectors are presented in Table 3-
2. 
 
Table 3-2. Summary of CRISPR type II gRNA containing vectors made in this study. 
Name Components Vector Origin 
pAG_12 gRNA1 pCas9 (Marafini) 
(SF_X) 
Generated in this study 
pAG_13 gRNA2 pCas9 (Marafini) Generated in this study 
pAG_14 gRNA3 pCas9 (Marafini) Generated in this study 
pAG_15 gRNA4 pCas9 (Marafini) Generated in this study 
pAG_16 gRNA5 pCas9 (Marafini) Generated in this study 
pAG_17 gRNA6 pCas9 (Marafini) Generated in this study 
pAG_18 gRNA7 pCas9 (Marafini) Generated in this study 
pAG_19 gRNA8 pCas9 (Marafini) Generated in this study 
pAG_20 gRNA9 pCas9 (Marafini) Generated in this study 
pAG_21 gRNA10 pCas9 (Marafini) Generated in this study 
pAG_22 gRNA11 pCas9 (Marafini) Generated in this study 
These eleven gRNAs targeting g17 of T7, were then tested for their ability to cut the T7 genome 
and thus reduce T7 progeny (Figure 3-6). The efficiency of each gRNA was determined by 
EOP (Section 2.3.5), with respect to a reference E. coli BW25113 containing a non-targeting 
gRNA (scr). It was found that gRNA2 was the most effective resulting in a 1000-fold reduction 
compared to the control. The majority of remaining gRNAs (gRNA5, gRNA7-gRNA13) 
showed a reduction in progeny numbers by less than 10-fold. gRNA3, gRNA4 and gRNA6 
showed a reduction more than 10-fold but less than 100-fold. Determination that CRISPR type 
II can reduce the T7 progeny suggested that it has a potential for being used as a selection 
method for engineered phage selection. CRISPR type II reduced the numbers of wild type 
phage by 1000-fold which surpasses the result seen for CRISPR type I (Section 3.3.1). 
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The next step was to determine the T7 reduction i.e. marker-based method selection potential 



















































Figure 3-6. Efficiency of plating for T7 against E. coli strain BW25113 containing CRISPR type II gRNAs; the 
T7 efficiency of plating was determined with respect to a reference E. coli strain BW25113/pAG1. EOP data 
were log10 transformed and are presented as the mean of three independent experiments, n=3. 
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3.3.3 Determination of marker-based (cmk and trxA) selection efficiency as a method for 
engineering phage T7 selection  
 
To determine the extent to which both of the host factors reduce T7 progeny, plaque assays 
were carried out on E coli strains that lacked cmk and trxA (Section 2.3.5). EOP on both strains 
were compared to the control strain E. coli BW25113. In the case of E. coli ∆cmk cells, the 
number of progeny phage was reduced by approximately 105 fold (Figure 3-7), whereas with 
E. coli DtrxA cells no progeny was detected (detection limit < 1) and is presented as zero. Thus, 















Figure 3-7. Efficiency of plating for T7 on E. coli BW25113, E. coli Dcmk and E. coli DtrxA strains was determined 
with respect to a reference E. coli strain BW25113.  EOP data were log10 transformed and are presented as the 
mean of three independent experiments, n=3. An asterisk indicates that the EOP was below the detection limit 




In addition, a T7 one-step growth assay (Section 2.3.7) was performed on E. coli BW25113, 
E. coli Dcmk and E. coli DtrxA strains to further show that there is no phage replication taking 























Figure 3-8. Burst size assay for T7 phage on E. coli BW25113, E. coli Dcmk and E. coli DtrxA strains 
was carried out over 40 minutes. The assay was carried out at MOI 0.1. 
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3.3.4 Comparison of marker-less and marker-based selection efficiencies 
The EOP of CRISPR type II BW25113/gRNA2 (the most efficient gRNA) and E. coli ∆trxA 
cells was directly compared (Figure 3-9). The marker-less method reduced T7 progeny 
numbers by ~1000-fold whereas the marker-based method gave undetectable amount of 
progeny (it is presented as zero in the Figure 3-9). Therefore, the marker-based method is the 
















Figure 3-9. Efficiency of plating for T7 on E. coli BW25113, E. coli DtrxA and E. coli DtrxA/pAG3 strains and 
was determined with respect to a reference E. coli strain BW25113; hence the value of 1 (0) for BW25113 strain; 
EOP data were log10 transformed and are presented as the mean of three independent experiments. An asterisk 
indicates that the EOP was below the detection limit (detection limit <1). 
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3.4 Discussion  
 
3.4.1 CRISPR type I  
 
The maximum reduction in wild-type T7, and hence the potential T7 mutant selection 
efficiency, was found to be 100-fold greater than that of a control for the CRISPR type I, when 
targeting g17. Interestingly, in the previous work by Kiro et al. (2014) showed a 1 x 104 fold 
decrease in wild-type T7 numbers when targeting g1.7 using the same CRISPR type I system 
suggesting a 100 times greater efficiency when compared to the results for g17 (Figure 3.3.1-
1)327. In contrast to g17 targeted in this chapter, the 1.7 gene, encoding a nucleotide kinase, is 
not essential for phage growth under standard laboratory conditions337. In principle, when a 
gene is non-essential it is perceived to be less conserved and more prone to adaptation when 
compared to an essential gene258,338. Therefore, a non-essential gene such as g1.7 being more 
tolerant to mutations would be better suited to avoid CRISPR targeting by mutating the region 
of interest and would result in lower CRISPR targeting efficiency when compared to g17. 
However, the opposite is the case, when the result generated in this chapter for g17 is compared 
with the data to that of g1.7, therefore potential explanations will be discussed next. 
A reason for the steep difference between the CRISPR type I efficiency numbers in this study 
and the work of Kiro et al. (2014) is likely caused by the recombinant phage selection protocol. 
In their study an additional dual pre-induction step of the selection strain was carried out before 
the addition of recombinant phage.  
 
CRISPR pre-induction prior to phage entry into the cell is likely to be very important factor to 
allow maximum efficiency when targeting a lytic phage. Phage infection is very rapid (T7 is 
17 min) and hence CRISPR component transcription and translation as well as complex 
formation are time consuming steps; therefore, having all of these components ready upon the 
lytic phage arrival would allow more time for the target sequence screening and hence more 
genomic cuts made226. If the system is solely dependent on the phage to provide the T7 RNA 
polymerase, which is one of the early genes (g1) of the T7 genome, for the initiation of 
CRISPR, the entire process is then delayed and then, most likely, results in lowered efficiency.   
To induce the CRISPR, Kiro et al. (2014) used the following. Firstly, all three vectors which 
make up the CRISPR type I are under control of T7lac promoter which means that addition of 
isopropyl β-D-1-thiogalactopyranoside (IPTG) would free the promoter region by binding to 
the lacI (that normally acts as an inhibitor for T7lac promoter regulated regions).  Secondly, 
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they used E. coli BL21-AI strain which is an arabinose-inducible strain because it has the 
tightly regulated arabinose-inducible araBAD promoter upstream of the T7 RNA polymerase 
gene. Therefore, when both araBAD promoter pre-induction is combined with a T7 promoter-
based vector (which all of the three CRISPR components were) it produces tight regulation for 
the T7 promoter. Thus, an active CRISPR was present at the time of T7 infection, whereas in 
the system here the system would not become active until after phage infection. Since it takes 
approximately six minutes after infection at 30°C (and potentially even less time at 37°C), for 
T7 encoded RNA polymerase to start transcription of the middle genes it is beneficial to have 
the CRISPR complexes expressed and assembled prior to phage entry230. 
 
3.4.2 CRISPR type II 
 
The maximum reduction in wild-type T7, and hence the potential T7 mutant selection 
efficiency, was found to be 1000-fold greater than that of a control for the CRISPR type II, 
when targeting g17. In a previous study a type II CRISPR of Streptococcus 
thermophilus DGCC7710 (not identical to the one used in this study, which is from 
Streptococcos pyogenes) has been used as a tool to select mutations in a specific region of a 
virulent phage329. The same study also replaced orf33 in the phage 2972 genome with 
LlaDCHIA (methyltransferase gene of the type II restriction/modification (R/M) system).  In 
contrast to this study they found that 1 x 106 fold efficiency was achieved when type II CRISPR 
was used to aid the homologous recombination329. As well as in the case of Kiro et al. (2014), 
a non-essential gene, g1.7, was targeted. This higher difference in CRISPR efficiency (1000-
fold) could be due to the following reasons. 
 
Firstly, CRISPR type II used in this study originated from S. pyogenes. Jiang et al. 2013 
generated this plasmid by amplifying Cas9, trcRNA and repeat regions, as well as 
accompanying native promoters for each, directly from S. pyogenes and inserting into pZE21- 
MCS1 vector333. The S. pyogenes promoters when in E. coli drive the expression constitutively, 
however, the strength of the promoter and hence the level of the expression has not been 
empirically compared between E. coli and S. pyogenes. The lack of an inducible promoter with 
the type II CRISPR system, means that the expression cannot be tuned in any way.  The reduced 
effective strength of S. pyogenes promoters in E. coli could be one of the potential reasons for 
reduction in CRISPR type II efficiency found in this study. In addition, in the previously 
mentioned study by Martel & Moineau (2014), they performed the CRISPR targeting in S. 
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thermophilus, the strain that harbours its own CRISPR system329. Therefore, only a vector 
containing a gRNA targeting the phage needed to be introduced in order for the system to work.  
 
Secondly, Martel & Moineau (2014) engineered bacteriophage 2972 rather than T7. The two 
phages in question have very different latent periods: 13 and 34-40 mins for phage T7 and 2972 
respectively339,340. It is noticeable that for phage with a longer latent period, type II CRIPSR 
was a more efficient method for the selection of mutants; this could be due to the fact that 
longer latent period time would allow more time for CRISPR assembly as well as target 
recognition. In addition both phages have a different GC content, 40.15% and 48.4% for phage 
2972 and T7 respectively, which can potentially affect CRISPR efficiency341,224. 
In addition, it seems that the CRISPR of S. thermophilus offers a few advantages over the 
CRISPR S. pyogenes, such as higher targeting efficiency and sequence specificity. This is due 
to the fact that S. pyogenes CRISPR system uses NGG as its PAM region, whereas S. 
themophilus  is able to detect longer PAM allowing greater target specificity and reducing of 
targets342. 
 
3.4.3 Potential Explanation for CRISPR inefficiency 
 
Interestingly, the most efficient gRNA for each CRISPR type (gRNA7 for type I and gRNA2 
for type II) in this study was in the region of 1402-1448 nt of g17 (they had a 5 bp overlap), 
suggesting a potential location/site preference for CRISPR targeting. For CRISPR type II 
there has been more analysis carried out to understand the factors contributing towards 
CRISPR efficiency. It has been suggested that coding vs non-coding strand targeting could 
potentially make a difference for efficiency343.  In a study carried out by Qi et al. 2013,  the 
non-coding strand targeting was shown to be more effective when a gene region is targeted; 
however when a promoter region is targeted, both coding and non-coding are effective343. It 
was shown that the most effective CRISPR type I gRNA7 targets the coding strand, whereas 
for CRISPR type II the most efficient gRNA2 type targets the non-coding strand.  The next 
efficient gRNA for CRISPR type I and type II was gRNA8 and gRNA3 respectively; both 
of which are coding strands. The next in line for efficiency for CRISPR type I was gRNA8 
targeting coding strand and for CRISPR type II gRNA6 targeting non-coding strand. Even 
though, non-coding targeting appears to be more efficient, the efficiency of the gRNAs 
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cannot be directly compared given the different CRISPR types as well as limited number of 
gRNAs investigated in this study.  
 
A previous large scale study that evaluated the cleavage activities of 218 gRNAs targeting 
mouse Neuro2A cell line proposed that the relationship between GC% content and cleavage 
efficiency is likely to be a non-linear one, with sgRNAs having GC% of 40–60 are 
optimal344.  The GC content of gRNA2 and gRNA7 were 59% and 65% respectively, which 
is within or just above the previously identified optimal range of GC% of 40–60 Figure 3-
10. Interestingly, when the GC% is compared between all of the gRNAs it is seems that the 











































































































Figure 3-10. Summary of GC content for gRNAs used in this study. (A) gRNAs for CRISPR Type I. 
(B) gRNAs for CRISPR Type II. 
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With the use of CRISPR to engineer phages, it is important to remember that phages have 
evolved anti-CRISPR systems. Both Martel, B. & Moineau, S 2014 and Kiro et al. 2014 
showed that phage mutants can bypass the interference activity (CEM, CRISPR-Escape 
Mutants) by point mutations in the protospacer (PS) sequence or adjacent motif329,327,339. The 
frequency of escape mutants varies from 1 x 10-5 - 1 x 10-7. Differences in the frequency of 
escape mutants could potentially affect CRISPR efficiency and hence explain the differences 
observed; the frequencies of escape mutants were not identified in this study.  
 
Potential approaches to improve CRISPR efficiency for bacteriophage engineering could be 
prolonging phage lysis as well as reducing the number of phage genome escape mutants. In 
the case of the phage lysis, as seen in section 3.4.1, it may occur faster than CRISPR protein 
assembly and provide with insufficient time for CRISPR proteins to perform an edit. In 
addition to CRISPR pre-induction in bacterial target host, one could employ physical factors 
i.e. temperature to extend phage lysis. For example, lowering the temperature would slow 
down phage infection giving more time for CRISPR to alter phage genome. In the case of 
escape mutant formation (as discussed in above) one could design multiple gRNAs targeting 
nearby region lowering the probability of successful escape mutant generation. 
 
3.4.4 Marker-based selection of T7 mutants 
A previous comparison between the efficiency of phage particle formation in the absence of 
trxA or cmk was carried out by Qimron in 2008328. In the study 100 pfu of T7 were plated on 
DtrxA and Dcmk cells and their EOP was worked out in respect to E. coli K-12 BW25113. The 
EOP value for trxA-based selection was <0.01, indicating a 100-fold reduction, which means 
that no viable progeny was observed, as only one hundred phages were plated. The EOP value 
for cmk selection was 0.05, indicating the recovery of 5 out of 100 phage particles and showing 
a 20-fold reduction. The data here for the selection using trxA, is in agreement with the values 
presented by Qimron et al. 2006328. However, the EOP value for cmk presented in this work 
showed a reduction of progeny by ~1 x105 fold, far exceeding previous reports328. This is could 
be due to the fact that in the previous study by Qimron, U. et al. 2006 only 100 T7 phages 
were used to enumerate the reduction by the lack of the host gene i.e. cmk; whereas in this 



















4.1 Introduction  
 
4.1.1 Expansion of phage host range via tail fibre swapping 
 
Although phages with similar tail fibres are usually similar genetically, there have been 
instances reported in which genetically unrelated phages share similar tail fibres345. For 
example, the E. coli-infecting P1 and P2 phages are unrelated genetically, despite sharing 
similar tail fibres and having been isolated from the same bacterial strain346. This disconnect 
between genetic similarity and tail fibre phenotype can be explained via tail fibre transfer, in 
which phages attain new host ranges by acquiring a portion of a tail fibre gene from another 
phage. In one study it was suggested that the similarities in the tail fibre genes of distantly 
related phages such as P2, P1, Mu, X, and T4 provide evidence that phages have undergone 
tail fibre exchange repeatedly115. Natural tail fibre domain swapping is most likely an 
evolutionary mechanism adopted by phages to enhance their survival115. Recently, advances in 
phage genome engineering allow for host range expansion via genetically engineered tail fibre 
manipulation; specifically, other studies have successfully expanded the host ranges of both 
T7 and T3 phages321. In this chapter, in order to test if tail fibre swapping is possible for 
distantly related phages, the tail fibres of E. coli-infecting T7 were swapped with those of 
Bordetella-infecting BPP-1.  
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4.1.2 Structure of the phage T7 tail fibre protein (Gp17)  
The function of the T7 tail fibre protein, Gp17, is to attach the phage to the lipopolysaccharide 
(LPS) of E. coli347. Even though it is clear that LPS is the main T7 receptor, it has been shown 
that porins such as OmpA and OmpF affect phage adsorption and infection, indicating that they 
take part in the initial virus-host interaction348. Each of the six T7 tail fibres consists of three 
copies of the Gp17 protein244. These homotrimers, and especially the C-terminus of Gp17, are 
responsible for the initial recognition and binding to the target host347,249. The crystal structure 
of the C-terminus of Gp17 has been determined, where the terminal domain is divided into two 
parts: a globular ‘tip’ domain (Ala465 - Glu553) and pyramid domain (Gly371 – Glu533) 











Figure 4-1. Representation of the structure of Gp17 (only C-terminus shown, as the structure for the N-terminus 
has not been determined). The C-terminus domain consists of pyramid (372-464aa) and tip (464-553aa) domains. 
The image was adapted from a previous study by Garcia-Doval, Carmel Van Raaij, Mark J. 2012. 
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4.1.3 Structure of the phage BPP-1 tail fibre protein (Mtd)  
The tail fibre of BPP-1, Mtd, binds to pertactin on the Bordetella pertussis cell surface and 
uses it for initial attachment130,350,351. Pertactin is an outer membrane autotransporter produced 
during the Bvg+ (virulent) phase by all members of the Bordetella bronchiseptica cluster, 
which includes B. pertussis, B. parapertussis, and B. bronchiseptica318,351,352.  The Mtd protein 
is divided into three domains: a N-terminal β-prism (1-48 aa), an sandwich domain formed by 
a β-sandwich (56-170 aa), and a C-terminal lectin C domain (170-381 aa) Figure 4-2350. In 
addition, the β-prism is connected to the sandwich domain by a short 310 – helix (49–54 aa) 
Figure 4.1.3-1350. Though the functions of the β-prism and sandwich domains are not clear, 
they may reinforce overall trimeric assembly and therefore have an indirect role in stabilizing 




Figure 4-2. Representation of Mtd structure. Mtd has three domains: prism (1-48aa), sandwich (54-170 aa) and 
C-type lectin (170-382 aa). In addition, a short helix (49–54 aa) connects the β-prism to the sandwich domain. 
The image was adapted from a previous study by S. McMahan et al. 2005. 
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4.1.4 Antibody-like versatility of the Mtd C-lectin domain 
 
The C-terminal domain of Mtd is composed of a C-lectin type domain that is able to tolerate 
massive sequence variation and is frequently compared to that of the immunoglobulin fold350. 
The C-lectin fold of Mtd is related to that of the macrophage mannose receptor as well as 
intimin353,354,355. The key structural features of the C-lectin fold in Mtd are two-stranded 
antiparallel β-sheets formed by the domain’s N and C termini (β1β5), which are then connected 
by two a-helices and a three-stranded antiparallel β-sheet (β2β3b4). The β2β3β4 sheet in Mtd 
contains an additional three-residue strand, β4, and a short 310-helix. The C-lectin domain 
allows the bacteriophage to bind to a vast diversity of B. pertussis surfaces, as theoretically the 
C-terminus of Mtd can be composed of 1012 different polypeptide sequences. This high 
sequence variation is due to a 134 bp long tropism-determining region called variable region 
1, located at the 3’ end of the Mtd locus.  
 
4.1.5 BPP-1 and its variants BMP-1 and BIP-1 
 
Phage BPP-1 infects B. pertussis and B. bronchiseptica via pertactin, an outer membrane 
autotransporter protein that is only expressed in Bvg+ phase Bordetella spp129. BPP-1 can give 
rise to two classes of tropic variants at a frequency of approximately 10−6. One of the classes, 
BMP-1 (Bvg minus-tropic phage), has acquired a tropism for Bvg− phase bacteria while the 
second class, designated BIP-1 (Bvg indiscriminate phage), can infect both Bvg+ and 
Bvg− phase B. bronchiseptica with equal efficiency129.  
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4.1.6 Aims  
 
The main aim of the chapter is to determine if the host range of T7 can be altered when tail 
fibre domains from a genetically distant host are appended to it. This aim is divided into the 
following sub-aims:  
 
1. To design Gp17 and Mtd tail fibre fusions 
2. To establish a method for in trans complementation with tail fibre fusions, where 
tail fibre defective phage T7 infect cells expressing mutant tail fibres, allowing tail 
fibre complementation 
3. To perform in vitro testing of tail fibre fusions for tail fibre folding and trimerization 
analysis 
4. To execute in vivo testing where the genes for the fusion tail fibres were integrated 
into the genome of the phage T7, generating T7 chimeras 





4.2.1 Design of T7 and BPP-1 tail fibre fusions 
When creating tail fibre fusions, the tail fibre encoding gene (Gp17) from phage T7 was used 
as the main scaffold (Figure 4-3). To that scaffold, the Mtd C-terminus domains of the BPP-1 
phage tail fibre were fused. The C-terminus domain was chosen because it is the key site for 
binding to the host surface. To assess which potential fusions of Gp17 and Mtd were likely to 
result in a functional tail fibre, the precise locations for fusions had to be chosen on both Gp17 





























CH:T7/BPP1 Fusion Group Gp17/g17 aa/bp Mtd/Mtd aa/bp 
1 (T7-CH1) B 437 - 466/1-1398 171 – 382/513 – 1146 
2 (T7-CH2) A 437 - 466/1-1398 55 – 382/165 – 1146 
3 (T7-CH3) B 437 - 466/1-1398 163 – 382/489 – 1146 
4 (T7-CH4) B 437 - 466/1-1398 170 – 382/510 – 1146 
5 (T7-CH5) A 437 - 466/1-1398 47 – 382/141 – 1146 




Figure 4-3. T7 and BPP-1 phage tail fibre fusion designs: (A) Representation of Gp17 and MtD domains. Only 
the C-terminus of Gp17 shown, as the structure for the N-terminus has not been determined. The Gp17 C-terminus 
domain consists of pyramid (372-464 aa) and tip (464-553 aa) domains. MtD has three domains: prism (1-48 aa), 
sandwich (54-170aa) and C-type lectin (170-382 aa) domains. Prism and sandwich domains are connected via 
flexible helix (49 – 54 aa).  (B) g17 and Mtd fusion representations at DNA level. Fusion group A consists of g17 
(1-1338 bp) fused to Mtd (141/150/165-1146 bp). Fusion group B consists of g17 (1-1338 bp) fused to Mtd 
(489/519/513-1146 bp). (C) Summary of all fusion designs for both A and B groups. 
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To ensure that the chosen Gp17 scaffold would provide stability and facilitate trimerization for 
the fusion protein the Gp17 C-terminal pyramid domain was chosen. It forms stable trimers 
(the calculated dissociation energy of the pyramid domain trimer is 90 kcal/mol whereas the 
calculated dissociation energy of the tip domain trimer is 17 kcal/mol), suggesting that it 
enables Gp17 C-terminal trimerization356. Furthermore, it was also found that the short loop 
(Val464-Lys466) between the pyramid and tip domains is flexible356. Therefore, it was decided 
to fuse the Mtd domain directly after the 464-466 region loop as this would most likely help to 
retain flexibility between Gp17 and Mtd domains.  
To determine which C-terminal parts of Mtd to fuse to Gp17 the following was considered. 
Since the Mtd C-lectin domain (C-t): 170 – 381 directly binds to the pertactin of B. pertussis, 
it is therefore essential for host recognition and must be included in the fusion with Gp17125. 
In an effort to ensure C-lectin domain stability and trimerization, the sandwich domain was 
also included in the fusion, as its extensive interaction with the C-lectin domain indicates it 
may be linked to C-lectin domain stability. To ensure a fusion tail fibre length variation for 
both in vivo and in vitro work, two types of fusions were designed. For the first set of fusions, 
named type A fusions, the pyramid domain of T7 tail fibre (Gp17) was fused with both the 
sandwich domain and the C-lectin domain of Mtd starting at amino acids 47, 50 and 55 (Figure 
4-3). For type B fusions a Gp17 pyramid domain was fused only with the C-lectin domain 
before amino acids 163, 170 and 171 (Figure 4-3). 
The fusions described above were adapted for three lines of work: 1) in trans complementation 
with tail fibre fusion experiments, where tail fibre defective T7 infects cells expressing mutant 
tail fibres, allowing tail fibre complementation. 2) in vitro experiments, for tail fibre folding 
and trimerization analysis. 3) in vivo experiments where the genes for the fusion tail fibres were 
integrated into the genome of the phage T7, generating T7 chimeras. 
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4.2.2 Experimental setup for in trans complementation of tail fibre mutants  
The production of engineered phage genomes, while possible, is still a time-consuming task357. 
The ability to assess if tail fibre fusions will produce functional tail fibres, without having to 
produce recombinant phage, is a valuable tool in the development of synthetic phage-based 
antimicrobials. A system to test this requires a defective tail fibre (non-infective) phage and a 
strain with a vector that expresses a non-defective tail fibre. Upon defective phage infection in 
the strain, a non-defective vector tail fibre would be integrated into the virion, ensuring further 
phage infectivity. Such system was referred to as in trans tail fibre complementation. For this 
system phage Q12, that is a T7 derivative, was used. Phage Q12 has an amber stop codon 
(Amber mutation) in the 12th amino acid of g17 of T7 and was only infective in amber 
suppressor E. coli strains such as R11 (Section 2.1.1)358–360. As an initial step to verify the in 
trans tail fibre complementation system, it was confirmed using EOP (efficiency of plating) 
that the Q12 cannot produce viable phage on a non-amber suppressor strain (MG1655) and can 















Figure 4-4. EOP of Q12 against R11 (amber suppressor) MG1655-Z1 strains. R11 as well as MG1655-Z1 were 
infected with Q12 phage; phage enumerated were compared against the R11 strain. Error bars show standard 
deviation of three biological repeats. 
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4.2.2.1 Construction of tail fibre mutants for in trans complementation 
 
To test if viable Q12 could be propagated in MG1655 cells when wild type g17 was provided 
in trans, a vector expressing wild type g17 was constructed. If successful in trans tail fibre 
complementation platform would allow the function of tail fibre fusions to be tested. T7 g17 
was amplified with overhangs and inserted into pSB6A1 in front of a T7 promoter and B0034 
RBS using Gibson cloning (Section 2.1.7) creating the vector pAG_25. To generate the in trans 
complementation vector pAG_26, with a fusion tail fibre coding gene, T7 g17 was removed 
from pAG_25 and replaced with one of the fusions designed as described in section 4.2.1 
(Figure 4-5). As a control for the pAG_26 vector, pAG_27 was created. In this instance, T7 
g17 was removed from pSEVA-551 vector (Appendix 1), containing codon optimised g17 that 
has been codon optimized for T7, and replaced with one of the fusions designed as described 




4.2.2.2 Phage Q12 complementation with wild type Gp17 and Gp17: Mtd fusion tail fibres  
 
To test if Q12 would recover its infectivity when provided the wild type g17 in trans, phage 
enumeration assays were performed using E. coli Z1/pAG_25. The efficiency of plating (EOP) 
phage Q12 on MG1655/pAG_25 was compared to that of plating on R11 and the negative 
control MG1655 Z1 (Figure 4-6). The EOP using MG1655/ pAG_25 was equal to that of R11 
and was 1 x 104 higher than the negative control, confirming in trans complementation of the 
defective tail fibre. However, complementation with both variants of fusion tail fibre using 
pAG_26 and pAG_27 resulted in approximately the same EOP value as the negative control. 
Name  Gp17/aa// 
g17/bp 





N/A N/A pSB6A1 
pAG_26 1-466*// 
1-1398 
B 171 – 382// 




B 171 – 382// 




Figure 4-5. Summary of the constructs made for the in trans experiments. (A) Partial vector sequence 
representing the order of the main elements of the in trans fusion plasmids. Main components are the T7 
promoter, RBS (B0034), the g17 sequence up to the end of the pyramid domain (until 1398 bp, or 466 aa), and 
the Mtd sequence of the C-lectin domain (513 – 1146 bp, 171 – 382 aa). (B)   Breakdown of the three plasmids 
made. pAG_25 contains the full sequence of WT g17 instead of Mtd fusion, and will be used as a control for the 
in trans experiments.   T – terminator; *-wild type Gp17; **- codon optimized Gp17. 
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This was expected given that these chimeric fusion tail fibers had their tip domain swapped for 
Mtd domain making the tail fiber no longer suitable for E. coli infection.  
As in trans complementation required a wild-type copy of g17 to be expressed, there was the 
potential for g17 to recombine with Q12 (unpublished data by Mark van Raaij’s laboratory). 
Therefore, a codon optimised version of g17 (pSEVA551) was also tested that is 78.9% similar 
to g17, and therefore less likely to recombine. The codon optimised Gp17 complemented the 
mutation in Q12 as seen by the same EOP when using R11 cells (Figure 4-6). It was therefore 
decided to use the codon optimised g17 in further chimeric tail fibre generation. 
 
Given that the fusion tail fibre did not sustain the complementation, most likely due to incorrect 
folding, it was decided that the functionality of each fusion tail fibre needs to be assessed in 
vitro prior to placement in the T7 genome. Therefore, the next step was to place all of the 
fusions into an expression vector followed by in vitro trimerization and solubility assays. 




























Figure 4-6. In trans complementation with wild type Gp17 as well as fusion tail fibre. The T7 tail fibre gene g17 
was expressed in trans in E. coli MG1655-Z1/pAG-25 and infected with phage Q12. In addition, a T7 and Mtd 
tail fibre Mtd fusion gene was expressed in trans in E. coli MG1655-Z1/ pAG_26 and infected with Q12. As an 
additional control, codon optimised tail fibre gene was expressed in E. coli MG1655-Z1/pAG-27 and infected 
with Q12. MG1655-Z1 and the amber suppressor strain R11 were used as negative and positive controls 
respectively. Efficiency of plating relative to R11 was calculated. Error bars show standard deviation of three 
biological repeats.  
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4.2.3  Construction of fusion tail fibre chimeras in an expression vector for in vitro tail fibre 
analysis  
 
It is known that Gp17 proteins can form trimers, either when both N-terminal and C-terminal 
domains are present or when only C-terminal residues (pyramid and tip domains) are 
present349,249. Therefore, the trimerization and solubility of tail fibres are good indicators of 
correct folding and infectivity249,361. Thus, it was decided to test tail fibre fusions designed in 
this study for potential trimerization and solubility. To achieve this, tail fibre fusions designed 
in Section 4.3 were cloned in pET30a (+) under control of a T7/lac promoter to allow tuneable 
expression by IPTG, using Gibson cloning (Section 2.1.7). The partial vector representation 
for the tail fibre fusion expression is showed in Figure 4-7. 
Previous work has shown that a T4 foldon domain can aid the folding of adenovirus tail fibres 
when used in a fusion protein362,363. To increase the likelihood of tail fibres trimerising and 
producing functional fibres, a second strategy of incorporating a foldon domain into fusion 
proteins was carried out. All of group A and B tail fibre fusions designed in Section 4.2.1 were 
redesigned to include a foldon domain that sits between the Gp17 pyramid domain and the Mtd 
fusion of interest (Figure 4-7). Constructs were made using Gibson cloning (Section 2.1.7) and 





Name Gp17/aa Mtd/aa Foldon Vector 
pAG_28 371 – 467 171 - 382 yes pET30a+ 
pAG_29 371 – 467 171 - 382 no pET30a+ 
pAG_30 371 – 467 55 - 382 yes pET30a+ 
pAG_31 371 – 467 55 - 382 no pET30a+ 
pAG_32 371 – 467 163 - 382 yes pET30a+ 
pAG_33 371 – 467 163 - 382 no pET30a+ 
pAG_34 371 – 467 170 - 382 yes pET30a+ 
pAG_35 371 – 467 170 - 382 no pET30a+ 
pAG_36 371 – 467 47 - 382 yes pET30a+ 
pAG_37 371 – 467 47 - 382 no pET30a+ 
pAG_38 371 – 467 50 - 382 yes pET30a+ 
pAG_39 371 – 467 50 - 382 no pET30a+ 
pAG_40 371 – 553* N/A yes pET30a+ 
pAG_41 371 – 553** N/A yes pET30a+ 




Figure 4-7. Summary of constructs made for the in vitro tail fibre assays, for both A and B group Gp17 and Mtd 
fusions. (A) Vector insertion sequence for the no foldon in vitro fusions. It consists of g17 (aa, bp) and Mtd (sequence 
dependent on if it is a type A or type B fusion). (B) Vector insertion sequence for the foldon containing in vitro fusions. 
It consists of g17 (aa, bp), foldon, and Mtd (sequence dependent on if it is a type A or type B fusion). (C) Summary 
of all fusions made in this study for the in vitro study. 
B 
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4.2.3.1 In vitro trimerization and solubility assays of tail fibre fusions  
 
To assess the solubility and the ability of tail fibre fusions to trimerize correctly, in vitro 
expression assays (Section 2.5.3) were carried out. The constructs made in section 4.2.3 were 
sent to Mark van Raaij’s research group where SDS PAGE as well as native gel were carried 
out for in vitro tail fibre analysis (Figure 4-8, Figure 4-9). 
 
To verify chimeric protein solubility SDS PAGE assay was carried out on all samples (only 
some of the samples are shown in Figure 4-8). Both wild-type g17 and a codon optimised g17 
fused to a foldon domain produced soluble protein as Gp17 monomers were seen in both 
supernatant as well as the pellet. To verify possibility of trimerization, native PAGE gels (only 
two of the samples are shown in Figure 4-9) were performed at 0, 1, 2, 3 and 16 hours post 
IPTG induction (Table 4-1). Trimerisation occurred for all of the tail fibre fusions with the 
exception of one (pAG_29), however, the trimers were only observed in the insoluble fraction 
(Table 4-1). No monomers were observed for any of the fusions in the soluble fraction, 







MW        - 1        2        3          4       5       6  
S        S        NS         S      S      NS  200 kDa
50 kDa
40 kDa
S = soluble 
NS = not soluble
Supernatant Pellet
Figure 4-8. SDS-PAGE polyacrylamide gel from attempt one. Lanes and their contents are labelled 1-6. Lane 1 
corresponds to the non-boiled supernatant fraction of IPTG induced pAG_40. Lane 2 corresponds to the non-
boiled supernatant fraction of IPTG induced pAG_41. Lane 3 corresponds to the non-boiled supernatant fraction 
of IPTG induced pAG_29. Lane 4 corresponds to the non-boiled pallet fraction of IPTG induced pAG_40. Lane 
5 corresponds to the non-boiled pallet fraction of IPTG induced pAG_41. Lane 6 corresponds to the non-boiled 
pallet fraction of IPTG induced pAG_29. The figure has been generated by Mark van Raaij’s research group. 
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Figure 4-9. Representation of a sample of Native PAGE gel. Lane 1 corresponds to the non-boiled 
supernatant fraction of IPTG induced pAG_40. Lane 2 corresponds to the non-boiled supernatant fraction 
of IPTG induced pAG_41. In both cases the sample was collected 16 hours post induction.  
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Table 4-1. Summary of tail fibre fusion in vitro expression assays. 
Name Conditions  Outcome 
 
Pellet   Supernatant 
 
 
Boiled  Non-boiled Boiled Non-boiled  
pAG_40 Monomer Trimer Monomer Trimer Protein expression detected at time 3 hours post 
IPTG induction; trimerization not detected since there 
was no trimer corresponding band neither in the pallet 
or the supernatant; a monomer band found in the 
supernatant (as well as the pallet) indicating that this 
fusion is soluble. 
pAG_41 Monomer Trimer Monomer Trimer Protein expression detected at time 3 hours post 
IPTG induction; trimerization not detected since there 
was no trimer corresponding band neither in the pallet 
or the supernatant; a monomer band found in the 
supernatant (as well as the pallet) indicating that this 
fusion is soluble. 
pAG_28 Monomer Trimer No No Protein expression detected at time 1, 2, 3, and 16 
hours post IPTG induction; the sample can trimerize since 
in the pellet two bands are seen at the expected MW for 
the monomer (when boiled) and trimer (when not boiled), 
but it's insoluble since these bands are not seen in the 
supernatant. 
pAG_29 No No No No Protein expression was not detected at time 3 hours 
post IPTG induction; the sample does not trimerize 
and is insoluble since there were no trimer or 
monomer corresponding bands neither in the pallet or 
the supernatant. 
pAG_30 Monomer Trimer No No Protein expression detected at time 1, 2, 3, and 16 
hours post IPTG induction; the sample can trimerize since 
in the pellet two bands are seen at the expected MW for 
the monomer (when boiled) and trimer (when not boiled), 
but it's insoluble since these bands are not seen in the 
supernatant. 
pAG_31 Monomer Trimer No No Protein expression detected at time 1, 2, 3, and 16 
hours post IPTG induction; the sample can trimerize since 
in the pellet two bands are seen at the expected MW for 
the monomer (when boiled) and trimer (when not boiled), 
but it's insoluble since these bands are not seen in the 
supernatant. 
pAG_32 Monomer Trimer No No Protein expression detected at time 1, 2, 3, and 16 
hours post IPTG induction; the sample can trimerize since 
in the pellet two bands are seen at the expected MW for 
the monomer (when boiled) and trimer (when not boiled), 
but it's insoluble since these bands are not seen in the 
supernatant. 
pAG_33 Monomer Trimer No No Protein expression detected at time 1, 2, 3, and 16 
hours post IPTG induction; the sample can trimerize since 
in the pellet two bands are seen at the expected MW for 
the monomer (when boiled) and trimer (when not boiled), 
but it's insoluble since these bands are not seen in the 
supernatant. 
pAG_36 Monomer Trimer No No Protein expression detected at time 1, 2, 3, and 16 
hours post IPTG induction; the sample can trimerize since 
in the pellet two bands are seen at the expected MW for 
the monomer (when boiled) and trimer (when not boiled), 
but it's insoluble since these bands are not seen in the 
supernatant. 
pAG_37 Monomer Trimer No No Protein expression detected at time 1, 2, 3, and 16 
hours post IPTG induction; the sample can trimerize since 
in the pellet two bands are seen at the expected MW for 
the monomer (when boiled) and trimer (when not boiled), 





4.2.4 Construction of tail fibre chimeras for homologous recombination  
 
The results of the in vitro folding assays suggested that the tail fibre fusions were probably not 
able to form functional proteins as they were insoluble and therefore were unlikely to fold 
correctly. To investigate if tail fibres fusions may work in vivo, the same tail fibre gene fusions 
were engineered into the genome of phage T7. Genome engineering was carried out using the 
previously developed homologous recombination and marker-based selection method on E. 
coli DtrxA (Sections 2.3.11 and 3.3.3). In order to perform homologous recombination, first 
plasmids had to be generated that contain recombination arms, gene fusions and the trxA 
selective marker Figure 4-10. All of the constructs were cloned in pSB6A1. Each of the 
constructs generated had homologous recombination arm (HR1) (sequence of 99 bp at the end 
of g17 genome region coding for Gp17 pyramid domain), Mtd sequence (depending on the 
fusion of interest) full trxA and HR2, which consisted of 99 bp after the g17 Figure 4-10. A 
total of seven different variants, three for each no-foldon A and B fusion group, as well as a 









































HR 2 Vector 
pAG_42 1 B 1309 – 1398 513 – 1146 full 
sequence 
90 bp after g17 pSB6A1 
pAG_43 2 A 1309 – 1398 165 – 1146 full 
sequence 
90 bp after g17 pSB6A1 
pAG_44 3 B 1309 – 1398 489 – 1146 full 
sequence 
90 bp after g17 pSB6A1 
pAG_45 4 B 1309 – 1398 510 – 1146 full 
sequence 
90 bp after g17 pSB6A1 
pAG_46 5 A 1309 – 1398 141 – 1146 full 
sequence 
90 bp after g17 pSB6A1 
pAG_47 6 A 1309 – 1398 150 – 1146 full 
sequence 
90 bp after g17 pSB6A1 




90 bp after g17 pAJ57 
A 
B 
Figure 4-10. Summary of constructs made for homologous recombination, for both A and B group Gp17 and Mtd 
fusions. (A) Partial vector sequence representing the components of the homologous recombination vector (Mtd 
fusion). From left to right, the components are: homology arm 1 (HR 1) which consists of g17 (1309-1398), the 
Mtd sequence of interest (depends on the fusion), a stop codon (not shown here), RBS (B0034), full trxA gene, stop 
codon, terminator, and then homology arm 2 (HR 2) that is 89 bp after the g17 stop codon. (B) Constructs made 
for homologous recombination. 
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4.2.4.1 Marker-based phage mutant selection with and without in trans complementation 
 
Prior to making all T7 tail fibre chimeras it was decided to test the applicability of marker-
based method selection on just one tail fibre chimera. Two sub-methods were devised to verify 
this. Both methods had the same initial step of phage T7 infection of E. coli BW25113, which 
contained the homologous recombination plasmid pAG_42 (Figure 4-11). The resulting 
progeny consisted of both T7 as well chimeric phages (Figure 4-11). The first method consisted 
of simply plating the above phage mixture on E. coli DtrxA for selection (Figure 4-11). The 
data collected up to this point suggested that the tail fibre fusions would be non-functional. If 
this is the case then there would be no plaques generated on the E. coli DtrxA because the 
recombinant phage with the fusion tail fibres would not infect the cells due to the non-
functional tail fibres. Therefore, a second selection method was devised. The phage mixture 
after the homologous recombination was plated on E. coli DtrxA/pSEVA551 (Figure 4-11). In 
the case of tail fibres not being functional, having g17 in trans complementation would enable 
the chimeric phage infectivity. At a genomic level these chimeric phages would retain the tail 
fibre fusions via the selection of trxA. However, the tail fibre phenotype would be a mixture of 
wild type and tail fibre fusions. This should retain the phage infectivity and generation of 
plaques on the E. coli DtrxA/pSEVA551 even if the tail fibre fusions were non-functional. 
 
Homologous recombination for T7 was carried out using vector pAG_42 and the resultant 
progeny was plated on E. coli DtrxA/pSEVA551 or E. coli DtrxA (Figure 4-11). Both selections 
resulted in plaque formation (Figure 4-12). Plaques for the E. coli DtrxA only selection 
generated half the size plaques when compared to E. coli DtrxA/pSEVA551 (Figure 4-12). 
Selection on E. coli DtrxA produced progeny at a titre of 1 x 102 PFU/ml, which was lower 
than the 1 x 108 PFU/ml when selecting on E. coli DtrxA/pSEVA551 (Figure 4-12). 
 
Plaques from both methods were tested by PCR (Section 2.3.12) to determine if recombinant 
phage were present using primers AG063 and AG064 that bind outside the g17 region. A 
difference of ~1 kb should be observed between wild type g17 and a chimeric g17. Selection 
on E. coli DtrxA only resulted in two bands: one for the recombinant phage and one for the 
wild type phage, which suggested that there was wild type phage contamination in all of the 
plaques (Figure 4-12). This was not the case for the plaques selected using E. coli 
DtrxA/pSEVA551. The plaques from the first method were plaque purified ten times, however, 
the two bands persisted at each purification step, indicating wild type contamination. The in 
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trans method was chosen to generate further chimeric phages (Table 4-2), where each of the 























Figure 4-11. Selection for recombinant phage. Step 1 - infection of phage T7 in E. coli BW25113 cells containing 
a tail fiber gene homologous recombination (HR) plasmid. The infection yields a mixture of phage, the wild type 
T7 as well as homologously recombined T7 (chimeric T7). Step 2 - selection of chimeric phage by infection of 
the phage mixture in the Step 1 into (A) E. coli DtrxA cells or (B) E. coli DtrxA/pSEVA551 cells.  Step 3 – plating 
the cells and phage from Step 2 on an agar plate. 
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Figure 4-12. Phage enumeration after T7 homologous recombination in E. coli BW25113/pAG_42 and its later 
genomic verification. (A) Enumeration of phage plated after homologous recombination of T7 on E. coli △trxA 
and E. coli △trxA/ pSEVA551. (B) Chimeric phage verification using PCR for g17 region (AG063 and AG064 
primers), WT T7 product is ~2 kb and chimeric of ~3 kb. ‘L’ lane represents GeneRuler 1 kb Plus DNA, 
samples/lanes 1-9 E. coli △trxA plaques. Lane/sample 10 product of T7 g17 (+ve control). Lane/sample 11 is a 
plaque generated on E. coli △trxA/pSEVA551. (C) Phage enumeration of the phage mixture after homologous 






Table 4-2. Tail fibre chimeric phages were generated using trxA in trans method, where each of the chimeric 
phages bellow were purified using E. coli △trxA complemented with g17 expressing vector (pSEVA551). 
Name Fusion Group HR 1/aa Mtd*/aa Rbs/trxA HR 2**/aa 
phAG_1 
(T7-CH1)  
B 437-466 171 - 382 full sequence end of Gp17 
phAG_2 
(T7-CH2) 
A 437-466 55 - 382 full sequence end of Gp17 
phAG_3 
(T7-CH3) 
B 437-466 163 - 382 full sequence end of Gp17 
phAG_4 
(T7-CH4) 
B 437-466 170 - 382 full sequence end of Gp17 
phAG_5 
(T7-CH5) 
A 437-466 47 - 382 full sequence end of Gp17 
phAG_6 
(T7-CH6) 
A 437-466 50 - 382 full sequence end of Gp17 
phAG_7 
(T7-CH7) 




4.2.4.2 Pertactin expression in E. coli for chimeric phage testing 	
 
In order to verify if the chimeric phages were able to infect, they were tested on B. pertussis 
and B. bronseptica. However, the strains were not initially available, so prior to this testing an 
alternative characterisation system was sought. It was decided to express the receptor protein 
pertactin in E. coli. If successful this would then be followed by assays with chimeric phage 
challenging (infecting) pertactin expressing E. coli, to determine if pertactin presence allows 
binding by the designed tail fibre fusions. Pertactin containing expression vector, pSLprn32 
(Section 2.1.1), was kindly provided by Angus Bonetti and was used in this study.  
 
To confirm that pertactin is expressed and localised in the outer membrane cellular layer, 
pertactin containing cultures were separated by ultracentrifugation post induction followed by 
Western blotting (Sections 2.5.1, 2.5.2 and 2.5.4). In Figure 4-13, lanes 1-3 show the OM 
fraction of pSLprn32 expressing cells. No pertactin equivalent band (P 69) was seen prior to 
induction, while by 1 hour a weak band was visible. Lower weight bands were also seen, which 




Figure 4-13. SDS-PAGE and Western Blotting of the pS-prn32 in BL21. ‘OM’ is the outer membrane, 
fractionated by ultracentrifugation and selective dissolution in sarkosyl. The location of P.69 was determined by 
overlaying the protein molecular weight marker on the membrane image which showed the corresponding band 
to be 58-80kDa. 
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4.2.4.3 Infection of pertactin expressing E. coli with chimeric phage 
Once the pertactin expression in E. coli was confirmed it was possible to test whether the 
chimeric phage was able to infect using pertactin as a receptor. To determine this, growth 
assays were conducted in which different types of host cells were subjected to either phage, 
IPTG induction, or both.  
The in trans method without complementation was used to generate chimeric phages. As seen 
in 4.2.4.1 this method results in chimeric and T7 phages. In order to test whether phage killing 
was due to pertactin-mediated entry or T7 entry via LPS, E. coli ΔwaaC cells were used to 
express pertactin. This strain has a kanamycin gene inserted into the coding region of its E. coli 
ΔwaaC gene, the product of which facilitates the biosynthesis of LPS. Consequently, it is 
unable to produce wild-type LPS and is resistant to T7 infection328. The use of E. coli ΔwaaC 
was to prevent any wild-type T7 infection and any infection had to be as a result of T7 chimeric 
phages. The pLprn34 construct was transformed into E. coli ΔwaaC as well as E. coli 
BW25113. Growth assays were conducted with and without phage (Section 2.2.3). No lysis 
was observed in any of the LPS-deficient E. coli ΔwaaC cells, whether or not they bore the 
pertactin-expression construct or were induced (Figure 4-14). Conversely, lysis was observed 
in the E. coli BW25113 control. However, this was likely due to wild type T7 contamination 
as the phage used in this experiment was E. coli ΔtrxA purified without in trans 











































Figure 4-14. E. coli DwaaC/pSLprn32 challenge: growth of E. coli strains bearing pertactin expression constructs 
was assayed by OD600 and under the following conditions: no treatment, induction with 0.05mM IPTG, challenge 
with chimeric phage at an MOI of 0.1, and both IPTG induction and challenge with phage. (A) E. coli DwaaC 
cells. (B) E. coli DwaaC cells containing pertactin, pLprn34, in trans. (C) E. coli BW25113 cells. N=3. 
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4.2.4.4 Infectivity of T7 chimeric and BPP-1 variant phages on E. coli, B. pertussis and B. 
bronchiseptica 
 
For all of the characterisation experiments, chimeric phage T7 were generated using the E. coli 
ΔtrxA without in trans tail fibre complementation. This means that the samples were wild type 
T7 contaminates as identified in section 4.9; however, this was not an issue since wild type T7 
does not infect either of the Bordetella strains and it will also be tested separately as a negative 
control. BPP-1, BMP-1, and BIP-1 phages were kindly sent by the research group of Dr Jeff F. 
Miller, based at the University of California, Los Angeles. 
 
4.2.4.5 Host range of chimeric T7 phages 
 
E. coli BW25113 was challenged with chimeric phages through a spot assay (Section 2.3.6). 
No spots were generated indicating that the chimeric tail fibres do not allow infection of E. coli 
Table 4-3. Phages BPP-1, BMP-1, and BIP-1 were also tested on E. coli and as expected, there 
was no indication of lysis Table 4-3.  
 




phAG_1 no lysis 
phAG_2 no lysis 
phAG_3 no lysis 
phAG_4 no lysis 
phAG_5 no lysis 
phAG_6 no lysis 
phAG_7 no lysis 
BPP-1 no lysis 
BMP-1 no lysis 




4.2.4.6 Infection assays on B. bronchiseptica  
In order to quantify the potential of chimeric phages to infect B. bronchiseptica it was necessary 
to test that T7 does not infect B. bronchiseptica. A dilution series of T7 was spotted onto lawns 
of B. bronchiseptica. Surprisingly it was found that T7 produced lysis on B. bronchiseptica 
(Figure 4-15). This was replicated three times for the two biological replicates of B. 
bronchiseptica with three different stocks of T7, all of which resulted in lysis. To ensure that 
the phage T7 stocks used were not contaminated the plaque from Figure 4-15 was used to 
perform PCR (amplification of g17) that confirmed the presence of T7; no TEM was used to 
further ensure the presence of T7. The B. bronchiseptica was taken directly from a frozen 
glycerol stock, created from the original stock sent by A. Preston (University of Bath); its 
genome was not verified using sequencing. To verify that T7 was causing the lysis, PCR was 
performed on all of the zones of lysis of B. bronchiseptica using T7 g17 specific primers 
(Appendix 2) and then sequenced which confirmed the presence of T7 in the zones of clearing. 
To determine if the T7 on B. bronchiseptica underwent replication the following work was 
carried out. First, the amount of phage that theoretically was present in the 10-2 dilution zone 
of lysis was calculated, using the assumption that no replication was taking place. The stock 
concentration of the phage used was 4 x 108 PFU/ml. After spotting 10 ul of each of the phage 
dilutions 100, 10-1, and 10-2, PFUs were generated of 4 x 106, 4 x 105, and 4 x 104, respectively. 
A 10 ul pipette (0.033 cm in diameter) was used to stab the 10-2 dilution spot (1.66 cm in 
diameter), allowing ~1/50th of the phages from the spot to be transferred to 110 ul of medium. 
This resulted in a phage concentration of 8 x 103 PFU/ml, calculated as shown below: 
4 x 104/50 = 8 x 102 PFU or 8 x 102 PFU/110 ul or ~8 x 103 PFU/ml 
After carrying out a plaque assay (see section 2.3.5) the empirical value for the phage 
concentration was found to be ~2.125 x 105 PFU/ml (Figure 4-14), which is ~27-fold greater 
than the theoretical phage concentration. This suggests that the amplification of phage was 
taking place to some extent.  
BPP-1 and its variants generated no lysis on B. bronchiseptica indicating that there might have 
been an issue either with phage storage (the phage was stored at 4C for seven months prior to 




4.2.4.7 Infection assays on B. pertussis 
Given the characterisation data up to this point, it is important to note that the positive controls, 
BPP-1 and its variants, have not worked on B. bronchiseptica. T7, T7 chimeric phages 
(ph_AG1, phAG_2 and phAG_3) as well as BPP-1 and its variants were assayed on B. pertussis 
(received from A. Preston, no sequencing performed) using a spot assay (see section 2.3.5). It 
was found that T7, T7-ph_AG1, T7-phAG_2, T7-phAG_3 as well as BPP-1 caused zones of 












Figure 4-15. (A) T7 against B. bronchiseptica spot assay plated on LB agar. The T7 stock concentration used for 
the assay was 10^8 PFU/ml. (B) Phage enumeration.  2 ul of phage was collected from the second dilution of T7 












Figure 4-16. Spot assay of T7, T7 tail fibre chimeric as well as BPP-1, BPP-2, BPP-3 phages against B. pertussis. 
Lane 1 shows the negative only LB control, lanes 2-4 represent phAG_1, phAG_2 and phAG_3 chimeric 
bacteriophages, lanes 5-7 represent BPP-1-3 phage variants, and lanes 8-10 represent T7 three biological controls. 
The spot assay was carried out on charcoal agar. 
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4.3 Discussion  
 
4.3.1 Fusion tail fibre design and insolubility  
 
In vitro tail fibre analysis (section 4.2.3.1) showed that the fusion tail fibres are not soluble 
and, in some instances, unable to form trimers. This is a strong indication that the fusion tail 
fibres either no longer form trimers due to instability, or that the Gp17 and Mtd domains fused, 
resulting in misfolded insoluble fusion tail fibre aggregates249,361. One potential cause of Mtd 
instability might be that only keeping two (sandwich and tip domains) out of three Mtd domains 
(prism, sandwich and tip domains) for the fusions was not sufficient to retain tail fibre stability 
and trimerization. The ‘prism’ domain, which wasn’t included in either A or B fusions, might 
be required for stability as it has a tight trimeric organisation when compared to the sandwich 
domain that branches away from the prism domain trimer axis. Therefore, potentially leaving 
the prism domain in when designing protein tail fibre fusions could aid the trimerization. 
However, leaving in the prism domain would also increase fusion tail fibre length. In the 
previous study it was suggested that upon tail fibre binding to the target bacterium receptor, 
the tail fibre reaches a confirmation that allows opening of the internal tail channel, resulting 
in DNA injection and capsid protein release364. Significant length alterations of the tail fibre 
could potentially interfere with the formation of the correct confirmation. Furthermore, even 
though the tip domain has a potentially independent fold from that of other Gp17 domains 
when the trimer is formed, it was also suggested that the tip domain monomer formation could 
initiate the trimer formation of the entire tail fiber tail fiber356. This could happen by the tip 
domain initially forming a monomer with a spontaneous formation of a monomeric carboxyl-
terminal b-barrel356. The interaction of three b-barrels could then lead to the trimer 
formation356. This suggests that by altering the tip of the tail fber may interfere with its ability 
to form trimers. 
 
4.3.2 Continuous contamination of chimeric phage with T7 
 
When E. coli DtrxA without in trans complementation was used for phage selection, wild type 
T7 was found after multiple rounds of plaque purification. The chimeric phage should make 
up the majority of the phage particles since it is able to undergo replication due to genomic 
insertion of trxA, while the T7 phage lacks trxA and is therefore is incapable of 
replication257,260,365. If the T7 persistence was to be due to contamination, multiple plaque 
purification steps should have removed it due to the contaminant being diluted out366.  
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Furthermore, it was found that on its own, the phage T7 titre was reduced from 4 x 108 PFU/ml 
to <1 PFU/ml when plated on E. coli DtrxA, whereas in this case the titre of 4 x 108 PFU/ml 
was reduced to 102 PFU/ml. This suggests that there are additional factors contributing to the 
persistence of T7.  When comparing different selection methods, it was found that using E. coli 
DtrxA resulted in visibly smaller plaques when compared to using E. coli DtrxA/pSEVA551, 
indicating a somewhat reduced phage burst size367,102. It is unlikely that this is due to 
homologous recombination between the wild type and the chimeric phage, as both wild type 
and chimeric variants were detected in plaques (Figure 4-12). In addition, the in vivo 
characterisation suggested that the tail fibre fusions are most likely not folded properly and 
therefore not functional. A potential explanation for this result could be a co-infection between 
the wild type and the chimeric phage, where one would provide correct tail fibres and the other 
provide the trxA gene required for replication. However, it is currently thought that T7 excludes 
coinfection368.   
 
4.3.3 Phage testing against B. pertussis and B. bronchiseptica 
 
T7, T7 tail fiber chimeric mutants and BPP variants yielded zones of clearance while there was 
no clearance in the negative control sample of LB only, suggesting that all phage types 
generated lysis. Attempts to test phage variant infectivity of B. pertussis were complicated by 
poor B. pertussis lawn formation during all assay attempts. Additional attempts by A. Preston’s 
lab (University of Bath, unpublished data) to grow B. pertussis also resulted in similar poor 
lawn formation. Therefore, the results for the phage infectivity against B. pertussis are 
inconclusive. 
 
In the case of phage testing against B. bronchiseptica it was found that the T7 negative control 
not only generated bacterial lysis but also achieved phage amplification. Given the differences 
between the E. coli and  B. bronchiseptica LPS surfaces, this result was surprising, if not 
unprecedented369. There are several reports of broad host range phage107,370,371. However, T7 
has only been reported to infect E. coli, rough S. typhimurium and some Shigella strains223,372. 
A possible explanation for the observed B. bronchiseptica lysis by T7 could be due to the lysis 
from without phenomenon, where multiple phage particles adhering to the bacterial cell result 
in cell death without any phage particles having replicated41. However, this possibility can be 
ruled out since it was calculated that after B. bronchiseptica lysis by T7 the resulting phage 
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In chapter 4, wild type T7 contamination was detected after numerous chimeric phage 
purification steps, suggesting co-infection between the two phages. Current literature suggests 
this would not be the case due to a widely accepted interpretation of T7 superinfection 
exclusion principle, where the entry of the first phage into a bacterial cell inhibits the entry of 
a secondary phage368,373. Although this conventional view of T7 infection lacks an elucidation 
of the precise exclusion mechanism, multiple conflicting studies have sought to interpret the 
mechanistic features causing this exclusion.  
 
5.1.1 Superinfection exclusion of T7 homologous phages  
 
There are multiple studies supporting the superinfection exclusion phenomenon. In one study 
a dual strategy was used to determine if the secondary attachment after primary infection is 
excluded from replication373. First, the conservative transfer of 32P labelled parental DNA was 
used to show that un-replicated parental DNA molecules are not linearly related to the number 
of phage adsorbed per cell, and that only a limited number of phages can replicate their DNA 
in each cell373. Secondly, the primary and secondary infections were examined using two 
different T7 amber mutants. The results revealed that if the amber mutants were added 
simultaneously the productive infection is equal to that of the number of bacteria infected. 
However, if the secondary amber mutant phage is added seven or more minutes post infection 
the number of productive infections is not influenced at all; it can no longer complement the 
primary infecting phage, supporting the T7 superinfection exclusion principle373. The same 
study also suggested that addition of chloramphenicol can reduce the exclusion principle, 
implying that the superinfection exclusion takes place after the initial protein synthesis of the 
primary phage373. Moreover, in a further study the chloramphenicol method for superinfection 
exclusion prevention was used to show that UV-irradiated wild-type T7 phage markers can be 
rescued by coinfection with a T7 amber mutant374. Superinfection exclusion inhibition was also 
demonstrated using alkylation of primary T7 phage by methyl methane sulfonate as it 
interfered with superinfection exclusion375. This interference could be potentially correlated 
with a delay in the synthesis of phage-specific proteins. Therefore, it has been suggested that 
protein synthesis directed by the primary infecting phage is key for efficient exclusion of 
superinfecting secondary phage particles. In contrast, it has been suggested that 
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chloramphenicol treatment does not prevent superinfection exclusion and that the phenomenon 
does not depend on protein exclusion368. 
 
5.1.2 Superinfection exclusion of heterologous phages 
 
Mixed infection of E. coli with phages T1 and T2 results in the exclusive development of T2376. 
Similarly, mixed infection by T3 and T7, closely related coliphages, usually gives rise to the 
exclusive development of either T3 or T7, with both phages generated only rarely368.  In some 
instances two phages that share the same host cell receptor but are genetically different maybe 
able to co-infect377. As demonstrated by infection of E. coli cells with ΦX-174 at an MOI of 
10 is insufficient to inhibit phage T7 progeny production, suggesting ΦX-174 does not interfere 
with T7 adsorption377. 
 
Heterologous superinfection has been systematically investigated by making early gene 
mutants of T7 that would interfere with their function368. These T7 mutants were then used as 
primary phages followed by infection with T3 as a secondary phage368. The most effective of 
the early genes in preventing superinfection appeared to be g1 and g0.3368.  In the case of g1, 
it was not clear whether the exclusion was due to the action of g1 coding phage RNA 
polymerase itself or if it was the result of the genes expressed by it368,378. In addition, to explain 
the superinfection exclusion between T7 and T3 phages, it was suggested that binding of the 
heterologous RNA polymerase enzyme to the DNA of co-infecting phage particles may 
interfere with the transcription of this DNA by the homologous enzyme379.  
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5.1.3 Aims  
  
The aim of the chapter is to determine if co-infection is possible between T7 and recombinant 
phage mutants. To meet this aim the chapter has been divided into following sub-aims: 
 
1) Further investigation into two phage co-infection in solid medium; 





5.2.1 Investigation of chimeric and wild type phage infection on solid medium  
 
To investigate the interaction between T7 and chimeric phages, T7-CH1, T7-g17::trxA, and 
T7 phages were used. T7-CH1 as described in Figure 4-3 and Table 4-2, is a tail fiber chimeric 
phage, where the tip domain of T7 Gp17 was replaced with the C-lectin domain of Bpp-1 Mtd. 
The gene sequence of the C-lectin domain was inserted together with trxA gene that confers 
selection advantage for engineered phage. T7-g17::trxA phage had the g17 tail fiber gene 
completely replaced by trxA gene. Each of the phages was amplified, purified (Section 2.3.3 
and 2.3.13) and the stock for each was diluted to approximately 1 x 108 PFU/ml.  Either T7-
CH1 or T7-g17::trxA was mixed with T7 in 1:1, 1:0.1, 1:0.01 and 1:0.001 ratios (the number 
of total phage was kept the same (108 PFU/ml) throughout all ratios and used to perform plaque 
assays on E. coli DtrxA (section 2.3.5). For the T7-CH1 and T7 mixture, the 1:1 ratio resulted 
in the highest number of progeny of approximately 104 PFU/ml. When one of the phages (either 
T7 or T7-CH1) was reduced by 10-fold the PFU reduced by approximately 5-fold (Figure 5-
1). An even greater decrease was seen when one of the phages was reduced 100 or 1000-fold, 
approximately 10 and 100-fold respectively. A similar trend is seen for the ratios between T7-








Figure 5-1. Phage enumeration for different chimeric and T7 phage ratios. T7 and chimeric phage stocks 
were diluted to approximately 108 PFU/ml and mixed in the following ratios: 1:0.001, 1:0.01, 1:0.1, 1:1 
for each phage. Plaque assays were performed, for each of the phage ratios; phages were then 
enumerated. (A) Phage enumeration for T7 and T7-CH1 ratios. (B) Phage enumeration for T7 and T7-
g17::trxA ratios. The PFU/ml data are presented as the mean of three independent experiments, n=3. 
 
 
T7 is constant T7-CH1 is constant 
T7 and T7-CH1 ratios 
T7 and T7-g17::trxA ratios 
T7 is constant T7-17::trxA is constant 
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5.2.2 Investigation into chimeric and T7 phage interaction in liquid medium  
 
In order to deduce if the two phages are co-dependent on each other for replication in liquid 
medium, the following experimental set-up was used. Bacterial growth/phage lysis assays 
(Section 2.3.14) at MOIs of 0.001, 1 and 3 with the following conditions: E. coli DtrxA cells 
only, E. coli DtrxA cells with phage T7, E. coli DtrxA cells with the chimeric phage T7-CH1 
and E. coli DtrxA cells containing both T7 and T7-CH1 phages (Figure 5-2). No lysis occurred 
when either T7 or T7-CH1 was added to E. coli DtrxA cells at an MOI of 0.001 or 1, but did 
occur for T7 at an MOI of 3. At this higher MOI some lysis occurred at ~40 minutes post 
infection, but E. coli growth was quickly resumed at 50 minutes. When both T7 and T7-CH1 
were added to E. coli DtrxA cells lysis occurred for all samples. This result in Figure 5-2 
potentially occurred due to the fact that T7 was not able to replicate in E. coli DtrxA, whereas 
T7-CH1 was unable to adsorb due to the altered tail fiber. To further verify that the replication 
only occurred when both T7 and T7-CH1 phages were present, the resulting phages after the 
MOI 0.001 growth/lysis assay (Figure 5-2) were enumerated using spot assay (section 2.3.6). 
Both T7 and T7-CH1 only samples resulted in 104 PFU/ml whereas the sample that contained 
both phages generated 107 PFU/ml (Figure 5-3) The original amount of phage added was 







Figure 5-2. Bacterial growth/phage lysis assays. Each of the assays had the following conditions: E. coli DtrxA cells only, E. coli  
DtrxA cells with wild type T7 (unable to replicate) added, E. coli DtrxA cells with T7-CH1 (unable to adsorb) added, and E. coli  
DtrxA cells with wild type T7 and T7-CH1 added. (A) Phages were added at an MOI of 0.001 (n=3 for each condition except for 
E. coli  DtrxA cells with wild type T7 and T7-CH1, which were n=2 due to lack of lysis in the third biological replicate). (B) Phages 
were added at an MOI of 1 (n=3 for each condition). (C) Phages were added at an MOI of 3 (n=3 for each condition). 
 
DtrA cells  
DtrA + T7, MOI=0.001 
DtrA + T7-CH1, MOI=0.001 
DtrA + T7 & T7-CH1,  
MOI=0.001 
DtrA cells  
DtrA + T7, MOI=1 
DtrA + T7-CH1, MOI=1 
DtrA + T7 & T7-CH1,  
MOI=1 
DtrA cells  
DtrA + T7, MOI=3 
DtrA + T7-CH1, MOI=3 




Figure 5-3. Phage enumeration was performed after the growth/lysis assays for MOIs of 0.001 and 3 presented in 
Figure 5.2.2 -1 on E. coli BW25113 cells. After completing the assay described in 5.2.2, plaque assays were 
performed on three samples from the plate reader wells: E. coli DtrxA cells containing T7 only, T7-CH1 only and 
T7 and T7-CH1 combined. Phages were enumerated using spot assay and the PFU/ml data are presented for one 
biological replicate per well. (A) Phage recovered from Figure 5.2.2 -1, A (MOI 0.001); the original amount of 
phage added was approximately 1 x 105 PFU/ml. (B) Phage recovered from Figure 5.2.2 -1, C (MOI of 3); the 












5.2.3 Removal of T7 replication using CRISPR-Cas type II 
 
The results of Section 5.2.2 demonstrated that co-infection was required to produce lysis, it 
was reasoned that if the replication of one of these phages could be halted the replication of 
both phages would be stopped. This was tested using the previously developed CRISPR system 
(Section 3.3.2). Since CRISPR only shows 1000-fold reduction in T7 phage plaque formation 
when using the most efficient gRNA (Section 3.3.2), it was reasoned that CRISPR would only 
be effective at ‘removing’ the co-infection at MOIs lower than 1. In order to verify this the 
following conditions were set-up: E. coliDtrxA/pAG_13 (gRNA2), E. coliDtrxA/pAG_12  
(non-targeting gRNA(scr)) and E. coli DtrxA. For each of the cell types one of the following 
was added: T7, T7-CH1 or both, at MOIs of 0.001 and 0.01 (Section 2.3.14). At all MOIs no 
lysis was observed when just T7 or phage T7-CH1 were added to E. coli DtrxA or E. coli 
DtrxA/pAG_13 cells, and lysis only occurred when T7 and T7-CH1 were added in combination 
to E. coli DtrxA cells. When the phages were combined and added to E. coli DtrxA/pAG_13 
cells that contain a CRIPSR system to target T7 replication, no lysis was observed at any MOI 
(Figure 5-4). Thus, stopping the replication of one phage also stopped the replication of the 






Figure 5-4. Bacterial growth/phage lysis assays. Each assay contains two cell types: E. coli DtrxA cells expressing 
either the CRISPR type II system with a non-targeting scrambled gRNA (noted as E. coli  DtrxA + gRNA(scr)) or the 
CRISPR type II system with a targeting gRNA2 (noted as DtrxA + gRNA2). In each of the cell types wild type T7, T7-
CH1 or both wild type T7 and T7-CH1 were added. (A) Phages were added at an MOI of 0.001 (n=3 for each condition 
except for DtrxA + gRNA(scr) with wild type T7 and T7-CH1 added, which was n=2 since the third biological replicate 
did not show lysis). (B) Phages were added at MOI of 0.01 (n=3 for each condition). 
DtrA/gRNA(scr) + T7 
DtrA/gRNA(scr) + T7-CH1 
DtrA/gRNA(scr) + T7&T7-CH1 
DtrA/gRNA2 + T7 
DtrA/gRNA2 + T7-CH1 
DtrA/gRNA2 + T7&T7-CH1 
 
DtrA/gRNA(scr) + T7 
DtrA/gRNA(scr) + T7-CH1 
DtrA/gRNA(scr) + T7&T7-CH1 
DtrA/gRNA2 + T7 
DtrA/gRNA2+ T7-CH1 
DtrA/gRNA2 + T7&T7-CH1 
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5.2.4 Delayed addition of a secondary phage effects on the potential co-infection  
 
In order to investigate whether both phage need to be added at the same point for co-infection 
to occur, the addition of the second phage was delayed. The primary phage was added at an 
MOI of 0.5 to E. coli DtrxA cells followed by addition of a secondary phage at an MOI of 0.5 
after 15, 30, 60 and 120 minutes marked as arrows in Figure 5.2.4-1 (Section 2.3.14). When 
the T7 was the primary phage the addition of T7-CH1 phage after 15, 30, 60 and 120 resulted 
in lysis after approximately 70, 90, 130 and 210 minutes respectively. When the reciprocal 
experiment was carried out, lysis occurred after 60, 90, 130 and 205 minutes respectively 
(Figure 5-5). This result further confirms that both phages are required to allow phage 
replication and lysis of the cells. In addition, this verifies that for co-infection to take place 






Figure 5-5. Bacterial growth/phage lysis assays in E. coli  DtrxA cells at an MOI of 1. (A) T7 and T7-CH1 are used as 
primary and secondary phages, respectively. At the start of the assay wild type T7 was added to four samples at an MOI 
of 0.5, followed by T7-CH1 at an MOI of 0.5 after either 15 min (15 min T7-CH1), 30 min (30 min T7-CH1), 1h (1 h T7-
CH1), or 2h (2 h T7-CH1). Two additional samples only contained either wild type T7 or T7-CH1, added at the start of 
the assay at an MOI of 1. (B) T7-CH1 and wild type T7 are used as primary and secondary phages, respectively. At the 
start of the assay T7-CH1 was added to four samples at an MOI of 0.5, followed by wild type T7 at an MOI of 0.5 after 
either 15 min (15 min T7), 30 min (30 min T7), 1 h (1 hr T7), or 2 h (2 hr T7). Two additional samples only contained 
either wild type T7 or T7-CH1, added at the start of the assay at an MOI of 1. Arrows represent time points of phage 
addition. N=3. 
15 min T7-CH1 
30 min T7-CH1 
1 h T7-CH1 
2 h T7-CH1 
T7 only  
T7-CH1 only 
 
15 min T7 
30 min T7 
1 h T7 
2 h T7 




5.2.5 Construction and characterisation of T7-g5::trxA mutant for further co-dependency 
verification  
 
To investigate if co-infection only occurrs when targeting a tail fiber gene, a T7 mutant was 
constructed lacking g5 which encodes DNA polymerase. To achieve this, vector pAG_60 
(Appendix 1), containing trxA in between 100 bp long homologous recombination arms (before 
and after g5), was constructed using Gibson assembly (Section 2.1.7). This vector was then 
used to generate the T7-g5::trxA phage using homologous recombination (Section 2.3.11), 
followed by selection and purification using E. coli DtrxA with g5 (pET24-gp5, see Appendix 
1) in trans as well as E. coli DtrxA only. In the latter, after multiple rounds of purification, PCR 
was performed on the plaques (Figure 5-6) with the resulting PCR product examined using gel 
electrophoresis and sequenced. Both T7 as well as T7-g5::trxA phage corresponding bands 
were found, replicating the result previously seen for the tail fiber chimeras (section 5.2.1). The 
next step was to perform a ratio experiment (Section 5.2). As seen previously for the tail fiber 
mutant, the 1:1 ratio resulted in the highest amount of phage enumerated, approximately 5 x 
105 PFU/ml (Figure 5-6). When one of the phages was reduced by 10-fold the resulting PFU 
was reduced approximately by 10-fold. Even greater PFU drops were seen when one of the 
phages was reduced 100 or 1000-fold, approximately 100 and 1000-fold respectively. To test 
the co-dependency in liquid medium, the experimental set-up used in section 5.2.2 was used, 
with assays performed at MOIs of 1 and 0.001 (Figure 5-7). As seen previously, lysis did not 
occur when either T7 or T7-g5::trxA phages were added to E. coli DtrxA cells at either MOI, 
but did occur when both T7 and T7-g5::trxA phages were added to E. coli DtrxA (Figure 5-7).  










Figure 5-6. Evidence for T7-g5::trxA and wild type T7 co-dependence. (A) Chimeric phage verification in which 
the phage g5 region from six E. coli △trxA plaques was amplified using PCR with the products examined via gel 
electrophoresis. All six plaques (lanes 1 – 6) contained both T7 (~2 kb) and chimeric (~600 bp) g5 regions. The 
far left lane, marked ‘bp’, contains the reference ladder GeneRuler 1 kb Plus DNA while the far right lane, lane 
7, contains the negative control (no DNA template). (B) Phage enumeration of wild type T7 and chimeric T7-
g5::trxA phage ratios. Phage stocks were diluted to approximately 108 PFU/ml and mixed in T7:chimeric ratios 
of 1:0.001, 1:0.01, 1:0.1, 1:1. Plaque assays were performed for each of the phage ratios, followed by phage 




 T7 is constant T7-g5::trxA is constant 
T7 & T7-g5::trxA ratios 
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A 
B 
Figure 5-7. Bacterial growth/phage lysis assays. Each assay had the following conditions: E. coli  DtrxA cells 
only, E. coli DtrxA cells with T7 added, E. coli DtrxA cells with T7-g5::trxA added, and E. coli DtrxA cells with 
T7 and T7-g5::trxA added. (A) Phages were added at an MOI of 1 (n=3 for each condition). (B) Phages were 
added at an MOI of 0.001 (n=3 for each condition). 
 
DtrA cells  
DtrA + T7, MOI=1 
DtrA + T7-g5::trxA, MOI=1 
DtrA + T7&T7-g5::trxA, 
MOI=1 
DtrA cells  
DtrA + T7, MOI=0.001 
DtrA + T7-g5::trxA, MOI=0.001 
DtrA + T7&T7-g5::trxA, 
MOI=0.001 
MOI = 1 




5.3.1 Stochasticity of infection at lower MOIs 
 
In section 5.2.2 liquid medium experiments in E. coli DtrxA cells, the samples containing both 
T7 and T7-CH phages yielded lysis in comparison to the samples containing each of the T7 
and T7-CH phages separately at the same MOIs. However, at the lowest MOI of 0.001 tested 
one in three biological controls did not result in lysis (Figure 5-2). This could be potentially 
explained by very low total phage numbers present in the system making the ‘lysis’ outcome a 
low probability event, and somewhat stochastic, as both T7 and T7-CH need to enter the cell 
to generate the lysis. The probability of two distinct phage particles being able to enter a cell 
at the same time and at a given MOI was previously described using a Poisson distribution 
using the following formula: "($) = '
(×*+,
-!
	× 	0$01023	"45, where m is MOI of total phage 
added and n is number of distinct phage particles380. This formula is written under assumption 
that both particles enter the cell at the same time. Therefore, in this co-infection system at total 
MOI of 0.001 (m = 0.001) and the two particles were T7 and T7-CH phages (n = 2). The 
probability of successful co-infections at MOI of 0.001 seems to be relatively low 




























≈ 5 × 10GH 
 
(3) 0$01023	"45 = 1 × 10GIMOI × 	2 × 10MCFU = 1 × 10QPFU 
 
(4) <61723	"(2) = 1	 × 	10QPFU	 × 	5 × 10GH = S. ST 
 
Figure 5-8. Determination of probability of successful co-infections taking place at MOI 0.001. (1) equation 
describes the relationship at two particles being able to infect a given cell under an assumption that they infect 
at the same time; this is then multiplied by the initial number of phages initial added. (2) Working out the P(2). 





This could explain the difference in outputs for the three biological controls at MOI = 0.001. 
Given that the E. coli cells are doubling at approximately every 25 min and the very low 
probability of successful co-infection, the E. coli may outpace the number of phages generated. 
This stochasticity was not present in the samples with higher MOIs because greater amount of 
each phage was present which meant a higher probability that both of the phages will enter the 
cell and yield lysis overcoming the growth rate effect. In the case of MOI = 1, the 
261723	"(2) = 0.18. Therefore, the probability of successful co-infections increases with the 
higher MOI applied. 
 
5.3.2 Partial T7 lysis of E. coli DtrxA at high MOIs 
 
The addition of T7 to E. coli DtrxA cells at an MOI of 3 resulted in some reduction of growth 
followed by a quick recovery of growth. This could potentially be due to the fact T7 enters the 
cells, but replication does not occur (or at a very low level) since the trxA is absent from the 
cells, but lysis of the cells, due to phage entry occurs381. Once T7 enters the cell its genes are 
transcribed and later translated. The product of one of the early genes g0.7 inactivates 
transcription of multiple host genes as well inhibits host proteins, including RNAse III and E, 
and E. coli polymerase234. This shuts down the E. coli metabolism preventing the bacterium 
from functioning, reproducing and eventually resulting in its death. The bacterial death after 
phage infection in such way could serve as phage sink. T7 would be able to enter its host, 
however, since close to no replication was taking place the concentration of holin and lysin in 
the host cytoplasm may not be sufficient to release the progeny. Therefore, the cell would 
undergo death prior to releasing T7. One of the potential ways to validate that T7 entry alone 
(without phage amplification) causes cell death could be to generate T7 mutant phage lacking 
in g0.7. Addition of such phage to E. coli DtrxA cells should less hinder bacterial growth since 
it would prevent host protein inhibition and show a better growth when compared to growth of 
E. coli DtrxA cells with T7 added. 
Another possibility is that T7 progeny is released due to eventual accumulation of lysin and 
holin genes in E. coli, however, since T7 replication is disabled, the quantity of the progeny is 
significantly reduced and eventually outcompeted by E. coli growth, hence the bacterial growth 
after the increase at time 40 mins, Figure 5-2. This is supported by the spot assay (Figure 5-3) 
that shows no T7 phage number increase confirming no replication taking place. In the previous 
work, it has been shown that no replication takes place when T7 is used to infect E. coli DtrxA 
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cells, verifying that trxA is essential for T7 replication, supporting the results obtained in this 
chapter328. In another, in vitro, study, it has been shown that in absence of trxA T7 DNA 
polymerase sustained 1% of its original activity. This may not directly translate to in vivo 
results seen this chapter. However, it is a good indicator that DNA polymerase activity is 
inhibited and replication does not take place382. 
5.3.3 A potential cause of superinfection  
 
In the previous studies it has been suggested that superinfection exclusion happens due to 
primary phage expressing proteins that inhibit second phage entry into the cell373. This was 
studied with amber mutants, where the addition of a secondary mutant past 7 minutes of 
primary mutant addition, productive infections were not affected by the secondary mutant 
addion373. However, the data collected in this chapter, surpasses the 7 minutes time point for 
the superinfection. The addition of a secondary phage 2 hours after the primary phage showed 
phage infection recovery. It is possible that probability of P (2) =0.05 described in section 5.3.1 
is significantly larger given that co-infection does not depend on two particles entering at the 
same as evidenced by the delay experiments. Therefore, co-infection probability increases with 
time. 
 
In both T7 and chimeric phage co-dependency cases, chimeric phage had the advantage of 
having trxA in its genome, whereas the wild type had either the correct tail fiber gene or DNA 
polymerase. In both instances the wild type phage is dependent on the chimeric phage to 
provide the means of replication, via its trxA, which is required for DNA polymerase 
processivity383. For the co-dependency between the T7 and T7-g5::trxA, both phages depended 
on each other for replication as the modified phage had its g5 replaced with trxA, and T7 had 
the g5. When comparing ratio experiments between wild type phages with either g17 and g5 
mutants, the latter reaches an approximately 10-fold higher PFU/ml when the same amount of 
phage was added. This could potentially be due to the fact that in g5 mutant phage trxA is 
placed earlier in the genome (in g5 rather than g17 region) that could potentially account for 
an earlier availability of the TrxA in the system resulting in more progeny being produced.   
 
5.3.4 Proposed mechanism for the observed co-infection phenomenon 
 
To explain how this potential co-infection takes place, chimeric phage selection using the E. 
coli DtrxA cells only (described in Chapter 4.2.4) will be used as an example. In this example, 
all of the phage is plated on E. coli DtrxA cells after homologous recombination. The resulting 
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phage progeny is a mixture of wild type and successfully recombined chimeric T7. In the 
Section 3.3.3 assays, it was determined that wild type T7 is not able to replicate in E. coli ∆trxA 
cells, as trxA is necessary for the formation of the DNA polymerase replication complex384,383. 
Therefore, wild type T7 is dependent on the trxA found on the chimeric genome for successful 
replication. In the case of the chimeric phage, we know that its has a non-functional tail fiber, 
requiring a wild type tail fiber from T7 to be infective. If both of the phages enter the cell the 
following potential progeny is generated: A) Chimeric genome and chimeric tail fibers; B) 
Chimeric genome and T7 tail fibers; C) T7 genome and T7 tail fibers; D) T7 genome and 
chimeric tail fibers (Figure 5.3.5-1). Due to experiments carried out in Chapter 4.2.4.3 we know 
that chimeric tail fibers are non-functional therefore progeny A and D are non-infective. This 
means that the burst size for samples containing phages with chimeric and WT genomes should 
be smaller than for those containing only phages with WT genomes. This is because phage 
types A – D are formed in mixed samples, resulting in approximately 50% of phages being 
non-infective, while only phage types B and C are formed in WT samples, resulting in 100% 
of infective phages. This could potentially explain why smaller plaques were observed (Figure 
4.2.4-3) and why a significant reduction of phage particles was seen in the ratio experiments 
(Section 5.2.1). Here 107 PFU of total phage was added; however only approximately103 and 







A) CH genome, 
CH tail fibers B) CH genome, 
WT tail fibers
C) WT genome, 
WT tail fibers
D) WT genome, 
CH tail fibers
Figure 5-9. Representation of  the proposed co-infection mechanism between T7 and chimeric phages. 
Once both phages enter the cell four types of phage progeny are generated: (A) chimeric genome and 
chimeric tail fibers; (B) Chimeric genome and T7 tail fibers; (C) T7 genome and T7 tail fibers; (D) T7 
genome and chimeric tail fibers. (A) produces non-infective particles due to non-functional chimeric tail 


















In the previous three chapters phage engineering methods and their applications for phage 
therapeutics were addressed. Phages could also be used as a delivery vehicle for therapeutically 
actively cargo i.e. phage lysins. Lysins are enzymes naturally produced by phages at the end 
of their replication to cause host lysis and release of phage progeny195. In this study, the lysins 
will be referred to as lysins since they will no longer exclusively from within a cell. Phage 
lysins are promising alternatives to antibiotics385,386. They have multiple advantages over the 
current infection treatment e.g. elimination of bacterial colonisation of mucous membranes that 
often provide a start for a systematic infection387. The current standard method of producing a 
lysin is achieved by expressing it in a heterologous bacterial strain that the lysin will not lyse. 
If a phage was to be engineered with a lysin targeting different bacterium to that of phage host, 
each such phage infection would result in the phage as well as lysin production. This could 
expand the range of bacteria that are killed, as will have a direct target (host targeted by phage 
infection) and secondary targets (bacteria that are killed by lysin production). Previous work 
focussed on mutagenesis of phage T7, however due to DNA packaging system used by T7, 
only a small insertions, up to 103% of its original genome size (~1198 bp), can be incorporated 
into the genome223,388–390. Therefore, for this work a T4-like phage (Slur 96) that was recently 
isolated by P Sazinas which has an average nucleotide identity of >95% with T4 (NC_000866)  
which has the potential to allow large insertions in the genome223,388–390 . Given the identity of 
this phage to T4, it will be referred to as T4 (see full T4-like sequence in the Appendix 4). 
 
6.1.1 Lysins chosen for this study 
 
Three lysins were chosen for study, all three have previously been purified and shown to have 
potential as therapeutic agents286,391–393. The first lysin chosen was lysH5, or H5, from the 
Staphylococcus aureus phage ΦH5391,286. The host for the phage ΦH5 and the target for the H5 
lysin is the Gram-positive bacterium Staphylococcus aureus391,286.  It has been shown that S. 
aureus can produce enterotoxins causing staphylococcal food poisoning, one of the leading 
causes for gastroenteritis394. S. aureus is also responsible for subclinical intramammary 
infections in dairy cows395. In a previous lysed multiple S. aureus bovine and clinical strains 
as well as S. epidermidis clinical strains when applied externally396. Up to this day very few 
phage lysins have been characterised, for example those of phages P68, phage K and 
phiWMY272,283,397. These lysins are made up from enzymatic (D-alanylglycyl endopeptidase, 
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L-muramoyl-L-alanine amidase, N-acetyl-glucosaminidase) and cell wall recognition 
domains398,399 . In the previous study sequence analysis and phylogenetic position of the phage 
H5 lysin was used to identify its domains286. CHAP (cysteine, histidine-dependent 
amidohydrolases/ peptidases) was found as its enzymatic domain and Ami_2 (N-
acetylmuramyl-L-alanine amidase) and SH3b (bacterial cell recognition) as H5 lysin host cell 
wall recognition domains286.  
 
The second lysin chosen for this study was PBC1 from phage PBC1392,400. The host and the 
target bacterium for the phage and the lysin PBC1 is B. Cereus392,400. PBC1 lysin has been 
shown to have a very narrow host range, showing lysis only 1 of 22 B. cereus strains i.e. ATCC 
21768, when applied externally400. PBC1 was found to have a N-terminal type 3 amidase 
domain (PF01520), as its enzymatically active domain and a C-terminal Amidase02_C domain 
(PF12123), as its cell wall binding domain400.  
 
The third lysin chosen was CD27L isolated from CD27 phage infecting C. difficile, and 
demonstrated that it can cause cell lysis when applied externally393. C. difficile produces spores 
that are resistant to some disinfectants, contributing to its persistence in the environment and 
causes a frequently hospital-acquired infection401,402. CD27L has been shown to lyse the 
following strains: Bacillus amyloliquefaciens, Bacillus cereus, Bacillus subtilis, Clostridium 
bifermentans, Clostridium sordellii and Listeria ivanovii when applied externally393.  CD27L 
is homologous to N-acetylmuramoyl-L-alanine amidases in the N-terminal part of the protein, 
while its C-terminal domain represents a novel fold that has been found in multiple lysins 
targeting Clostridia bacteria403,404. 
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6.1.2 Acridines based T4 mutagenesis  
 
It has been shown that acridines inhibit phage development at lower concentrations to those 
that inhibit bacterial growth102,405. The mechanism by which acridines inhibit phages is 
unknown102,405. It has been shown that when treated with acridine phage T4 DNA packaging 
has been interrupted406. It has also been shown that mutations in a T4 gene 52.2 , called ac, 
confers acridine resistance by a proposed mechanism where the cells permeability to acridines 
is reduced for the cells infected with phage405,407. Despite the mechanism not be being fully 
understood ac gene confers acridine resistance, the link between ac gene disruption and 
acridine has been used for T4 mutagenesis408–410.  The disruption of ac will be used for selecting 
mutants in this chapter. 
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6.1.3 Aims  
 
The main aim for this chapter is to determine if T4like phage can be engineered to kill a broader 
range of bacteria. The main aim was subdivided into the following sub-aims: 
 
1) Engineer T4 phage with the three chosen lysins; 
2) Characterise T4 mutants on solid and liquid medium; 






6.2.1 Engineering of phage T4  
 
To engineer and select for phage T4 mutants an ac gene based method was adapted from a 
previous study405. The principle for gene insertion was to interrupt the ac gene region with a 
lysin gene of interest (X, C< B) as shown in Figure 6-1. To achieve this a plasmid containing 
homologous recombination arms (as described in section 6.2.2) was used (Section 2.3.11) 
followed by selection of phage that undergone a successful homologous recombination. The 
selection was carried out by performing modified plaque assay (Section 2.3.5) on a 
homologous recombination phage mixture. The modification consisted of addition of 15 ul of 
acriflavine (ACR) at a concentration of 1 mg/ml to each of the samples after mixing the phage, 
the cells and the soft agar, prior to plating on agar405. These samples were then plated on agar 
plates with ampicillin and acriflavine at 1 ng/ml. Ampicillin is required to maintain the 
homologous recombination vector (Figure 6-2) that facilitates a lysin insertion into phage T4, 
whereas acriflavine interferes with the T4 replication and hence allows for selection of 
engineered phage (phage that had lysin inserted and ac gene disrupted). The entire engineering 

















Figure 6-1. Schematic representation of lysin gene insertion into the T4 genome. (A) T4 genome with ac intact. (B) 






Figure 6-2. The outline of T4 engineering procedure used in this study. (A) design of homologous 
recombination plasmid (see section 6.2.2) containing homologous recombination arms, RBS B0034, a lysin 
gene of interest, all inserted into pMAT vector that confers resistance to ampicillin. (B) homologous 
recombination where T4 was used to infect E. coli MG1655/ pAG_50. (C) Selection for successfully 
recombined T4 mutant phage on 1 ng/ml acriflavine (ACR) containing agar plates.  
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6.2.2 Design of vector for homologous recombination 
 
To insert a lysin of interest into the ac gene of phage T4, a vector was designed (Figure 6-2) 
containing an RBS (B0034) followed by a lysin gene of interest in between homologous 
recombination arms411. The first homologous recombination arm consisted of total of 200 bp, 
122 bp before the ac gene and the first 78 bp of the ac gene. The second homologous 
recombination arm also consisted of total of 200 bp, the remaining 78 bp of ac as well as 122 
bp that comes after ac. The design was such that the original ac promoter would be used for 
the transcription of the inserted lysin gene. The designed vector was then ordered as a synthetic 
gene in pMAT-1 vector from IDT (Appendix 1). 
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6.3 Results  
 
6.3.1 Lysin insertion vector construction 
 
Each of the lysin genes (lysH5, lysPBC1 and lysCD27L) were inserted in between homologous 
recombination arms together with an RBS (B0034) (Sections 6.2.1 and 6.2.2) using Gibson 
cloning method generating homologous recombination vector. Each of the constructs were 
PCR verified and sequenced Table 6-1. 
 
Table 6-1. Summary of lysin gene containing homologous recombination vectors generated in this study. 
Name Vector HR arm 1 Lysin HR arm 2 
pAG_49 pMAT-1 200bp* N/A 200bp** 
pAG_50 pAG_49 200bp H5 200bp 
pAG_51 pAG_49 200bp PBC1 200bp 
pAG_52 pAG_49 200bp CD27L 200bp 
pAG_53 pAG_49 200bp H5 and PBC1 200bp 
* The first homologous recombination consists of total of 200 bp, 122 bp before the ac gene and first 78 bp of the 
ac gene. 
** The second homologous recombination arm consists of total of 200 bp, the remaining 78 bp of ac as well as 
122 bp that comes after ac. 
  
 
6.3.2 Generation of phage T4 mutants 
 
The vectors constructed in the previous section were used to yield T4 mutants (Table 6-2) using 
homologous recombination (Section 2.3.11) followed by mutant selection described in section 
6.2.1. 
 
Table 6-2. Summary of T4 mutants made for this study. 
Vector Name Lysin Resultant Phage 
pAG_50 H5 T4-ac::lysH5 
pAG_51 PBC1 T4-ac::lysPBC1 
pAG_52 CD27L T4-ac::lysCD27L 




6.3.3 Determination of lysin gene stability in T4 
 
In order to determine if the lysin genes were able to remain in T4 genome over multiple 
generations serial transfer experiment ‘T4 mutant stability assay’ (Section 2.3.10) was 
performed over the period of 24 hours for each of the mutants. To verify the presence of the 
gene encoding for the lysin was maintained in the phage population PCR, on the T4-ac::lysH5 
population sample was performed after 4, 8, 16 and 24 hours (Figure 6-3 only 16 and 24-hour 
samples are shown). This confirms that the lysin gene is stable to remain in population for 96 
(approximately 4 generations per hour) generations. 
 
  
Figure 6-3. H5 lysin verification after phage mutant stability assay. Lane 1, shows H5 (~1.5 kb) 
after 16 hours of the assay. Lane 2, shows H5 (~1.5 kb) after 24 hours of the assay. The reference 
ladder is1 kb Plus DNA ladder. Lane 3 contains the negative control (no DNA template). Lane 4 




6.3.4 Spot assays to detect lysin activity  
 
In order to characterise each of the T4 mutants (H5, PBC1 and CD27L) the lysate from E. coli 
MG1655 infected with T4 lysin mutants (Section 2.3.9) were spotted (Section 2.3.8) on a range 
of strains that the respective lysins maybe active against (Table 6-3). As a negative control, 
wild type T4 lysate was also spotted resulting in no lysis. All of the C. difficile strains presented 
in Table 6-3 were sequenced by Martha Clokie laboratory (University of Leicester). B. subtilis 
and B. cereus strains were sequence verified by Emma Denham (University of Bath) and Nick 
Waterfield (university of Warwick) laboratories. The remaining strains in Table 6-3 are clinical 
isolates that were not genome verified.  
 
Phage T4-ac::lysH5 was tested on S. aureus clinical isolates some of which, after streaking out 
on Chromoagar Orientation, turned out to be Enterococcus or Klebsiella 
Enterobacter/Citrobacte instead of S. aureus (Table 6-3). Phage T4-ac::lysH5 lysed 15 out of 
17 S. aureus and 4 out of 4 Enterococcus strains tested, and 2 out of 2 Klebsiella, Enterobacter, 
Citrobacte strains tested (Table 6-3). An example of lysis is showed in Figure 6-4. PBCD1 was 
tested on two strains B. subtilis and B. cereus, and showed clear lysis for B. subtilis, however, 
it generated some lysis for B. cereus (Table 6-3). CD27L was tested on 20 bacterial strains 
unfortunately generating no lysis.  
 
 
  A B C 
D E F 
Figure 6-4. T4-ac::lysH5 and T4 lysate spot assay against (A) Klebsiella, Enterobacter, Citrobacte, (B)  S. aureus, 
(C) S. aureus, (D) S. aureus, (E & F) Enterococcus. Samples marked with 1 = T4 lysate, 0 = T4-ac::lysH5 For 
both phages, the lysates were generated by infecting E. coli MG1655. 
 
B  
D F E 
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Table 6-3. Summary of the T4-lysin output on a range of strains. All of the C. difficile strains presented here were 
sequenced by Martha Clokie laboratory (University of Leicester). B. subtilis and B. cereus strains were sequence 
verified by Emma Denham (University of Bath) and Nick Waterfield (university of Warwick) laboratories. The 
remaining strains are clinical isolates that were not genome verified.  
 
Strain name /Clinical isolate no Phage tested Outcome (lysis vs no lysis) 
Enterococcus sp1/3047211 T4-ac::lysH5 lysis 
Enterococcus sp2/31608-21 T4-ac::lysH5 lysis 
S. aureus sp1/33077-11 T4-ac::lysH5 lysis 
S. aureus sp2/3047221 T4-ac::lysH5 lysis 
S. aureus sp3/33077-31 T4-ac::lysH5 lysis 
S. aureus sp4/32421-12 T4-ac::lysH5 lysis 
S. aureus sp5/30472-31 T4-ac::lysH5 lysis 
S. aureus sp6/31554-1 T4-ac::lysH5 lysis 
S. aureus sp7/33503-12 T4-ac::lysH5 lysis 
Klebsiella, Enterobacter, Citrobacter* sp1/31608-31 T4-ac::lysH5 lysis 
S. aureus sp8/32827-31 T4-ac::lysH5 lysis 
S. aureus sp9/32827-11 T4-ac::lysH5 lysis 
Klebsiella, Enterobacter, Citrobacter* sp2/3393011 T4-ac::lysH5 lysis 
S. aureus sp10/3047211 T4-ac::lysH5 lysis 
S. aureus sp11/31608-11 T4-ac::lysH5 lysis 
Enterococcus sp3/32957-11 T4-ac::lysH5 lysis 
Enterococcus sp4/32957-12 T4-ac::lysH5 lysis 
S. aureus sp12/31530-12 T4-ac::lysH5 lysis 
S. aureus Newman T4-ac::lysH5 no lysis 
S. aureus sp13 T4-ac::lysH5 no lysis 
S. aureus sp14 T4-ac::lysH5 lysis 
S. aureus sp15 T4-ac::lysH5 lysis 
S. aureus sp16 T4-ac::lysH5 lysis 
S. aureus sp17 T4-ac::lysH5 lysis 
Bacilus subtilis ATCC 6051 T4-ac::lysPBC1 lysis 
Bacilus cereus G9241 T4-ac::lysPBC1 lysis 
C. difficile K20 T4-ac::lysCD27L no lysis 
C. difficile H5C T4-ac::lysCD27L no lysis 
C. difficile H431024 T4-ac::lysCD27L no lysis 
C. difficile M68 T4-ac::lysCD27L no lysis 
C. difficile AML T4-ac::lysCD27L no lysis 
C. difficile A14 T4-ac::lysCD27L no lysis 
C. difficile R018 T4-ac::lysCD27L no lysis 
C. difficile K10 T4-ac::lysCD27L no lysis 
C. difficile CD89 T4-ac::lysCD27L no lysis 
C. difficile AJV T4-ac::lysCD27L no lysis 
C. difficile R20291 T4-ac::lysCD27L no lysis 
C. difficile K6 T4-ac::lysCD27L no lysis 
C. difficile B19 T4-ac::lysCD27L no lysis 
C. difficile T6 T4-ac::lysCD27L no lysis 
C. difficile ATM T4-ac::lysCD27L no lysis 
C. difficile 1342 T4-ac::lysCD27L no lysis 
C. difficile TL178 T4-ac::lysCD27L no lysis 
C. difficile AIP T4-ac::lysCD27L no lysis 
C. difficile CD84 T4-ac::lysCD27L no lysis 
C. difficile AIJ T4-ac::lysCD27L no lysis 
 
*After streaking out the clinical isolates, Chromoagar Orientation generated metallic blue colour which is 




6.3.5 Co-culturing E. coli with B. subtilis and S. aureus  
 
The results of spot assays suggested the production of an active lysin during T4 replication that 
could kill a Gram-positive host. To verify if the lysins inserted into the T4 genome are still able 
to lyse their target bacterium in the liquid culture, both E. coli and S. aureus or B. subtilis would 
have to be co-cultured together and phage added. Prior to doing this, it was necessary to test 
that E. coli could be cultured with S. aureus or B. subtilis. C. difficile was not included in these 
experiments due to anaerobic growth conditions required and the lack of any lysis based on 
spot assays (Table 6-3).  
 
Both E. coli and B. subtilis, and E. coli and S. aureus, were co-cultured and allowed to grow 
until an OD600nm 0.4 was reached (Section 2.2.5). In the case of E. coli and B. subtilis, E. coli 
MG1655/pSB6K1-RFP was used to distinguish between E. coli and B. subtilis colonies. E. coli 
colonies have a red morphology. In the case of E. coli and S. aureus, both strains were plated 
on Chromoagar Orientation selective medium (Section 2.1.2), that allows differentiation 
between E. coli, as it forms pink colonies, and S. aureus, as it forms white colonies.  
 
When E. coli MG1655 was cultured separately and in co-culture with B. subtilis, it yielded 
approximately 6 x 107 cfu/ml in both conditions (Figure 6-5). Reciprocally B. subtilis when 
grown separately and in co-culture with E. coli MG1655 yielded 2.5 x107 cfu/ml (Figure 6-5). 
Therefore, co-culturing both strains does not interfere with their growth. A similar result was 
found when E. coli and S. aureus were co-cultured or cultured separately, with 6 x107 and 1 
x108 cfu/ml found in all conditions for both E. coli and S. aureus respectively (Figure 6-5). 
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Figure 6-5. The colony enumeration assays for the co-culturing experiments. (A) E. coli MG1655 and B. 
subtilis strains were plated after growing them separately at OD600 0.4. The colony counts for either E. coli or 
B. subtilis, were labelled as ‘E. coli’ or ‘B. subtilis’ respectively and represented in grey column ‘single strain’. 
The strains were also plated after growing them both in co-culture at OD600 0.4. The colony counts for either 
E. coli or B. subtilis were grown in co-culture were labelled as ‘E. coli’ or ‘B. subtilis’ respectively and 
represented in black column ‘strain in co-culture’. (B) E. coli MG1655 and S. aureus strains were plated after 
growing them separately at OD600 0.4. The colony counts for either E. coli or S. aureus, were labelled as ‘E. 
coli’ or ‘S. aureus’ respectively and represented in grey column ‘single strain’. The strains were also plated 
after growing them both in co-culture at OD600 0.4. The colony counts for either E. coli or S. aureus were grown 




6.3.6 Assessing efficacy of T4 mutants in liquid medium  
 
In order to characterise lysins in liquid medium the following experiment was set-up using co-
culturing experiment described with two additional treatments. Either T4 or T4 mutants were 
added to the co-cultures when they reached an of OD600nm of 0.4 (Section 2.2.5). T4-
ac::lysPBC1 was added to E. coli MG1655/B. subtilis co-culture and T4-ac::lysH5 was added 
to the E. coli/ S. aureus co-culture, phage T4 was used as a control in both systems. Samples 
from co-cultures were collected after 30 minutes and 1 hour followed by colony enumeration 
(Section 2.3.5). 
For E. coli and B. subtilis co-culture, there was no change in the number of colonies for B. 
subtilis when untreated, or the addition of T4 or T4-ac::lysPBC1 (Figure 6-6 an example of 
the assay output colonies Figure 6-7). For B. subtilis the control and two treatments 
approximately 107 and 108 cfu/ml were enumerated for 30 min and 1-hour time points 
respectively. After 30 min the number of E. coli was reduced 10-fold for both T4 and T4-
ac::lysPBC1  treatments when compared with the no phage control (Figure 6-6). After 1-hour, 
E. coli was reduced >100-fold for both T4 and T4-ac::lysPBC1 treatments when compared 
with the no phage added control. The same pattern was observed for E. coli and S. aureus co-
cultures, with reduction in E. coli numbers when phage T4 or T4-ac::lysH5 were added, 
without a reduction in S. aureus. 
 
CFU assays presented in Figures 6-5 and 6-6 indicate higher E. coli numbers when compared 
to B. subtilis, and greater S. aureus numbers when compared to E. coli. To evaluate if co-
culturing of E. coli and either B. subtilis or S. aureus would maintain lysin production and its 
associated lysis, the growth rate needs to be determined for each of the strains in question. If 
the growth rate of either of lysin target strains is much greater than that of E. coli and lysin 
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A B 
Figure 6-6. Colony enumeration assays after the co-culturing experiments. (A) B. subtilis and E. coli were 
co-cultured and once reached OD 0.4 were subjected to two treatments (addition of either T4 or T4-
ac::PBC1 phage at an MOI of 1) and a no treatment control (cells only). Bacterial numbers were 
determined after 30 min and 1 hour. (B) S. aureus and E. coli were co-cultured and once they had reached 
OD 0.4 were subjected to two treatments (addition of either phage T4 or T4-ac::H5 at an MOI of 1) and a 
no treatment control (cells only). The samples were enumerated using cfu assays after two time points 







Figure 6-7. Summary of post E. coli MG1655/B. subtilis co-culture CFU 
assays. Each of the rows represent different time points, from top to bottom: 
time 0 (each of the strains were grown up to OD 0.4, mixed in equal ratios and 
100ul of the mixture was plated), time 30 min (the mixture from time 0 was 
grown for 30 min), time 1 hour (the mixture from time 0 was grown for 1 hour). 
Each of the columns represent different treatment conditions, from left to right: 
no phage added, T4 added at MOI=0.1, T4-ac::PBC1  added at MOI=0.1. 























6.3.7 T4 mutant virulence assays 
 
To determine if engineering T4 with additional payload conveys any burden for its infectivity, 
virulence assays were performed (Section 2.3.15) for T4 its mutants as well as T7 phages Table 
6-4. All of the T4 mutants’ virulence indices generated were the same as the T4 phage. 
 
Table 6-4. Summary of virulence indices. 









6.4 Discussion  
 
6.4.1 Recombinant lysin expression  
 
In multiple studies lysins have been  over expressed in a heterologous bacterial system followed 
by purification of the lysin. In one instance, lysins of phages targeting Listeria monocytogenes, 
Ply118 and Ply511, were introduced into a vector in Lactococcus lactis412. Upstream of the 
lysin gene an  purification tag sequence was inserted to allow the use of metal chelate affinity 
chromatography for the later lysin purification steps413. In another study, LysB4, an lysin from 
the Bacillus cereus-infecting bacteriophage B4 was expressed in E. coli with an N-terminal 
His-tag followed by purification using affinity chromatography414. His tag insertion followed 
by affinity chromatography in multiple other cases415,416. The ability to express lysins using 
phage expression system described in this chapter, would remove the need for a purification 
step, as large numbers of phage would be released during an infection cycle. However, this 
may result in increased lysin instability due to uncontrolled and possible suboptimal conditions 
during phage lysis. Each of the lysins used in this chapter were previously verified to be stable 
at 37°C pH 7, however what the conditions are following cells lysis are is unknown. It has been 
hypothesised that respiring cell produces a proton gradient just outside its cytoplasmic 
membrane417. Therefore, the pH may vary during lysis affecting lysin activity. Furthermore, it 
has been observed that lysin activity and autolysis are inhibited by growth at low pH in multiple 
bacterial species including pneumococci, staphylococci, streptococci, and B. subtilis418.  
 
6.4.2 The host range of T4 mutants’ lysate on solid medium 
 
It has been showed that a phage lysins have a broader lytic spectrum than the phages they are 
found in419–421. This was true for  phage ΦH5 and its encoded LysH5 lysin396. In the previous 
work,  in addition to lysing the host bacterial strain, LysH5 managed to lyse multiple S. aureus 
strains despite their origin, bovine or human396. Furthermore, LysH5 showed activity against 
clinical strains of S. epidermidis isolated from humans. However, no lytic activity was observed 
against Bacillus, Clostridium, Streptococcus, Enterococcus and Listeria396. The results 
generated in this chapter confirms LysH5 activity against multiple S. aureus strains. However, 
here Enterococcus as well as potentially one of the Klebsiella, Enterobacter, Citrobacter 
strains were also lysed by LysH5. This implies that LysH5 is able to lyse both Gram-positive 
and Gram-negative bacteria. 
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Both Gram-negative and Gram-positive bacteria targeting lysins contain enzymatically active 
domain (EAD) as part of their lysin structure201. Since the Gram-positive bacteria do not have 
an outer membrane, a lysin can access the bacterial peptidoglycan when applied externally 
resulting in lysis201. In a previous study, lysin LysAB2 showed lytic activity against both Gram-
negative and Gram-positive bacteria, A. baumannii and S. aureus422. It has been shown that 
some lysins, mainly the ones from Gram-positive bacteria are capable of disrupting bacterial 
cells by a mechanism independent to their enzymatic mechanism423. It has been showed that 
helix-forming amphipathic peptides containing basic amino acids cooperate with negatively 
charged membrane components such as lipopolysaccharides424.  
In the case of LysPBC1 lysin, the phage that encodes LysPC1 has a very narrow host range, 
infecting only 1 of 22 B. cereus strains (B. cereus ATCC 21768)400392. However, LysPBC1 
showed lysis when applied against 22 out of 22 B. cereus strains, as well as 3 out of 4 B. subtilis 
strains, B. thuringiensis, B. mycoides, B. weihenstephanensis400392.  The results generated in 
this chapter confirms LysPBC1 activity against B. subtilis ATCC 6051. 
 
For the third lysin LysCD27L, the phage ΦCD27 has a reported narrow host range, infecting 
only four of the 30 C. difficile strains tested404. The host range of the lysin LysCD27L is 
significantly broader lysing all 30 strains tested, in addition to Bacillus amyloliquefaciens, 
Clostridium bifermentans, Clostridium sordellii, Listeria ivanovii, Bacilus cereus and Bacilus 
subtilis393,404. The results generated in this chapter were not able to confirm the lytic activity of 
LysCD27, as it showed no lysis when tested against 20 different C. difficile strains. The lack 
of lysin activity could be due to the lack of stability due to suboptimal conditions occurring 
during the lysis as discussed in 6.4.1.  
 
Another explanation for reduced lysis of the three lysins in question could be due to insufficient 
gene expression levels. As previously mentioned, ac gene is a T4 gene found late in the genome 
(position 52.2), therefore lysin expression would only be initiated at a later stage of T4 
infection. The strength of ac promoter has also not been evaluated in the literature, therefore 
prediction of successful transcription events is not possible. Late and potential weak 
transcription would delay the translation and may have a significant impact for the generation 




6.4.3 The T4 mutants’ bacterial killing in liquid medium  
 
The classical way of assaying for lysin activity in liquid medium is turbidity reduction assay270. 
In this assay the decrease in light scattering due to live cells is measured270. Since the system, 
described in this chapter, requires a co-culture between E. coli and a lysin target the turbidity 
assay could not be used. As it would be impossible to determine which strain was being cleared 
solely based on OD reading. Therefore, co-culture followed by addition of phage T4-ac::lysin, 
incubation and subsequent enumeration of colony forming units was carried out. No lysis was 
detected in liquid conditions when T4 mutants’ lysate was tested against different hosts. This 
could be due to the fact that in the previous studies, the lysins of interest were first purified and 
then used for the lysis assays, allowing higher concentrations of the active lysin. In this chapter, 
all of the lysins were produced using T4 infection a means of generating the lysin, which could 
potentially not reach the levels required for lysis generation. When comparing to the solid 
medium experiments, the lysis in liquid medium could potentially be affected by the change in 
kinetics and finding the host in the co-culture may require higher concentration of the lysin. In 
addition, it is important to note the possibility that lysins may be one-use enzymes267. As 
previously shown, a listeria phage lysin had a binding affinity to its substrate similar to that of 
IgG molecule to its substrate, meaning that several molecules may be needed to attack a local 
















Chapter 7   Engineering phage to be tissue specific 
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7.1 Introduction  
 
Phages have multiple advantages over antibiotics and hold a lot of promise for an alternative 
therapy133. One of the major factors for effective phage therapy treatment of infection is 
sufficient exposure to the phage at the site of bacterial infection (a tissue or an organ)150,181. A 
limitation of phage therapy is insufficient localisation of phage to the tissue of interest (targeted 
tissue)181. Engineering phages to improve their tissue-specificity is a promising avenue that is 
set out to explore in details in this chapter. Furthermore, some clinically significant pathogens 
are able to invade and localize inside host cells which protects them from the host immune 
system as well as antibacterials425–428. The ineffective delivery of pathogen targeting drugs 
leads to only partial clearance of the pathogen resulting in persistent infections429–431. If tissue-
specific phages were engineered this would potentially enhance their endocytosis in 
mammalian cells allowing greater killing of the intracellular bacteria.  
 
7.1.1 Homing peptides and their potential to aid tissue specific phage targeting  
 
Previous studies have shown that vascular endothelium cells are heterogenous and express 
tissue specific-markers432. Specifically, the vascular endothelium of healthy or diseased organs 
possess organ specific molecular markers or receptors, and ligands binding to them are referred 
to as ‘‘homing peptides (HP)’’433. In vivo phage display technology has been used for tissue-
specific marker recognition, to identify extensive molecular differences in vasculature434. 
Multiple peptides targeting normal and tumour blood vessels, or tumour lymphatic vessels have 
been isolated435–440. In addition, homing peptides have been identified that target the 
vasculature of various organs, including the lung, heart, prostate, skeletal and cardiac muscle, 
and adipose tissue435,436,441–443. Homing peptides have been exploited for targeting drug 
molecules, liposomes, and inorganic nanoparticle to tissues433. Their use has not only increased 
the targeting specificity and efficacy of drug delivery but has also reduced drug associated side 
effects, presumably by reducing unspecific targeting of healthy tissues and organs444,445. 
Arming phages with homing peptides, a technique previously applied to other nano-particles, 




7.1.2 Lungs as a target for tissue-specific phages 
 
The human lung filter through approximately 10,000 litres of air making it susceptible to 
airborne pathogens on the daily basis182. This air can contain approximately 100,000 bacteria 
per litre, some of which will get into the lung and beyond447. A wide range of pulmonary 
infectious agents have been identified over the years including Mycobacterium tuberculosis, 
Streptococcus pneumoniae Haemophilus influenzae and many others448–450. Many pathogens 
overcame antibiotics that resulted in various degrees of resistance, compromising treatment of 
the pulmonary infections183. Having considered all of the above, the lung tissue has been 
chosen as a target tissue for the homing peptide engineered phage targeting. 
 
 
7.1.3 T7 Capsid engineering  
 
The T7 capsid has previously been modified for phage display revealing protein – protein  
interactions and  protein – targeting by chemical compounds451–454. The T7 capsid consists of 
10A (major) and 10B (minor) proteins224,455. They share the same start codon, but the 10B 
protein is generated by a shift in translational reading frame ahead of the normal termination 
codon, which adds 53 amino acids to the C-terminal end of the 10A protein224. This frameshift 
occurs rarely, which explains why 10B is transcribed at a lower frequency and makes up 
approximately ∼5–10% capsid protein translated455,456. Both the major (10A) and minor (10B) 
proteins are combined to make up the T7 phage capsid particle455,457. 
The 10B minor capsid protein has been mainly used for modifications as it is produced at lower 
frequency and hence is less likely to affect the capsid integrity if a ligand of interest is 
attached458. Previously the T7 capsid has been modified to incorporate a fluorescent protein 
enabling a direct visualisation of the interaction between displayed proteins and their binding 
particles459. In all studies so far, the modifications to the capsid protein have been done using 
in trans complementation, where modified capsid protein of interest is expressed in E. coli 
followed by T7 phage infection allowing the modified protein integration into the phage 
capsid459. This method allows an in trans complementation of the desired altered capsid protein 
resulting in some protein being complemented and some retaining the wild type features. If the 






The main aim of the chapter is to determine whether T7 engineered with homing peptides could 
allow increased adsorption/absorption to the mammalian cells. This aim was divided into the 
following sub-aims:  
 
1) To select homing peptides and design their insertions in T7 minor and major capsid 
proteins; 
2) To engineer/insert homing peptides in the minor and major capsid proteins of phage 
T7;  
3) To verify if HP insertion has any effect on capsid structure; 
4) To compare T4 vs T7 adsorption to lung endothelial tissue cells; 
5) To compare wild type and homing peptides – engineered T7 phages’ 





7.2.1 Determination of homing peptides and the mammalian cell line to be used 
 
The target organ for this study was chosen to be the lungs. Lung epithelial tissue targeting HPs 
have been previously extensively identified (Table 7-1)446,460–464. Therefore, adenocarcinomic 
human alveolar basal epithelial cells, specifically A549 cells, were chosen to mimic lung 
epithelial tissue for the in vitro experiments detailed in this chapter465–467. It has to be noted 
that A549 is a cancerous lung epithelial cell line, and hence the expression profile and cellular 
membrane surface differ from that of a healthy cell line. However, A549 cell line has not been 
reported to upregulate or downregulate the receptor membrane dipeptidase that is the receptor 
for GFE-1/2 homing peptides, suggesting that its levels are the same to that of a healthy 
tissue468. The receptor for MTDH domain is a putative one therefore its regulation in cancerous 
vs healthy epithelial cell line was not identified.  
The small reported DNA sequence sizes of homing peptides do not surpass the 1 kb genomic 
insertion limit for the T7 phage, therefore their insertions should be tolerated by T7 
phage446,460–464. 
 
Table 7-1. Summary of homing peptides chosen to be inserted in T7 capsid proteins. 
HP 
No. 
Name HP Sequence Receptor 
1 GFE-1 CGFECVRQCPERC membrane dipeptidase460,462 
 







lung endothelium putative 
receptor421  
 
7.2.2 Marker based selection for T7 capsid engineering  
 
Previously it was demonstrated that trxA marker-based selection is the most efficient method 
of engineering bacteriophage T7 (Section 3.3.4). Therefore, to insert a homing peptide into the 
capsid proteins, homologous recombination was carried out followed by marker-based 
selection. For this homologous recombination a vector was designed that contains ~100 bp 
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homologous recombination arms flanking the homing peptide, an RBS site and the trxA gene 
(Figure 7-1). 
 





E. coli (△trxA )
T7T7-HP
Figure 7-1. Engineering and selection of T7 containing homing peptides (T7-HP). (A) The homologous 
recombination (HR) vector was constructed by inserting a sequence encoding the homing peptide DNA 
and trxA, flanked by homologous recombination arms, into the backbone pSMART. (B) Transformation 
of E. coli BW15113 with the HR vector, followed by the addition of wild type T7 phages. (C) Phage 
selection on E. coli DtrxA. 
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7.2.3 Design of capsid 10A and 10B fusion proteins for homing peptide display   
 
The C-terminus of 10B has been used for insertions in multiple studies451–454,458. However, the 
C-terminus of 10A has not been used in a similar manner, potentially due to its higher 
translation frequency and the inherent risk of compromising the capsid integrity. For all homing 
peptides (listed in section 7.2.1) it was decided to exploit the C-terminus end of not only 10B 
but also 10A capsid proteins. To this end, the translational frame shift required for 10B is 
represented in Figure 7.2.3-1. 10Bi represents the part of the 10B gene translated using frame 
0, whereas 10Bii is translated using frame -1 (Figure 7-2). Having this in mind, it was possible 
to append the homing peptides to both 10B (Figure 7-2) and 10A capsid proteins (Figure 7-2) 
using homologous recombination regions 1 and 2 (HR1/2) Table 7-2. By inserting a HP at the 
end of 10B C terminus, wild type functional 10A is made at the same time as 10B now 
containing the HP of interest. By inserting a HP at the end of 10A C terminus, 53 aa of wild 
type 10B are removed generating 10B that may or may not be functional. At the same time 
10A is made with a HP of interest. Each insertion for a homing peptide was followed by trxA 
insertion as described in the methods section and section 7.2.2. 
 
Table 7-2. Homologous recombination regions 1 and 2 (HR1/2) for 10A and 10B homing peptide insertions. 
 















Figure 7-2. HP insertion strategies. (A) Representation of 10A and 10B translational shift. When 10A is translated (Frame 0), only a hypothetical portion 
of 10B is translated (10Bi), however 10B itself is not produced. When 10A is being translated and before its stop codon, it undergoes a translational shift 
(Frame -1), the full 10B is translated 10% of the time. (B) Representation of HP insertion after 10B. This means that only 10B protein is going to have HP 
attached to it and 10A will not be altered. (C) Representation of HP insertion after 10A. This means that 10A will have HP attached to it. 10B will not be 
formed at all as the insertion of HP disrupts sequence after 10A, removing part of 10B. This means that no 10B will be formed. (*) represents the part of 




7.3.1 T7 engineered with homing peptides  
 
The vectors designed in the methods section 7.2.3 were transformed into E. coli DtrxA cells 
and then used for homologous recombination (Section 2.3.11). This was followed by marker-
based selection (section 7.2.2) and phage plaque purification (Chapter 2.3.13). This resulted in 
the generation of the mutant T7 phages that were PCR verified and sequenced (see Appendix 
4) Table 7-3.  
 
 
Table 7-3. Summary of T7 mutants generated in this study. 
Plasmid used* 10A/B HP RBS/trxA Name 
pAG_54 A GFE-1 Ú T7-HP1 
pAG_55 A GFE-2 Ú T7-HP2 
pAG_56 A MTDH Ú T7-HP3 
pAG_57 B GFE-1 Ú T7-HP4 
pAG_58 B GFE-2 Ú T7-HP5 
pAG_59 B MTDH Ú T7-HP6 
*-vectors used here were synthesised by IDT, for the vector map see Appendix 1, for the 
insert sequences see Appendix 4. 
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7.3.2 10A modifications do not affect the capsid structure 
 
To the best of my knowledge nobody has ever attempted to modify the major 10A capsid 
protein. Interestingly, we were able to generate T7 phages with mutated 10A. These phages 
were not only able to infect and complement E. coli ∆trxA (Figure 7-4) but were also not 
displaying any structural defects when viewed under TEM (Figure 7-3) (Section 2.3.16). 
Indeed, phage MTDH::10A-T7 (Figure 7-3) looked similar in shape and size to the wild type 







Figure 7-3. TEM images for mutant T7 and T7 phages. (A) T7-10A::MTDH. (B) phage T7.  
Figure 7-4. Plaque comparison between (A) T7-10A::MTDH. (B)  phage T7. 
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7.3.3 Comparison of T4 and T7 adsorption to A549 cells  
 
Prior to testing mutant T7 phages, the adsorption of wild type phage T4 and T7 to A549 cells 
was tested. This was done by adsorption/absorption assays (Section 2.4.3), where the wash step 
allows the identification of loosely bound phages whereas the lysis step allows quantification 
of phages either bound strongly to the cell surface or that have entered the cell. T4 and T7 were 
used at six different concentrations (103 to 108 PFU/ml) and two phage incubation time points 
(1 and 4 hours) to evaluate if higher phage amount application allows greater phage 
entry/adsorption to the epithelial cells. For this experiment total phage recovery was evaluated 
by combining the total amount of loosely bound phages (after the wash step) with the total 
amount of cell associated phages (lysis). In general, adding higher amounts of phage to the 
samples resulted in higher phage recovery after the wash and lysis steps. The highest number 
of total phage recovered after adding 108 PFU/ml, was approximately 104 PFU/ml for T4 and 
T7 phages after 1 hour of incubation (Figure 7-5). The incubation time was found to have 
different effects on T4 and T7 recovery. When increasing the incubation time from 1 to 4 hours, 
after addition of 108 PFU/ml of each phage, approximately 106 PFU/ml and 104 PFU/ml were 
recovered for T4 and T7, respectively (Figure 7-5). This assay showed that both T4, and more 
importantly, T7 phage can be adsorbed to and potentially be internalized into mammalian cells.
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Figure 7-5. Phage recovery from A459 cells. 103 to 108 PFU/ml of T7 or T4 phage was incubated with A549 cells (80-90% confluence) for 1 or 4 hours. 
The cells were then washed and lysed, with the phages recovered and counted after both steps. PFU/ml data represented here is from one biological 
sample, no replicates (N=1 for all conditions). The PFU for each sample was determined on the E. coli strain BW25113 using the spot assay method. 
Phage species and incubation times: (A) T4, 1 hour, (B) T4, 4 hours, (C) T7, 1 hour, and (D) T47 4 hours. Recovered (*) refers to the total amount of 
phage recovered when phage numbers after the lysis and wash steps combined.  
T4, 1 hour T4, 4 hours 
T7, 1 hour T7, 4 hours 
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7.3.4 Mutant T7 and T7 phage adsorption to A549 cells  
 
Another set of adsorption/absorption assays were carried out on mutant and wild 
type T7 phages to determine if the addition of homing peptides provides greater 
binding to the mammalian cell surface. After 1 h of infection, all T7 phages with 
homing peptides incorporated showed increased numbers of loosely bound phages 
(wash step) as compared to the wild type T7 phage (Figure 7-6). Although, only 
three of them had significantly higher values to that of T7: HP1, HP3 and HP4. 
This held true for cell-associated phages (cell-adherent and intracellular phages) 
after the cell lysis step with the exception of the GFE-2::10B-T7 (HP5), which had 
approximately a 10-fold lower recovery post-lysis than the wild type (Figure 7-6). 
A prolonged infection (4h) resulted in greater phage recovery numbers for both 
wash and lysis steps. In the case of the lysis HP2, HP3, HP4 and HP5 showed 
significantly greater values to that of T7; whereas strongly cell-associated phages, 
after the lysis step, showed significantly greater amounts of phage recovered for 
all HP-engineered phages when compared to T7 (7-6).  
 
In order to determine if there is a significant difference between the amount of 
phage recovered for different phage types (T7 and T7 mutants) a two-way 
ANOVA was performed using Statistical Package for the Social Sciences (SPSS) 
software. This statistical method tested three hypotheses, listed in Table 7-4, to 
determine if there is both a significant difference between the phages recovered 
given the type of phage (T7 vs T7 mutants) and incubation time, and whether there 
is a significant interaction between phage type and incubation time. The analysis 


















































































































Figure 7-6. Phage enumeration after recovery from A549 cells after wash and lysis steps. 2 x 108 
PFU/ml of each mutant T7 (HP1-HP6) and T7 phages were incubated with A549 cells (80-90% 
confluence) for 1 (A, B) or 4 hours (C, D). The cells were then washed and lysed, with phages 
recovered and counted after wash (A, C) and lysis (B, D) steps. PFU/ml data are from three 
technical replicates (N=3 for all conditions). The PFU for each sample was determined on the E. 
coli BW25113 strain using the plaque assay. * - p < 0.05, when compared to T7 (Appendix 5). 
N=1, error bars come from technical replicates and in some instances too small to be represented 










* * * 
* * * * 
* * * 
* * * * * * 
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Table 7-4. Summary of the tested hypotheses. 
Set No H0 H1 
1 The mean amounts of phages 
recovered after the wash/lysis 
step across each phage type are 
equal. 
The mean amounts of phages 
recovered after the wash/lysis 
step across each phage type are 
not all equal.   
2 The mean amounts of phages 
recovered after the wash/lysis 
step across each incubation 
time are equal. 
The mean amounts of phages 
recovered after the wash/lysis 
step across each incubation time 
are not all equal. 
3 There is no significant 
correlation between the phage 
type and incubation time for the 
wash/lysis step. 
There is significant correlation 
between the phage type and 




The results of the two-way ANOVA for the wash step allowed rejection of the null 
hypothesis (H01) (p-value = 0.091) demonstrating there is a statistically significant 
difference in the recovery for phage types across samples. In the case of the second 
hypothesis set the p-value was found to be 0.501, implying that there is not enough 
evidence to reject H02 and support H12. Therefore, the mean amount of phage 
recovered could be the same for the two incubation times. For the third hypothesis, 
there was statistically significant difference between the phage type and incubation 
time (p-value <0.001). Given that the first and the third hypothesis sets were 
statistically significant further analyses were carried out. For the first hypothesis 
set a post-hoc test (Least Significant Difference) was used to determine which 
phage types had statistically significant different mean amounts of recovered 
phage. The test revealed that there was a statistically significant increase in phage 
recovery for phages that contained homing peptides (HP1-5) with p-values <0.05. 
For the third hypothesis set t-tests were used to determine which phage types and 
incubation times had significant interactions T7 mutant phages with (HP2, HP5 
and HP6) yielded p-values <0.05 meaning that the incubation time has a significant 
effect upon phage recovery. 
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Applying the statistical techniques used for the wash step, it was found that there 
was a statistically significant increase in phage recovery for phages that contained 
homing peptides (HP1 – 6) with p-values <0.05. When the mean amount of phage 
recovered between incubation time points for each phage type was analysed T7 
mutant phages (HP2, HP5 and HP6) yielded p-values <0.05 meaning that the 
incubation time has a significant effect upon phage recovery.  
When p-values for a post-hoc test were compared for each of the lysis and wash 





7.4.1 Stability of T7 capsid 
 
10B protein was used more frequently for phage display capsid modifications as 
it is expressed at lower frequency than 10A, and hence its modifications were less 
likely to affect the integrity of the capsid458. Perhaps a more frequent use of 10B 
for phage display is a safer option that does not affect the capsid protein integrity 
when fusing larger proteins to the capsid. It has been shown that stable phage 
capsids can be formed only from 10A protein, suggesting that 10B is not necessary 
for stable capsid formation469,455. Furthermore, in the previous study, T7 10A 
protein was tagged to display peptides homing directly to the placenta. Even 
though, the capsid was not modified at the genome level (complementation of 10A 
capsid with appended peptide in trans was used)  the result suggested that major 
capsid protein tagging did not disrupt the overall structure of the capsid470. In this 
study, it has been confirmed with both TEM as well as plaque assays that 10A 
protein tagging with homing peptides does not alter T7 structure and infectivity 
respectively. GFE-1 and GFE-2 are relatively small peptides 13 and 8 amino acids 
in length respectively, both identified using phage display method464. In contrast, 
the third homing peptide (MTDH) is 63 amino acids long and been identified as a 
protein that migrates and binds to lungs during breast cancer metastasis463. The 
size of this homing peptide could potentially be riskier when tagged after 10A 
protein. However, this was not the case as the T7-HP3 not only forms a visibly 
intact capsid as supported with TEM data but also shows the greatest increase of 
phage recovered for both lysis and wash steps. Which could be due to the fact that 
the peptide was attached to 10A capsid protein, resulting in more abundant peptide 
on the capsid protein.  
 
7.4.2 Adsorption/absorption assay distinguishes between loosely and tightly 
associated phage   
 
In this work an adsorption/absorption assay was used to quantify the phage 
recovered from wash and lysis steps. The wash step allows the identification of 
loosely bound phages. Given the recent study where phage entry into different 
mammalian tissues was demonstrated, the assay used in this study did not allow 
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the discrimination  between phages bound strongly to the cell surface or phages 
that have entered the cell471.  In this recent study an in vitro method was used to 
demonstrate the rapid and directional transcytosis of different phages across the 
lung, gut, kidney, liver and brain471. It was also shown that phage transcytosis 
across cell layers had a significant preferential directionality for apical-to-
basolateral transport471.  
 
In a previous study, with a similar experimental set-up to this chapter, T7 and T4 
phage adsorption/absorption onto mammalian cells was evaluated on A549 
cells471. It was found that after applying approximately 108 PFU/ml of T4 and T7 
to the cell surface, approximately 103 to104 PFU/ml was recovered for both phages 
after two hours of incubation. In the results presented in this chapter, a similar 
output of approximately 104 PFU/ml was recovered for both phages after one hour 
of incubation, and for the T7 phage after 4 hours of incubation. However, 
incubating the T4 phage for 4 hours resulted in a phage recovery level of 
approximately 100-fold higher than the amount recovered by this previous 
study471. 
 
7.4.3 HP engineered phages towards the greater concentration at a site of 
infection  
 
Homing peptides have previously been used to enhance treatment specificity and 
drug concentrations at target site472–474. In all instances, a drug tagged with a 
homing peptide resulted in greater amounts at the target site when compared to the 
non-tagged drug472–474. In one of the studies a nanoparticle drug, abraxane, was 
modified with tumour specific homing peptides472. It was shown that LyP-1 
homing peptide tagged abraxane, improved the efficacy of the drug472. The results 
generated in this chapter showed statistically significant increase in phage 
recovery for phages that contained a homing peptide for HP3-5 for the strongly-
associated phages and HP1-3 for the loosely bound phages, as showed by wash 
and lysis phage enumeration results respectively.  
In general, all of the T7 mutants showed greater amounts of phage recovery, 
suggesting that homing peptides facilitate greater attachment of T7 phage to the 
lung tissue epithelium cells. The amount of phage recovered for phage T7 was 
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approximately 104 Pfu/ml whereas for some T7 mutants it was approximately 107 
Pfu/ml. Given, the surface are of the flask (75 cm2), the confluence that was 
approximately 85%, as well as approximate size of A549 cell (100µm2), the 
approximate number of cells per flask was 6 x 107. This suggest that approximately 
one phage per mammalian cell was strongly bound or internalised. It has been 
shown previously that to achieve effective killing at a site of infection the phage 
concentration should reach the concentration of 107 or higher150. This suggests that 
T7 mutants, generated in this study, would be preferable for therapeutic 
applications over the T7 phage. Furthermore, phages generated in this study would 
provide a more effective treatment when targeting intracellular bacteria such 
as  Listeria monocytogenes, Salmonella typhi, Mycobacterium spp475. 
 
7.4.4  Potential use of homing peptides for tissue targeting in vivo 
 
Results generated in this chapter suggest that when using the phage T7 tagged with 
homing peptides, higher phage concentrations can be achieved at a target site in 
vitro. To confirm if this translates to in vivo systems further experimentation is 
required. However, previous studies have shown comparability between in vitro 
and in vivo outcomes471,473,476. In one of the studies, F3 peptide, homing to tumour 
endothelial cells, when bound to cisplatin loaded nanoparticles showed greater 
drug concentration and binding specificity to the target tissue (when compared to 
non-tagged drug) for both in vitro and in vivo studies476. In another study, cage-
like protein nanoparticle genetically engineered with LyP-1 peptide showed 
greater binding to vascular macrophages in vitro and in vivo studies. Even though 
these studies did not use phage, they strongly suggest that, in vivo studies with 
homing peptide tagged phages could confirm the very promising results obtained 
in vitro.  
When considering a target mammalian tissue for phage targeting and localisation 
a potential constrains need to be considered e.g. the presence of lysosomes. Due 
to its acidic pH, lysosomes may affect bacteriophage activity477. In the previous 
study, in order to determine if phage activity may be altered by the lysosomes, the 
lysosomal acidic environment was neutralised478. Phage activity prior and post 
neutralisation was compared, showing approximately 2-fold greater total phage 
recovery indicating that the lysosome does inactivate the internalised phages to an 
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Chapter 8   Conclusions and Future Directions 
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In this thesis, the limitations for the phage therapy were assessed and potential 
engineering solutions to address them were suggested. In this chapter, the 
conclusions and future work of this thesis are discussed in the context of the 
original aims of the study highlighted in Chapter 1.24.  
Firstly (Aim 1), comparison of the efficiencies of marker-based and marker-less 
methods in the selection efficiency for engineered bacteriophages was sought. It 
was determined that trxA marker-based method was the most efficient method for 
engineered bacteriophage selection. Out of two marker-less methods compared, 
CRISPR type II was the more efficient one at targeting wild type sequence and 
hence allowing more effective engineered phage selection. For both, marker-based 
and marker-less, methods T7 essential structural gene was targeted for the first 
time. These results will aid future bacteriophage engineering and more optimal 
method design.  
 
In order to improve CRISPR type I and type II efficiencies a pre-induction step 
before the addition of homologously recombined phage could be included in the 
future work. IPTG induction would be used to prevent T7 promoter inhibition 
whereas moving into BL21-AI strain and consequent induction with arabinose 
would provide even further control of the Cas protein expression. In the case of 
CRISPR type II, Cas9, trcRNA as well as the spacer region control could be 
exchanged with E. coli inducible promoters instead of S. pyogens native ones. This 
would then allow induction of the system in question. In reference to section 3.7.3 
the genomic contexts of target DNA as well as the GC percentage contribute to 
sgRNA performance therefore both should be considered when designing CRISPR 
gRNAs. In addition, base pair positions might be considered when designing 
gRNAs as it has been showed that some base pairs might be preferred over others 
for the gRNA design, for example: 1) cytosine is preferred at the -3 position, which 
is the DNA cleavage site by the CRISPR/Cas9 complex, 2) guanines are strongly 
preferred at the -1 and the -2 positions proximal to the PAM sequence, which are 
associated with the sequence preference in Cas9 loading479–481. Moreover, 
screening for escape mutants should be carried out to find out if these mutants 
emerge when essential genes of phage are targeted, in the same manner as it has 
been shown for non-essential genes329,327.  
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Secondly (Aim 2), the possibility of T7 host range of alteration when tail fibre 
domains from a genetically distant host are appended to it, was disseminated. The 
finding from Aim 1 on trxA being the most effective selection for engineered 
phage, facilitated the means of obtaining the Aim 2. When trxA method without in 
trans complementation was used, a persistent wild type T7 contaminant was 
detected throughout the purification process and after; therefore, trxA method with 
in trans complementation was used to generate seven different chimeric tail fibre 
phages. Fusion tail fiber characterisation in vitro indicated that foldon, as a linker 
between the fusion tail fiber components, was not sufficient to ensure tail fiber 
stability and folding. In addition, varying the fusion tail fiber length did not 
influence the tail fiber stability. The data obtained indicates that further factors 
need to be considered to aid future fusion tail fiber designs, if fusions between 
such distant phages, as T7 and BPP1, are feasible at all. 
Furthermore, an interesting find was stumbled upon, where T7 showed lysis 
against B. bronchiseptica strain on the solid medium, implying previously 
unexpectedly broader host range of phage T7.  
 
To potentially improve the stability of fusion tail fibers, future studies should 
consider a wider range linkers to be included between two of the domains fused as 
well as inclusion of the b-prism domain reinforce overall trimeric assembly482. In 
addition, shorter regions of C-terminal domain of Mtd could be used for the 
fusions, in particular, only the variable regions to enhance the fusion tail fiber 
stability. Moreover, to better understand B. bronchiseptica infection by T7, further 
examination is needed. This could be done by carrying out 16S to verify the strain 
as well as transcriptomics to understand if LPS expression profile is maintained 
throughout the experimentation and perhaps if its changes lead to susceptibility to 
T7. 
 
The finding in Chapter 4 (to answer aim 2), where a persistent wild type T7 
contaminant was present throughout the purification process when no in trans 
method was used to select for chimeric phages, led to further experiments in 
Chapter 5. Here the aim was to determine if co-infection is possible between T7 
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and recombinant phage mutants. To achieve this T7 and chimeric phage 
interactions were assessed in solid and liquid media. In Chapter 5, for the first time 
I have demonstrated co-infection in phage T7. This is an important finding as it 
implies novel possible ways of phage co-evolution and cross-effects that haven’t 
been considered before. This result indicates that if two T7 phages can co-evolve 
in the laboratory a similar behaviour must be present in the nature. Therefore, lytic 
phage evolution may not occur in isolation but with other phages. The data also 
shows that combining the marker-based method with CRISPR/Cas results in 
removal of the co-infection, providing a solution for future phage engineering.  
 
Future work should seek to unravel the potential mechanism suggested in Chapter 
5.3.4. This could be achieved by incorporating fluorescent markers in both T7 and 
chimeric phages to understand their better interplay. 
 
The Aim 3, that was assessed in Chapter 6, sought to determine if T4 can be 
engineered to kill a broader range of bacteria. To achieve this, the study yielded 
four T4 mutants, for three of which their infectivity on solid medium was tested 
against multiple strains. This work confirms that T4 can be engineered with 
different lysis yielding functional phage that is capable of cargo delivery. LysH5 
when expressed as part of T4-ac::lysH5 lysate after infection of E. coli MG1655, 
showed broad host range, including lysis of Gram-negative bacterium that hasn’t 
been shown before. LysPBC1 showed lysis on B. subtilis and partial lysis on B. 
cereus. LysCD27L generated no lysis in this study. None of the three lysins tested 
showed lysis in liquid culture. Lysin gene stability in T4 genome as well as 
virulence assays showed that the lysin is stable in T4 genome for over 72 
generations and does not alter phage infectivity when compared to wild type T4. 
The activity of two lysins was verified on solid medium validating that lysin 
production in T4 serves as a reliable expression system that can generate stable 
lysin with its catalytic intact. T4 engineered with a lysin is a promising therapeutic 
that would allow two-fold, Gram-negative and Gram-positive targeting, by T4 and 
its cargo respectively. 
Future work should include showing lysin expression by RT-PCR or proteomics. 
In addition, lysin quantification in the T4 lysate should be attempted by modifying 
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lysin sequence to include by His-tag followed affinity chromatography. Tunability 
of lysin expression should be also achieved by placing the lysin gene under 
different promoters in addition to that of T4 ac gene. Further liquid 
characterisation assays including MIC assays should be performed.  
Chapter 7, Aim 4, examined the potential for applying phage engineering to 
determine whether T7 engineered with homing peptides could allow increased 
adsorption/absorption to the mammalian cells. In this chapter it was determined 
that both wild type T4 and T7 phages can be adsorbed to and potentially absorbed 
by mammalian cells. T7 engineered with three different homing peptides provided 
greater association with lung epithelium tissue when compared to the phage T7. 
This is the first study to show homing peptide benefits for phage delivery. This 
finding proposes that the potential use of these engineered phages in therapeutic 
setting would yield higher pathogen kill at a site of infection. 
 
Future work should assess phage T7 engineered with homing peptides using 
Imunno-gold TEM should to quantify the amount of homing peptides in the T7 
capsid. Furthermore, T7-HP phages should be characterised on different tissues to 
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AG MTD 001 g17_371-467_foldon_MtdC FWR gtgacagcttcgttgcgaagAAGTTTCGCCCGGCTGCGCT    
AG MTD 002 pSB6A1_yepphi_g_block REV  AGCGCAGCCGGGCGAAACTTcttcgcaacgaagctgtcac    
AG MTD 003 g17_371-467_foldon_MtdC REV ctttccttgtgatttaccaatTAACAAAAAACCCCTAGCCGCCC
AG MTD 004 pSB6A1_yepphi_gblock FWD   GGCTAGGGGTTTTTTGTTAattggtaaatcacaaggaaagacg 
AG MTD 005 HR MTDC FWD_1 atcacgaggccctttcgtcttc
AG MTD 006 HR MTD FWD_2 CATGACGCTGGTTGCCGGC   
AG MTD 007 HR MTD REV_1 CCCCTAGCCGCCCGATAAG   
AG MTD 008 HR MTDC REV_2 gatgcgtccggcgtagagc   
HRg17_MtdC_trx_HRg17.5
AG MTD 009 pSB6A1 + yep-phi g-block FWD gactttaacaacgaattgatACTAGtagcggccgctgcag
AG MTD 010 pSB6A1 + yep-phi g-block REV AGCGCAGCCGGGCGAAACTTcttcgcaacgaagctgtcac
AG MTD 011 gblock_His_g17_foldon_MtdC FWD gtgacagcttcgttgcgaagAAGTTTCGCCCGGCTGCGCT
AG MTD 012 gblock_His_g17_foldon_MtdC REV tgaatgattttatcgctcatACAAAAAACCCCTAGCCGCCC
AG MTD 013 trxA gp17 homology (flanking gp17) no bioBrick sites g-block FWD GGCGGCTAGGGGTTTTTTGTatgagcgataaaatcattcacc
AG MTD 014 trxA gp17 homology (flanking gp17) no bioBrick sites g-block REV ctgcagcggccgctaCTAGTatcaattcgttgttaaagtctaatg
AG MTD 015 HR MTD TRX FWD ccgacgtgctgaaagctgatgg
AG MTD 016 HR MTD TRX REV gccaggttggcgtccaggaa  
*these primers are not valid since they produce an insert with no rbs before trxA; the MTD 037-MTD 042 primers should be used instead
Gibson_InTrans_COg17_MtdC
AG MTD 017 gblock_His_g17_foldon_MtdC REV gcgggctaggggttcgagtaACAAAAAACCCCTAGCCGCCC  
AG MTD 018 gblock_His_g17_foldon_MtdC FWD GAGATTCTTTTGTCGCTAAAAAGTTTCGCCCGGCTGCGCT   
AG MTD 019 pSEVA551_COgp17 REV           AGCGCAGCCGGGCGAAACTTTTTAGCGACAAAAGAATCTCGCA
AG MTD 020 pSEVA551_COgp17 FWD           GGCGGCTAGGGGTTTTTTGTtactcgaacccctagcccgc   
Gibson_InTrans_COg17_MtdC_RBS_Trx
AG MTD 021 gblock_His_g17_foldon_MtdC FWD GAGATTCTTTTGTCGCTAAAAAGTTTCGCCCGGCTGCGCT      
AG MTD 022 gblock_His_g17_foldon_MtdC REV tgacctccttaaagtaaatcCGGTTGCCTTGGCGGGGCCT      
AG MTD 023 pSEVA551_COg17 REV            AGCGCAGCCGGGCGAAACTTTTTAGCGACAAAAGAATCTCGCA   
AG MTD 024 gblock_trxA FWD               AGGCCCCGCCAAGGCAACCGgatttactttaaggaggtcaaatgag
AG MTD 025 pSEVA551_COg17 FWD            acgccaacctggcttaatgatactcgaacccctagcccgc      
AG MTD 026 gblock_trxA REV               gcgggctaggggttcgagtatcattaagccaggttggcgt      
Gibson_InTrans_WTg17_MtdC
AG MTD 027 His_foldon_MtdC REV gtgacagcttcgttgcgaagAAGTTTCGCCCGGCTGCGCT 
AG MTD 028 His_foldon_MtdC FWD agaccgagcgttctgaacaaACAAAAAACCCCTAGCCGCCC
AG MTD 029 pSB6A1_WTg17 REV   GGCGGCTAGGGGTTTTTTGTttgttcagaacgctcggtct 
AG MTD 030 pSB6A1_WTg17 FWD   AGCGCAGCCGGGCGAAACTTcttcgcaacgaagctgtcac 
Gibson_InTrans_WTg17_MtdC_RBS_Trx
AG MTD 031 His_foldon_MtdC REV gtgacagcttcgttgcgaagAAGTTTCGCCCGGCTGCGCT       
AG MTD 032 His_foldon_MtdC FWD tgacctccttaaagtaaatcCGGTTGCCTTGGCGGGGCCT       
AG MTD 033 gblock_trxA FWD    agaccgagcgttctgaacaattaagccaggttggcgtcca       
AG MTD 034 pSB6A1_WTg17 REV   tggacgccaacctggcttaattgttcagaacgctcggtct       
AG MTD 035 gblock_trxA REV    AGGCCCCGCCAAGGCAACCGgatttactttaaggaggtcaaatgagc
AG MTD 036 pSB6A1_WTg17 FWD   AGCGCAGCCGGGCGAAACTTcttcgcaacgaagctgtcac       
HRg17_MtdC_rbs_trx_HRg17.5
AG MTD 037 gblock_His_g17_foldon_MtdC FWD gtgacagcttcgttgcgaagAAGTTTCGCCCGGCTGCGCT      
AG MTD 038 gblock_His_g17_foldon_MtdC REV tgacctccttaaagtaaatcCGGTTGCCTTGGCGGGGCCT      
AG MTD 039 pSB6A1+yrp-phi g-block REV    AGCGCAGCCGGGCGAAACTTcttcgcaacgaagctgtcac      
AG MTD 040 trxAgp17 homology g-block FWD AGGCCCCGCCAAGGCAACCGgatttactttaaggaggtcaaatgag
AG MTD 041 pSB6A1+yep-phi g block FWD    acgccaacctggcttaatgattggtaaatcacaaggaaagacg   
AG MTD 042 trxA gp17 homology g-block REV ctttccttgtgatttaccaatcattaagccaggttggcgt      
AG 043 Paj57(trxA-gp17 homology) FWD TtATGGTaGAGAAtGAGTAAgatttactttaaggaggtcaaatga
AG 044 Paj57(trx-gp17 homology) REV ATTTCCCCTCTTTCTCTAGTtaagagactacagggagaaga    
AG 045 pSEVA551+COg17 FWD           cttctccctgtagtctcttaACTAGAGAAAGAGGGGAAATAC   
AG 046 pSEVA551+COg17 REV           tgacctccttaaagtaaatcTTACTCaTTCTCtACCATaATTGC 
AG 047 pAJ57 FWD 1 gaaaaggaatattcagcaatttgcccg
AG 048 pAJ57 FWD 2 gaaatacggtatccgtggcatccc   
AG 049 pAJ57 FWD 3 cacgacggggagtcaggcaac      
AG 050 pAJ57 REV 1 cctccttgagagtccatccgtg     
AG 051 pAJ57 REV 2 cgctcagtggaacgaaaactcac    
AG 052 pAJ57 REV 3 gaaagcggtcctcgccgaaaatg    
AG 061 g17_rev ccccaccgccagcactac  
AG 062 g17_rev cggggccagtacggaagaa
AG 063 g17 FRW (before gp17) tcggctggctttgtggctaacg
AG 064 g17 REV (after gp17) acctccttgagagtccatccgtgg
AG065 Michail TCAAGACCCGTTTAGAGGCCCCAAGGGGTTATGCTAGtcagtggcaaatcgcccaatt
AG066 Michail tgccggataatacgactcactataggATAAACAGAGGAGATATCACatgatcgtttctgacatcgaagc
AG074 Mtd_g_block02.02.16 FWD gtgacagcttcgttgcgaagACGGCTTTCATCAAGGCCGA
AG075 Mtd_g_block02.02.16 REV tgacctccttaaagtaaatcacaaaaaacccctagccgcc
AG076 pSB6A1 + yep-phi g-block FWD acgccaacctggcttaatgattggtaaatcacaaggaaagacg
AG077 pSB6A1 + yep-phi g-block REV TCGGCCTTGATGAAAGCCGTcttcgcaacgaagctgtcac
AG078 trxA gp17 homology (flanking gp17) ggcggctaggggttttttgtgatttactttaaggaggtcaaatgag
AG079 trxA gp17 homology (flanking gp17) ctttccttgtgatttaccaatcattaagccaggttggcgt
AG080 Mtd_g_block02.02.16 FWD gtgacagcttcgttgcgaagAACGAATACAGCCTGTGGGA
AG081 Mtd_g_block02.02.16 REV tgacctccttaaagtaaatcacaaaaaacccctagccgcc
AG082 pSB6A1 + yep-phi g-block FWD acgccaacctggcttaatgattggtaaatcacaaggaaagacg
AG083 pSB6A1 + yep-phi g-block REV TCCCACAGGCTGTATTCGTTcttcgcaacgaagctgtcac
AG084 Mtd_g_block02.02.16 FWD gtgacagcttcgttgcgaagATCAAGTTtCGCCCGGCTGC
AG085 Mtd_g_block02.02.16 REV tgacctccttaaagtaaatcacaaaaaacccctagccgcc
AG086 pSB6A1 + yep-phi g-block FWD acgccaacctggcttaatgattggtaaatcacaaggaaagacg
AG087 pSB6A1 + yep-phi g-block REV GCAGCCGGGCGaAACTTGATcttcgcaacgaagctgtcac
AG088 plasmid: pCDF-1b_Qimrons_pWUR400, pRSF-1b_Qimrons_pWUR397, pACYCDuet-1_Qimron's_pWUR478TCGACGCTCTCCCTTATGCGAC


















AG090 plasmid: pCDF-1b_Qimrons_pWUR400 GTCTAACAATTCGTTCAAGCCG
AG091 plasmid: pRSF-1b_Qimrons_pWUR397 GGAGACCCGGTCGTCAGC
AG092 plasmid: pACYCDuet-1_Qimron's_pWUR478 GCTAGTTATTGCTCAGCGG
AG093 plasmid: pCAS9_Marafini_JaramilloLab cagacaggcggattctccaagg
AG094 plasmid: pCAS9_Marafini_JaramilloLab ccgcaaggaatggtgcatgc
AG095 plasmid: forward primer for pET30a+-MVR-gp17-foldon467, pET30a+-MVR-gp17-mtd_171-381, pET30a+-MVR-gp17-WTg17_468-533gtatgaaaga accgctgctgc
AG096 plasmid: reverse primer for pET30a+-MVR-gp17-foldon467, pET30a+-MVR-gp17-mtd_171-381, pET30a+-MVR-gp17-WTg17_468-533ctttcgggctttgttagcagc 
AG097 plasmid: pSB6A1_HRgp17_Mtd_HRgp17, pSB6A1_HRgp17_Mtd_trx_HRgp17, pSB6A1-WTgp17 _Mtd_intrans, pSB6A1-WTgp17_Mtd_trx_intranscaccagcgtttctgggtgagc
AG098 plasmid: pSB6A1_HRgp17_Mtd_HRgp17, pSB6A1_HRgp17_Mtd_trx_HRgp17 ctcaagggcatcggtcgacg 
AG099 plasmid: pSEVA551-cogp17 (S189I) _Mtd_trx_intrans ctagcgcagcgaatagaccag
AG100 plasmid: pSEVA551-cogp17 (S189I) _Mtd_trx_intrans cacggtgcctgactgcgtta 
AG101 plasmid: HR_COg17_trx_HR gccagtgagttgattgctacgt
AG102 plasmid: HR_COg17_trx_HR caaaagcctccggtcggagg
AG103 plasmid: HR_COg17_trx_HR gccagtgagttgattgctacgt
AG104 gcagcggccgctactagtt
AG105 to make QNQ_trxA(AKOS), HR_trxA_2Stopcodons FWD aattcgcggccgcttCTAGAtgttaacttgagggagcgta
AG106 to make QNQ_trxA(AKOS), HR_trxA_2Stopcodons REV ctgcagcggccgctaCTAGTatcaattcgttgttaaagtctaatg
AG107 to make QNQ_trxA(AKOS), pSB6A1_yepphi FWD gactttaacaacgaattgatACTAGtagcggccgctgcag
AG108 to make QNQ_trxA(AKOS), pSB6A1_yepphi REV tacgctccctcaagttaacaTCTAGaagcggccgcgaatt
AG109 to make QNQ_gp17 & stop_N_stop_gp17 (AKOS), HR_QNQ_COgp17_RBS_trxA_HR FWD tcaagaattcgcggccgcttgataacaacaatgactgtacct
AG110 to make QNQ_gp17 & stop_N_stop_gp17 (AKOS), HR_QNQ_COgp17_RBS_trxA_HR REV ctgcagcggccgctaCTAGTatcaattcgttgttaaagtctaatg
AG111 to make QNQ_gp17 & stop_N_stop_gp17 (AKOS), pSB6A1_yepphi FWD gactttaacaacgaattgatACTAGtagcggccgctgcag
AG112 to make QNQ_gp17 & stop_N_stop_gp17 (AKOS)), pSB6A1_yepphi REV gtacagtcattgttgttatcaagcggccgcgaattcttga
Gibson to make HRg1_mKate2_trxA: pAJ57 (trxA-gp17 homology) FWD ataaacagaggagatatcacatgagcgataaaatcattcacctg
Gibson to make HRg1_mKate2_trxA:pAJ57 (trxA-gp17 homology) REV tgagtcgtattgatttggcGtcattaagccaggttggcgt
Gibson to make HRg1_mKate2_trxA:pIDTSmartAmp_T7HRmini1 FWD acgccaacctggcttaatgaCgccaaatcaatacgactcact
Gibson to make HRg1_mKate2_trxA:pIDTSmartAmp_T7HRmini1 REV GTTTCCTGTGTGACTCTAGCttacgcgaacgcgaagtccg
Gibson to make HRg1_mKate2_trxA:pLtet-mKate2 FWD cggacttcgcgttcgcgtaaGCTAGAGTCACACAGGAAAC
Gibson to make HRg1_mKate2_trxA:pLtet-mKate2 REV GTGATATCTCCTCTGTTTATTTATTAACGGTGACCCAGCT
Gibson to make HRg6.3_mKate2_trxA:pAJ57 (trxA-gp17 homology) FWD ataaacagaggagatatcacatgagcgataaaatcattcacctg
Gibson to make HRg6.3_mKate2_trxA:pAJ57 (trxA-gp17 homology) REV atttagggaccttgagtttAtcattaagccaggttggcgt
Gibson to make HRg6.3_mKate2_trxA:pIDTSmartAmp_T7HRmini2 FWD acgccaacctggcttaatgaTaaactcaaggtccctaaattaatac
Gibson to make HRg6.3_mKate2_trxA:pIDTSmartAmp_T7HRmini2 REV GTTTCCTGTGTGACTCTAGCtcacttagtgtcgtgtaacg
Gibson to make HRg6.3_mKate2_trxA:pLtet-mKate2 FWD cgttacacgacactaagtgaGCTAGAGTCACACAGGAAAC
Gibson to make HRg6.3_mKate2_trxA:pLtet-mKate2 REV GTGATATCTCCTCTGTTTATTTATTAACGGTGACCCAGCT
Gibson to make HRg17_mKate2_trxA:pAJ57 (trxA-gp17 homology) FWD ataaacagaggagatatcacatgagcgataaaatcattcacctg
Gibson to make HRg17_mKate2_trxA:pAJ57 (trxA-gp17 homology) REV ctttccttgtgatttaccaAtcattaagccaggttggcgt
Gibson to make HRg17_mKate2_trxA:pIDTSmartAmp_T7HRmini3 FWD acgccaacctggcttaatgaTtggtaaatcacaaggaaagac
Gibson to make HRg17_mKate2_trxA:pIDTSmartAmp_T7HRmini3 REV GTTTCCTGTGTGACTCTAGCttactcgttctccaccatga
Gibson to make HRg17_mKate2_trxA:pLtet-mKate2 FWD tcatggtggagaacgagtaaGCTAGAGTCACACAGGAAAC
Gibson to make HRg17_mKate2_trxA:pLtet-mKate2 REV GTGATATCTCCTCTGTTTATTTATTAACGGTGACCCAGCT
Gibson to make HR_deltagp17:pAJ57 (trxA-gp17 homology) FWD ataaacagaggagatatcacatgagcgataaaatcattcacctg
Gibson to make HR_deltagp17:pAJ57 (trxA-gp17 homology) REV TTGATCAGTTCGCTTACCATttgacctccttaaagtaaatctaag
Gibson to make HR_deltagp17:pLtet-mKate2 FWD atttactttaaggaggtcaaATGGTAAGCGAACTGATCAA
Gibson to make HR_deltagp17:pLtet-mKate2 REV GTGATATCTCCTCTGTTTATTTATTAACGGTGACCCAGCT
 231 
 





































Gibson primers to make construct to insert H5lysin into T4 (inside ac gene), name: 
Gibson_HR1_RBS_H5Lysin_HR2_T4, Primer name: H5Lysin_RBS FWD aaagaggagaaatactagATGCAAGCAAAACTAACTAAAAA
AG150
Gibson primers to make construct to insert H5lysin into T4 (inside ac gene), name: 
Gibson_HR1_RBS_H5Lysin_HR2_T4, Primer name: H5Lysin_RBS REV TGCGAAAACACACTGCTAGCTTAACTGATTTCTCCCCATAAGT
AG151
Gibson primers to make construct to insert H5lysin into T4 (inside ac gene), name: 
Gibson_HR1_RBS_H5Lysin_HR2_T4, primer name: ac flaniking g_block FWD TATGGGGAGAAATCAGTTAAGCTAGCAGTGTGTTTTCGCA
AG152
Gibson primers to make construct to insert H5lysin into T4 (inside ac gene), name: 
Gibson_HR1_RBS_H5Lysin_HR2_T4, primer name: ac flaniking g_block REV ctagtatttctcctctttATCGATACAGATAGTTAAAACACATG
AG153
Gibson primers to make construct to insert H5lysin into T7 (inside ac gene), name: 
Gibson_HR1_trxA_RBS_H5Lysin_HR2_T7, Primer name: H5Lysin_RBS FWD aaagaggagaaatactagATGCAAGCAAAACTAACTAAAAA
AG154
Gibson primers to make construct to insert H5lysin into T7 (inside ac gene), name: 
Gibson_HR1_trxA_RBS_H5Lysin_HR2_T7, Primer name: H5Lysin_RBS REV tgacctccttaaagtaaatcTTAACTGATTTCTCCCCATAAGT
AG155
Gibson primers to make construct to insert H5lysin into T7 (inside ac gene), name: 
Gibson_HR1_trxA_RBS_H5Lysin_HR2_T7, Primer name: HR1(end of 
gp17)_trxA_HR2(after gp17)(new g_bock ordered)  FWD TATGGGGAGAAATCAGTTAAgatttactttaaggaggtcaaatga
AG156
Gibson primers to make construct to insert H5lysin into T7 (inside ac gene), name: 
Gibson_HR1_trxA_RBS_H5Lysin_HR2_T7, Primer name: HR1(end of 
gp17)_trxA_HR2(after gp17)(new g_bock ordered)  REV ctagtatttctcctctttttactcgttctccaccatga
AG157 primer to sequence g_block: HR1(end of gp17)_trxA_HR2(after gp17) ggtggatggttacgattcc
AG158 primer to sequence g_block: HR1(end of gp17)_trxA_HR2(after gp17) ggagcagccttaatcaattcg
AG159 Gibson primer to make HR plasmid to insert PBC1 lysin, amplifies g_block PBC1 FWD GTTTTAACTATCTGTATCGATaaagaggagaaatactagATGGAC
AG160 Gibson primer to make HR plasmid to insert PBC1 lysin, amplifies g_block PBC1 REV TGCGAAAACACACTGCTAGCTTAGTATTCGATTACTTCCTCCT
AG161
Gibson primer to make HR plasmid to insert PBC1 lysin, amplifies ac flanking plasmid 
FWD AGGAAGTAATCGAATACTAAGCTAGCAGTGTGTTTTCGCA
AG162
Gibson primer to make HR plasmid to insert PBC1 lysin, amplifies ac flanking plasmid 
REV ATctagtatttctcctctttATCGATACAGATAGTTAAAACACATG
AG163 Gibson primer to make HR plasmid to insert CD27L lysin, amplifies g_block CD27L FWD TGTTTTAACTATCTGTATCGATaaagaggagaaatactagATGAAGA
AG164 Gibson primer to make HR plasmid to insert CD27L lysin, amplifies g_block CD27L REV TGCGAAAACACACTGCTAGCCTAGCGGTTGATAAAATCCAG
AG165
Gibson primer to make HR plasmid to insert CD27L lysin, amplifies ac flanking plasmid 
FWD TGGATTTTATCAACCGCTAGGCTAGCAGTGTGTTTTCGCA
AG166
Gibson primer to make HR plasmid to insert CD27L lysin, amplifies ac flanking plasmid 
REV ATctagtatttctcctctttATCGATACAGATAGTTAAAACACATG
AG167 sequencing primer for PBC1 FWD CAAGTTTACCGTCCATGCCGGGC
AG168 sequencing primer for CD27L FWD GCATTACGGTGGGCCACAGC
AG169 sequencing primer for phoh FWD CACGCGATGCTCGTGTTGCTATTCG
AG170 for sequencing after AC ccaaggtccgctacaccacc
AG171 for sequencing before AC CAGCTTGCGCGTACTATTGC
AG172 inside PBC1 lysin forward CGCTTGGCGGAGGAGCTAGTGG
AG173 inside PBC1 lysin reverse CACGCGAAATACTCGCGAGCGG
AG174 inside H5 forward GCGCAACCTGGCGACATGGTTG
AG175 inside H5 reverse CGTTTCCATGCACTTGCAACTGGC
AG176 inside CD27L frw CTGAAGAGTGGTGCTTGCACTTCCG
AG177 inside CD27L rev CAGCGGTAGGCTTGCTTGAGTTAAGG
AG178 AC_2 fwd cactatgaggaagaatgtaagttgc
AG179 AC_2 rev cgtttactcgtaatcatcattctgag
AG180 10B_HR_GFE-2 g block in a plsamid FWD ctgccaccgctgagcaataaataaacagaggagatatcacatga
AG181 10B_HR_GFE-2 g block in a plsamid REV atatctccttcttaaagttaTTAACAAGTCTCTAGCTCAAATCC
AG182 SEVA631_gp10 FWD  AB plasmid for GFE-2 TTGAGCTAGAGACTTGTTAAtaactttaagaaggagatatacatatggc
AG183 SEVA631_gp10 REV AB plasmid for GFE-2 gtgatatctcctctgtttatttattgctcagcggtggcag
AG184 10B_metadherin in a plsmid FWD ctgccaccgctgagcaataaataaacagaggagatatcacatga
AG185 10B_metadherin in a plsmid REV atatctccttcttaaagttaTTAtttggatttcccagttgga
AG186 SEVA631_gp10 FWD for the AB plasmid to be inserted in metadherin plasmid caactgggaaatccaaaTAAtaactttaagaaggagatatacatatggc
AG187 SEVA631_gp10 REV for the AB plasmid to be inserted in metadherin plasmid gtgatatctcctctgtttatttattgctcagcggtggcag
AG188 10B_HR_GFE-1 in plasmid FWD ctgccaccgctgagcaataaataaacagaggagatatcacatga
AG189 10B_HR_GFE-1 in plasmid REV atatctccttcttaaagttaTTAGCATCTTTCGGGGCATT
AG190 SEVA631_gp10 FWD for the AB plasmid to be inserted in GFE-1 AATGCCCCGAAAGATGCTAAtaactttaagaaggagatatacatatggc






Sequence inserted in pSMART amp to generate pAG_1 vector schematic 






Insert for pAG2 
TCCTTACGATTAATACAGACTATCGCTTTGCT 
 
Insert for pAG3 
AAATATTCACGCTAACGGGCGCCTTTACATGA 
 
Insert for pAG4 
CGGTAACATCCAGTTAGTAGTAAACGGACAGA 
 
Insert for pAG5 
TTACTCGACGTAACTCGATGGTCGTGTAGCCA 
 
Insert for pAG6 
TACAGTCATTGTTGTTATCTGACCCTCTACCA 
 
Insert for pAG7 
CGTGGACTCAGGTGTGGTCTGGTAGTGCTGGC 
 
Insert for pAG8 
TGTGGTCTGGTAGTGCTGGCGGTGGGGTAAGT 
 
Insert for pAG9 
ATCTCCGCTTCCGCAATATCTGGATTAAGTGT 
 
Insert for pAG10 
CTATGAAGTAGATTCCATCGGGGCCAGTACGG 
 
Insert for pAG11 
TACTGAACGACTGTCTGCAATATTCTTGAATC 
 
Insert for pAG12 
AAGTGTGACTGTTTCACAGG 
 
Insert for pAG13 
AGGCGTGGACTCAGGTGTGG 
 
Insert for pAG14 
AGTGTGCCAACAACTCTTGG 
 
Insert for pAG15 
TTCCGCTGCGCATCAATCTG 
 




Insert for pAG17 
CAGCATCCGCTAACTCTGCTC 
 
Insert for pAG18 
TACAGTTCCGTAATGAGGCT 
 
Insert for pAG19 
GGTAAGTGTGACTGTTTCAC 
 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Representation of post-hoc analysis of the wash step 
Control  
Phage Comparison Phage Mean Difference  p-value 




T7 HP-1 -1398500.00* .011 -2451880.94 -345119.07 
HP-2 -1715166.67* .002 -2768547.60 -661785.73 
HP-3 -3548500.00* .000 -4601880.94 -2495119.07 
HP-4 -4065166.67* .000 -5118547.60 -3011785.73 
HP-5 -2415166.67* .000 -3468547.60 -1361785.73 
HP-6 -865166.67 .104 -1918547.60 188214.27 
HP-1 HP-2 -316666.67 .543 -1370047.60 736714.27 
HP-3 -2150000.00* .000 -3203380.94 -1096619.07 
HP-4 -2666666.67* .000 -3720047.60 -1613285.73 
HP-5 -1016666.67 .058 -2070047.60 36714.27 
HP-6 533333.33 .309 -520047.60 1586714.27 
HP-2 HP-3 -1833333.33* .001 -2886714.27 -779952.40 
HP-4 -2350000.00* .000 -3403380.94 -1296619.07 
HP-5 -700000.00 .184 -1753380.94 353380.93 
HP-6 850000.00 .110 -203380.93 1903380.94 
HP-3 HP-4 -516666.67 .324 -1570047.60 536714.27 
 
HP-5 1133333.33* .036 79952.40 2186714.27 
HP-6 2683333.33* .000 1629952.40 3736714.27 
HP-4 HP-5 1650000.00* .003 596619.07 2703380.94 
HP-6 3200000.00* .000 2146619.07 4253380.94 













Representation of post-hoc analysis of the lysis step 
 
Control 
Phage Comparison Phage 
Mean  
Difference  p-value 




T7 HP1 -65416.67* .000 -74026.73 -56806.60 
HP2 -42750.00* .000 -51360.06 -34139.94 
HP3 -32250.00* .000 -40860.06 -23639.94 
HP4 -10800.00* .016 -19410.06 -2189.94 
HP5 -13250.00* .004 -21860.06 -4639.94 
HP6 -10916.67* .015 -19526.73 -2306.60 
HP1 HP2 22666.67* .000 14056.60 31276.73 
HP3 33166.67* .000 24556.60 41776.73 
HP4 54616.67* .000 46006.60 63226.73 
HP5 52166.67* .000 43556.60 60776.73 
HP6 54500.00* .000 45889.94 63110.06 
HP2 HP3 10500.00* .019 1889.94 19110.06 
HP4 31950.00* .000 23339.94 40560.06 
HP5 29500.00* .000 20889.94 38110.06 
HP6 31833.33* .000 23223.27 40443.40 
HP3 HP4 21450.00* .000 12839.94 30060.06 
HP5 19000.00* .000 10389.94 27610.06 
HP6 21333.33* .000 12723.27 29943.40 
HP4 HP5 -2450.00 .565 -11060.06 6160.06 
HP6 -116.67 .978 -8726.73 8493.40 
HP5 HP6 2333.33 .583 -6276.73 10943.40 
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Summary of wash step t-tests, relationship between incubation time and type of phage. 
Equal variances assumed  
Phage_No 
Levene's Test for 
Equality of Variances 
F Sig. t df p-value 
1 W 4.030 0.115 -2.476 4 0.068 
    -2.476 2.026 0.130 
2 W 4.000 0.116 1.732 4 0.158 
    1.732 2.000 0.225 
3 W 11.253 0.028 -12.583 4 0.000 
    -12.583 2.000 0.006 
4 W 0.396 0.563 -2.568 4 0.062 
    -2.568 3.604 0.069 
5 W 1.665 0.266 2.755 4 0.051 
    2.755 2.669 0.080 
6 W 3.826 0.122 -4.427 4 0.011 
    -4.427 2.427 0.033 
7 W 0.216 0.667 2.822 4 0.048 
    2.822 3.931 0.049 
 
Summary of t-tests for the lysis step for the relationship between time and type of phage. 
Phage_No 
Levene's Test for 
Equality of Variances 





13.892 0.020 0.387 4 0.719 
    0.387 2.015 0.736 
HP1 
 
14.530 0.019 -7.834 4 0.001 
    -7.834 2.000 0.016 
3 
 
0.746 0.437 -3.268 4 0.031 
    -3.268 3.571 0.036 
4 
 
5.918 0.072 -1.273 4 0.272 
    -1.273 2.025 0.330 
5 
 
15.747 0.017 -3.836 4 0.019 
    -3.836 2.000 0.062 
6 
 
6.897 0.058 -7.667 4 0.002 
    -7.667 2.278 0.011 
7 
 
6.606 0.062 -4.152 4 0.014 
    -4.152 2.358 0.040 
 
 
Wash for time 1 and time 2 
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Time Mean Difference (I-J) Std. Error Sig. 
1 HP_3 HP_4 1900000.00* 873602.267 0.047 
HP_5 -866666.67 873602.267 0.338 
HP_6 -4333333.33* 873602.267 0.000 
HP_7 733333.33 873602.267 0.415 
HP_8 533333.33 873602.267 0.551 
T7 1970333.33* 873602.267 0.041 
HP_4 HP_3 -1900000.00* 873602.267 0.047 
HP_5 -2766666.67* 873602.267 0.007 
HP_6 -6233333.33* 873602.267 0.000 
HP_7 -1166666.67 873602.267 0.203 
HP_8 -1366666.67 873602.267 0.140 
T7 70333.33 873602.267 0.937 
HP_5 HP_3 866666.67 873602.267 0.338 
HP_4 2766666.67* 873602.267 0.007 
HP_6 -3466666.67* 873602.267 0.001 
HP_7 1600000.00 873602.267 0.088 
HP_8 1400000.00 873602.267 0.131 
T7 2837000.00* 873602.267 0.006 
HP_6 HP_3 4333333.33* 873602.267 0.000 
HP_4 6233333.33* 873602.267 0.000 
HP_5 3466666.67* 873602.267 0.001 
HP_7 5066666.67* 873602.267 0.000 
HP_8 4866666.67* 873602.267 0.000 
T7 6303666.67* 873602.267 0.000 
HP_7 HP_3 -733333.33 873602.267 0.415 
HP_4 1166666.67 873602.267 0.203 
HP_5 -1600000.00 873602.267 0.088 
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HP_6 -5066666.67* 873602.267 0.000 
HP_8 -200000.00 873602.267 0.822 
T7 1237000.00 873602.267 0.179 
HP_8 HP_3 -533333.33 873602.267 0.551 
HP_4 1366666.67 873602.267 0.140 
HP_5 -1400000.00 873602.267 0.131 
HP_6 -4866666.67* 873602.267 0.000 
HP_7 200000.00 873602.267 0.822 
T7 1437000.00 873602.267 0.122 
T7 HP_3 -1970333.33* 873602.267 0.041 
HP_4 -70333.33 873602.267 0.937 
HP_5 -2837000.00* 873602.267 0.006 
HP_6 -6303666.67* 873602.267 0.000 
HP_7 -1237000.00 873602.267 0.179 
HP_8 -1437000.00 873602.267 0.122 
2 HP_3 HP_4 -2533333.33* 542776.519 0.000 
HP_5 -3433333.33* 542776.519 0.000 
HP_6 -1000000.00 542776.519 0.087 
HP_7 -2766666.67* 542776.519 0.000 
HP_8 533333.33 542776.519 0.342 
T7 826666.67 542776.519 0.150 
HP_4 HP_3 2533333.33* 542776.519 0.000 
HP_5 -900000.00 542776.519 0.120 
HP_6 1533333.33* 542776.519 0.013 
HP_7 -233333.33 542776.519 0.674 
HP_8 3066666.67* 542776.519 0.000 
T7 3360000.00* 542776.519 0.000 
HP_5 HP_3 3433333.33* 542776.519 0.000 
HP_4 900000.00 542776.519 0.120 
HP_6 2433333.33* 542776.519 0.001 
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HP_7 666666.67 542776.519 0.240 
HP_8 3966666.67* 542776.519 0.000 
T7 4260000.00* 542776.519 0.000 
HP_6 HP_3 1000000.00 542776.519 0.087 
HP_4 -1533333.33* 542776.519 0.013 
HP_5 -2433333.33* 542776.519 0.001 
HP_7 -1766666.67* 542776.519 0.006 
HP_8 1533333.33* 542776.519 0.013 
T7 1826666.67* 542776.519 0.005 
HP_7 HP_3 2766666.67* 542776.519 0.000 
HP_4 233333.33 542776.519 0.674 
HP_5 -666666.67 542776.519 0.240 
HP_6 1766666.67* 542776.519 0.006 
HP_8 3300000.00* 542776.519 0.000 
T7 3593333.33* 542776.519 0.000 
HP_8 HP_3 -533333.33 542776.519 0.342 
HP_4 -3066666.67* 542776.519 0.000 
HP_5 -3966666.67* 542776.519 0.000 
HP_6 -1533333.33* 542776.519 0.013 
HP_7 -3300000.00* 542776.519 0.000 
T7 293333.33 542776.519 0.597 
T7 HP_3 -826666.67 542776.519 0.150 
HP_4 -3360000.00* 542776.519 0.000 
HP_5 -4260000.00* 542776.519 0.000 
HP_6 -1826666.67* 542776.519 0.005 
HP_7 -3593333.33* 542776.519 0.000 










(I-J) Std. Error Sig. 
1 HP_3 HP_4 2666.67 5592.058 0.641 
HP_5 5666.67 5592.058 0.328 
HP_6 35566.67* 5592.058 0.000 
HP_7 28666.67* 5592.058 0.000 
HP_8 30666.67* 5592.058 0.000 
T7 32933.33* 5592.058 0.000 
HP_4 HP_3 -2666.67 5592.058 0.641 
HP_5 3000.00 5592.058 0.600 
HP_6 32900.00* 5592.058 0.000 
HP_7 26000.00* 5592.058 0.000 
HP_8 28000.00* 5592.058 0.000 
T7 30266.67* 5592.058 0.000 
HP_5 HP_3 -5666.67 5592.058 0.328 
HP_4 -3000.00 5592.058 0.600 
HP_6 29900.00* 5592.058 0.000 
HP_7 23000.00* 5592.058 0.001 
HP_8 25000.00* 5592.058 0.001 
T7 27266.67* 5592.058 0.000 
HP_6 HP_3 -35566.67* 5592.058 0.000 
HP_4 -32900.00* 5592.058 0.000 
HP_5 -29900.00* 5592.058 0.000 
HP_7 -6900.00 5592.058 0.238 
HP_8 -4900.00 5592.058 0.396 
T7 -2633.33 5592.058 0.645 
HP_7 HP_3 -28666.67* 5592.058 0.000 
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HP_4 -26000.00* 5592.058 0.000 
HP_5 -23000.00* 5592.058 0.001 
HP_6 6900.00 5592.058 0.238 
HP_8 2000.00 5592.058 0.726 
T7 4266.67 5592.058 0.458 
HP_8 HP_3 -30666.67* 5592.058 0.000 
HP_4 -28000.00* 5592.058 0.000 
HP_5 -25000.00* 5592.058 0.001 
HP_6 4900.00 5592.058 0.396 
HP_7 -2000.00 5592.058 0.726 
T7 2266.67 5592.058 0.691 
T7 HP_3 -32933.33* 5592.058 0.000 
HP_4 -30266.67* 5592.058 0.000 
HP_5 -27266.67* 5592.058 0.000 
HP_6 2633.33 5592.058 0.645 
HP_7 -4266.67 5592.058 0.458 
HP_8 -2266.67 5592.058 0.691 
2 HP_3 HP_4 42666.67* 6276.917 0.000 
HP_5 60666.67* 6276.917 0.000 
HP_6 73666.67* 6276.917 0.000 
HP_7 75666.67* 6276.917 0.000 
HP_8 78333.33* 6276.917 0.000 
T7 97900.00* 6276.917 0.000 
HP_4 HP_3 -42666.67* 6276.917 0.000 
HP_5 18000.00* 6276.917 0.012 
HP_6 31000.00* 6276.917 0.000 
HP_7 33000.00* 6276.917 0.000 
HP_8 35666.67* 6276.917 0.000 
T7 55233.33* 6276.917 0.000 
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HP_5 HP_3 -60666.67* 6276.917 0.000 
HP_4 -18000.00* 6276.917 0.012 
HP_6 13000.00 6276.917 0.057 
HP_7 15000.00* 6276.917 0.031 
HP_8 17666.67* 6276.917 0.014 
T7 37233.33* 6276.917 0.000 
HP_6 HP_3 -73666.67* 6276.917 0.000 
HP_4 -31000.00* 6276.917 0.000 
HP_5 -13000.00 6276.917 0.057 
HP_7 2000.00 6276.917 0.755 
HP_8 4666.67 6276.917 0.469 
T7 24233.33* 6276.917 0.002 
HP_7 HP_3 -75666.67* 6276.917 0.000 
HP_4 -33000.00* 6276.917 0.000 
HP_5 -15000.00* 6276.917 0.031 
HP_6 -2000.00 6276.917 0.755 
HP_8 2666.67 6276.917 0.677 
T7 22233.33* 6276.917 0.003 
HP_8 HP_3 -78333.33* 6276.917 0.000 
HP_4 -35666.67* 6276.917 0.000 
HP_5 -17666.67* 6276.917 0.014 
HP_6 -4666.67 6276.917 0.469 
HP_7 -2666.67 6276.917 0.677 
T7 19566.67* 6276.917 0.008 
T7 HP_3 -97900.00* 6276.917 0.000 
HP_4 -55233.33* 6276.917 0.000 
HP_5 -37233.33* 6276.917 0.000 
HP_6 -24233.33* 6276.917 0.002 
HP_7 -22233.33* 6276.917 0.003 
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HP_8 -19566.67* 6276.917 0.008 
 
 
 
 
 
 
 
 
